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1 Introduction 
1.1 Characteristics of Amyotrophic lateral sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS) belongs to the spectrum of neurodegenerative 
diseases, which also include Alzheimer’s, Parkinson’s, Huntington’s disease, and 
Frontotemporal dementia (FTD). Most neurodegenerative diseases are age-dependent 
disorders affecting the nervous system. They are incurable diseases that are becoming more 
prevalent as the elderly population has increased in recent years (Heemels 2016). The 
underlying pathophysiology is diverse with some disorders causing primarily memory and 
cognitive impairment as seen in Alzheimer’s and FTD, while others affect mainly the motor 
system (movement, speech, and breathing) as in ALS (Abeliovich and Gitler 2016, Canter, 
Penney et al. 2016, Taylor, Brown et al. 2016, Wyss-Coray 2016). 
In ALS, neurodegeneration specifically affects upper (corticospinal) and lower (spinal) 
motor neurons (Van Langenhove, van der Zee et al. 2012, Vance, Scotter et al. 2013). The 
selective death of motor neurons (MNs) results in a progressive muscular weakness and palsy. 
The clinical symptoms of ALS consist of a characteristic combination of signs of upper motor 
neuron (UMN) degeneration, which includes muscular spasticity and hyperreflexia, together 
with signs of lower motor neuron (LMN) degeneration, which comprises muscular atrophy and 
fasciculation (Van Langenhove, van der Zee et al. 2012). ALS patients differ significantly in 
presentation of clinical symptoms including site of onset, rate of progression, presence of 
cognitive dysfunction, and comorbidity with frontotemporal lobar degeneration (FTLD) (Lomen-
Hoerth 2011).  
ALS occurs with an incidence of 1 to 2 cases per 100,000/year and a prevalence of 3 to 8 
per 100,000 (Worms 2001, Van Damme, Robberecht et al. 2017). Symptoms most commonly 
develop in the age between 55 and 75. Death, usually through respiratory failure, occurs on 
average 2 to 5 years after symptom onset (Van Damme, Robberecht et al. 2017). At present, 
ALS remains an incurable disease. Riluzole is one of two FDA-approved drugs to treat patients 
suffering ALS. It can increase lifetime for 3 to 6 months but cannot entail any cure of disease 
(Bensimon, Lacomblez et al. 1994, Gurney, Cutting et al. 1996). Edaravone (trading name: 
Radicava®) was approved by FDA for treating ALS only in 2017. However, clinical trials only 
showed an effect on subgroups of ALS patients and further studies need to be conducted to 
clarify the benefits of edaravone on ALS disease progression (Abe, Itoyama et al. 2014, Writing 
and Edaravone 2017).  
ALS neuropathology is characterized by axon retraction, the loss of cell bodies of upper and 
lower MNs and the occurrence of astro- and microgliosis (Saberi, Stauffer et al. 2015). 
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Reactive astrocytes were shown to surround degenerating neurons (McGeer and McGeer 
2002); (Boillee, Yamanaka et al. 2006); (Yamanaka, Chun et al. 2008). Microglia become 
activated as response to neuronal distress and lead to higher degree of inflammation. The 
effects of neuroinflammation in disease progression are still under debate, as it was shown to 
protect neurodegeneration but also to drive it (Boillee, Vande Velde et al. 2006); (McGeer and 
McGeer 2002); (Boillee, Yamanaka et al. 2006). Another neuropathological hallmark in 
sporadic and familial ALS patient’s tissue are ubiquitin-positive cytoplasmic inclusion (Saberi, 
Stauffer et al. 2015). They are observed most commonly in neurons but occasionally also occur 
in glial cells. Ubiquitin-positive inclusion in ALS are negative for proteins commonly associated 
with neurodegenerative disease such as TAU or α-SYNUCLEIN.  In 95% of patients, TDP43 
is the main component of such inclusions (Arai, Hasegawa et al. 2006); (Neumann, Sampathu 
et al. 2006). In addition to pathological cytoplasmic redistribution of the protein, a loss of 
nuclear TDP43 can be observed (Giordana, Piccinini et al. 2010). Even though most 
neuropathological hallmark characteristics can be associated with sporadic and familial ALS, 
a number of genetic causes exist that demonstrate distinctive molecular and neuropathological 
features. 
About 90% are sporadic cases (sALS) with largely unknown genetic etiology and 10% are 
familial cases (fALS) (Rowland and Shneider 2001, Pasinelli and Brown 2006, Debray, Race 
et al. 2013, Al-Chalabi, van den Berg et al. 2017). It is of great interest to investigate 
monogenetic forms causing fALS to understand its underlying disease pathologies and 
mechanisms to be able to develop new treatments (Dion, Daoud et al. 2009, Bento-Abreu, Van 
Damme et al. 2010). Disease causing gene mutation are typically inherited in an autosomal 
dominant manner and over 20 genes have been linked to ALS until now (Bento-Abreu, Van 
Damme et al. 2010, Al-Chalabi, Jones et al. 2012, Al-Chalabi, van den Berg et al. 2017). In 
1993, Superoxide dismutase 1 (SOD1) was the first gene to be identified to cause ALS (Rosen 
1993). ALS-causing mutations were also found in TARDBP coding for TAR DNA-binding 
protein 43 (TDP43) (Kabashi, Valdmanis et al. 2008, Sreedharan, Blair et al. 2008, Van 
Deerlin, Leverenz et al. 2008) and shortly after in the gene Fused in sarcoma (FUS) 
(Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009). Only some years later, 
chromosome 9 open reading frame 72 (C9ORF72) was found to be the most common disease-
causing gene (Renton, Majounie et al. 2011). 
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1.2 ALS-associated genes FUS and C9ORF72 
1.2.1 Fused in sarcoma (FUS) 
FUS, also known as Translocated in liposarcoma (TLS), was initially identified as a fusion 
oncogene in human myxoid liposarcomas (Crozat, Aman et al. 1993). FUS is located on 
chromosome 16, consists of 16 exons, and codes for a 526 amino acid long protein (Lagier-
Tourenne, Polymenidou et al. 2010, Dormann and Haass 2011, Dormann and Haass 2013). 
The protein structure of FUS contains an N-terminal serine, tyrosine, glycine and glutamine-
rich domain (transcriptional activation domain), followed by an RNA-recognition motif (RRM) 
and a zinc finger domain (ZnF) (Figure 1.1). Interspaced between those domains are three 
RRG-repeat regions. Moreover, FUS contains a C-terminal non-classical nuclear localization 
signal (NLS) which consists of a proline-tyrosine NLS (PY-NLS) and the RGG3 domain (Lee, 
Cansizoglu et al. 2006, Dormann, Rodde et al. 2010, Dormann, Madl et al. 2012).  
FUS belongs to the FET (FUS, EWS and TAF15) family of proteins, which also includes 
Ewing’s sarcoma (EWS) and TATA box-binding protein (TBP)-associated factor (TAF15) 
(Powers, Mathur et al. 1998, Andersson, Stahlberg et al. 2008). FET proteins are RNA-binding 
and structurally similar multifunctional proteins. FUS is a ubiquitously expressed protein that 
predominantly localizes to the nucleus but is able to shuttle between nucleus and cytoplasm 
(Zinszner, Sok et al. 1997). It was found to be a DNA-/RNA-binding protein which is involved 
in the regulation of gene expression, RNA metabolism, and DNA processing (Zinszner, Sok et 
al. 1997, Powers, Mathur et al. 1998, Lagier-Tourenne, Polymenidou et al. 2012, Ling, 
Polymenidou et al. 2013). Moreover, FUS regulates its own gene expression by alternative 
splicing and nonsense-mediated decay (Zhou, Liu et al. 2013). Even though FUS is known to 
play a role in various cellular processes, its precise function is still poorly understood.  
About 4% of fALS cases are caused by dominant mutations within FUS (Kwiatkowski, 
Bosco et al. 2009, Vance, Rogelj et al. 2009, Kaneb, Dion et al. 2012) representing the third 
most common fALS form in Germany. Figure 1.1 shows that the C-terminus of FUS is a hotspot 
for disease-causing mutations (Zhang and Chook 2012). Two-thirds of known FUS mutations 
cluster within exon 12 to 15, which encode for ZnF-motif, RGG2+3 domain, and PY-NLS 
(Deng, Gao et al. 2014). One-third of mutations cluster within exon 3 to 6, encoding for SYGQ- 
and RGG1-domains. R521C and R521H are the most common ALS-causing FUS-NLS 
mutations and lead to a typical late disease onset (Kwiatkowski, Bosco et al. 2009). In contrast, 
FUS-P525L mutation is associated with an early onset (in the 20s or even earlier) and rapid 
disease progression (Dormann, Rodde et al. 2010, Conte, Lattante et al. 2012). Thus, disease 
onset and course of disease highly depend on the severity of the underlying FUS mutation.  
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Neuropathological features in FUS-associated ALS include the loss of MN. It was found, 
that MN loss in FUS-ALS patients is most severe in the spinal cord, while within brainstem MN 
loss occurs to a lesser degree, and loss of UMN within the motor cortex occurs at moderate to 
mild levels only (Deng, Gao et al. 2014). Hallmark neuropathology of FUS-ALS is a cytoplasmic 
mislocalization of mutant FUS, followed by formation of cytoplasmic inclusions (Vance, Rogelj 
et al. 2009, Bosco, Lemay et al. 2010, Dormann, Rodde et al. 2010, Gal, Zhang et al. 2011, 
Kino, Washizu et al. 2011, Niu, Zhang et al. 2012, Zhang and Chook 2012, Vance, Scotter et 
al. 2013, Wang, Pan et al. 2013, Deng, Gao et al. 2014). FUS positive inclusions can be found 
within the nucleus as well, however to a much lesser extent than cytoplasmic ones (Vance, 
Rogelj et al. 2009, Verbeeck, Deng et al. 2012). Moreover, the severity of the underlying FUS 
mutation was found to affect FUS inclusion formation. FUS-R521C mutation, causing a rather 
slow disease progression, is associated with a more widespread FUS pathology, including glial 
and neuronal cells (Blair, Williams et al. 2010, Hewitt, Kirby et al. 2010, Rademakers, Stewart 
et al. 2010, Suzuki, Aoki et al. 2010). In general, FUS positive inclusion were distributed more 
widely in neurons and glia from patient with longer disease progression than observed in fast 
progressing cases (Suzuki, Kato et al. 2012, Deng, Gao et al. 2014). Severity of FUS mutation 
also affects the type of aggregates, e.g. if rather round inclusions are formed, as associated 
with FUS-P525L, or if more tangle-like inclusion can be found as observed in FUS-R521C 
carriers (Mackenzie, Ansorge et al. 2011). FUS-associated neuropathology in ALS needs 
further characterization, given the variability of FUS pathology in patients with different 
mutations (and even among individuals with the same mutation)(Huang, Zhang et al. 2010, 
Mackenzie, Rademakers et al. 2010, Deng, Gao et al. 2014).  
 
   
Figure 1.1 FUS domain structure. 
The illustration shows human FUS protein domain structure and ALS-associated mutations. Red marked 
mutations are object of this study. The illustration was adopted by Dormann & Haas 2011 and modified 
by the author of this study.  
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1.2.2 Chromosome 9 open reading frame 72 (C9ORF72) 
The gene C9ORF72, located on chromosome 9, confers for three transcriptional variants 
that can be translated into two possible protein isoforms (Rohrer, Isaacs et al. 2015). C9ORF72 
contains a hexanucleotide GGGGCC (G4C2) repeat region either in the promoter region or in 
intron 1 of the gene, depending on the transcript variant (Figure 1.2).  The normal repeat size 
in healthy individuals, in most cases, is in the range of 1 to 40 G4C2 repeat units (Renton, 
Majounie et al. 2011). Repeat lengths larger than 50 units are considered to be pathogenic. Of 
note, in individual cases repeat lengths of only 20 to several hundred have been linked to ALS 
(Buchman, Cooper-Knock et al. 2013, Dobson-Stone, Hallupp et al. 2013, Gomez-Tortosa, 
Gallego et al. 2013, Byrne, Heverin et al. 2014, Dols-Icardo, Garcia-Redondo et al. 2014) but 
also to healthy control individuals (Simon-Sanchez, Dopper et al. 2012, Beck, Poulter et al. 
2013). Clear pathogenic repeats consist of several hundred to several thousand G4C2 repeat 
units (Renton, Majounie et al. 2011, Beck, Poulter et al. 2013, van Blitterswijk, DeJesus-
Hernandez et al. 2013).  
 
 
Figure 1.2 The C9ORF72 gene and transcript variants. 
The illustration shows the C9ORF72 gene and its three possible transcription variants. Exons are 
depicted as boxes and the G4C2 hexanucleotide repeat region is depicted as a red circle. Possible 
repeat lengths are depicted below as chains of red circles with their pathogenic relation. The illustration 
was adopted from Rohrer et al. 2015 and modified by the author of this study. 
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The G4C2 hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most 
common cause for FTD and ALS (DeJesus-Hernandez, Mackenzie et al. 2011, Renton, Chio 
et al. 2014). C9ORF72-HRE mutations can cause either FTD or ALS alone, or a combination 
of both (Rohrer, Isaacs et al. 2015). Cognitive or behavioral impairment seem to be much more 
common in ALS with C9ORF72-HRE than in those cases caused by other mutations 
(Millecamps, Boillee et al. 2012, Montuschi, Iazzolino et al. 2015). Patients with C9ORF72-
HRE, who present initial ALS-associated symptoms, are often indistinguishable from classic 
ALS (Rohrer, Isaacs et al. 2015). On a cellular level, C9ORF72-HRE carriers typically show 
the formation of neuronal inclusions containing TDP43, irrespective of the clinical phenotype. 
Unique for C9ORF72-associated neuropathology is the formation of ubiquitin and p62 positive 
neuronal inclusion that are negative for TDP43 (Ash, Bieniek et al. 2013, Mackenzie, Arzberger 
et al. 2013, Mori, Weng et al. 2013, Schludi, May et al. 2015). Those inclusions are typically 
positive for C9ORF72-specific dipeptide repeat (DPR) proteins. 
How C9ORF72-HRE causes neurodegeneration is controversially discussed and loss- and 
gain-of-function hypotheses exit (Gendron, Bieniek et al. 2013, Gendron, Belzil et al. 2014, 
Rohrer, Isaacs et al. 2015, Taylor, Brown et al. 2016)(Figure 1.3). Loss of function is associated 
with a decreased expression of C9ORF72 in various cell types carrying the G4C2 repeat 
expansion (Donnelly, Zhang et al. 2013, Sivadasan, Hornburg et al. 2016). Gain of function 
mechanisms are thought to be conferred by the accumulation of toxic RNA foci (DeJesus-
Hernandez, Mackenzie et al. 2011, Gendron, Bieniek et al. 2013) and DPR-mediated toxicity 
(Mori, Arzberger et al. 2013, Mori, Weng et al. 2013, Zu, Liu et al. 2013).  
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Figure 1.3 Potential mechanism of neurodegeneration due to C9ORF72 G4C2 repeat expansion. 
Potential mechanisms leading to neurodegeneration in C9ORF72-HRE-associated ALS include: loss of 
function (1), toxicity conferred by accumulating RNA (2), and DPR-mediated toxicity (3). The illustration 
was adopted from Rohrer et al. 2015.  
1.3 Putative disease mechanisms in ALS 
The identification of mutant SOD1 as an ALS-causing gene set the start point of an era of 
investigation of possible molecular pathomechanisms underlying ALS (Rosen 1993). Despite 
26 years of research on SOD1, no consensus of the main toxicity conferred by mutant SOD1 
has emerged. Similar is true for ALS-associated genes C9ORF72 and FUS. The precise 
mechanisms by which mutations in those genes cause ALS are still poorly understood. 
Nevertheless, various possible mechanisms have been identified (some depending on the 
underlying mutation, some independent of it), including protein aggregation, non-cell 
autonomous toxicity, axonal transport defects, prion-like spreading, and impaired RNA 
metabolism (Taylor, Brown et al. 2016). The following chapters will summarize putative 
mechanisms involved in ALS neurodegeneration with relevance to FUS- and C9ORF72-
associatted ALS. 
1.3.1 Protein aggregation 
The formation of cytoplasmic protein aggregates is a hallmark pathology of sporadic and 
familial ALS (Nishihira, Tan et al. 2008, Zhang, Tan et al. 2008, Blokhuis, Groen et al. 2013, 
Mori, Arzberger et al. 2013, Ederle and Dormann 2017). The accumulation of proteins is 
thought to be a key event in ALS neuropathology. Various mechanisms have been proposed 
how protein aggregates form and how they contribute to disease. However, if aggregation is 
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cause or consequence of ALS pathology is still under debate. Predominately, ubiquitinated 
aggregates can be found in ALS patients (Blokhuis, Groen et al. 2013), but otherwise protein 
aggregation seems to depend on the underlying mutation. 
1.3.1.1 FUS 
The formation of FUS positive cytoplasmic protein aggregates is a hallmark of FUS-
associated ALS. Nuclear import defects that are caused by a disrupted NLS are thought to be 
a key event in ALS pathology (Dormann, Rodde et al. 2010, Dormann and Haass 2011, 
Dormann, Madl et al. 2012, Zhang and Chook 2012). As aforementioned, most FUS mutations 
cluster in the C-terminal part of the protein. Those mutations typically lead to a cytoplasmic 
mislocalization of FUS, which is followed by the formation of cytoplasmic FUS positive 
inclusions (Vance, Rogelj et al. 2009, Bosco, Lemay et al. 2010, Dormann, Rodde et al. 2010, 
Gal, Zhang et al. 2011, Kino, Washizu et al. 2011, Zhang and Chook 2012, Vance, Scotter et 
al. 2013, Wang, Pan et al. 2013). The amount of mislocalized FUS was shown to depend on 
the severity of the underlying mutation (Dormann, Rodde et al. 2010, Japtok, Lojewski et al. 
2015, Higelin, Demestre et al. 2016). Mutant FUS causing an early disease onset (e.g. FUS-
P525L and FUS-R495X) shows a severe cytoplasmic mislocalization, while typical late-onset 
mutations (FUS-R521C/G/H) show only mild cytoplasmic expression and remain mainly 
nuclear. 
FUS also contains a prion-like domain within its SYGQ- and RGG2 region (King, Gitler et 
al. 2012). Even though, mutations within this region are associated with ALS, this domain was 
shown to be necessary but not sufficient to induce FUS aggregation and toxicity (Sun, Diaz et 
al. 2011). This means that the prion-like domain within FUS makes it prone for aggregation. 
Sun et al. and others hypothesize furthermore, that FUS-associated pathology is caused by a 
prion-like propagation of misfolded or aggregated FUS protein (Figure 1.4)(Polymenidou and 
Cleveland 2011, King, Gitler et al. 2012). Aggregation transmission can be explained by the 
ability of prion-like proteins to convert normal protein conformation into an infectious state that 
is susceptible to aggregation (Blokhuis, Groen et al. 2013).  
Moreover, mutant FUS proteins are shown to incorporate into stress granules (SGs) upon 
different types of cellular stress, where mutant FUS can bind and sequester normal FUS into 
SGs (Figure 1.4) (Andersson, Stahlberg et al. 2008, Bosco, Lemay et al. 2010, Dormann, 
Rodde et al. 2010, Bentmann, Neumann et al. 2012, Li, King et al. 2013, Vance, Scotter et al. 
2013). If stress is sustained, FUS-positive SGs are thought to turn into irreversible protein 
aggregates (Ling, Polymenidou et al. 2013). However, it was also shown that recruitment into 
SGs rather protects cytoplasmic FUS from irreversible aggregation (Shelkovnikova, Robinson 
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et al. 2013). Thus, if SGs function as a disease initiating event followed by aggregation during 
disease progression needs to be further investigated. 
Various mechanisms, such as SG formation and prion-like spreading, are proposed to 
cause neurodegeneration in FUS-ALS. However, the precise underlying functional 
mechanisms are still unclear. Therefore, further investigations are needed to find the 
consensus of how pathological FUS aggregates confer toxicity in ALS. 
 
 
Figure 1.4 Potential mechanisms of FUS-associated neuropathology. 
Normal FUS localizes to the nucleus but is also able to shuttle to the cytoplasm (1). Mutations within the 
nuclear localization signal (NLS) of FUS make the protein prone to cytoplasmic mislocalization. 
Cytoplasmic FUS is incorporated into stress granules upon cellular stress (2). When stress resolves, 
the stress granules rapidly dissociate and release sequestered RNAs and FUS protein, which resume 
their normal function. Sustained stress causes mutant FUS to form irreversible aggregates either directly 
or because FUS mutations impair SG disassembly (3). A prion-like transmission from cell to cell of FUS 
aggregates possibly causes FUS-associated pathology. The illustration was adopted from Deng et al. 
2014.  
1.3.1.2 C9ORF72 
The G4C2 repeat sequence, located upstream of the C9ORF72 coding region, does not 
possess an ATG start codon. In carriers with C9ORF72-HRE, the expanded repeat sequence 
is unconventionally translated via repeat-associated non-ATG dependent (RAN) translation. 
RAN translation of C9ORF72-HRE furthermore results in the generation of five DPR species: 
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glycine-alanine (GA) and glycine-arginine (GR) DPRs from the sense RNA strand; glycine-
proline (GP), proline-alanine (PA), and proline-arginine (PR) DPRs from the antisense RNA 
strand (Ash, Bieniek et al. 2013, Gendron, Bieniek et al. 2013, Mori, Arzberger et al. 2013, 
Mori, Weng et al. 2013, Zu, Liu et al. 2013). All five DPR species can be found in neuronal 
inclusion in C9ORF72-HRE carriers.  
Various cell- and animal models showed the toxicity induced by the expression of DPRs 
(Wen, Tan et al. 2014, Freibaum, Lu et al. 2015, Ohki, Wenninger-Weinzierl et al. 2017). 
However, those models work with an overexpression, which exceeds endogenous levels and 
can cause an aggravation of observed pathologies. In post-mortem tissue, DPRs are 
detectable at high levels in cortical regions, hippocampus and cerebellum but only at low 
amount in spinal cord (Ash, Bieniek et al. 2013, Mackenzie, Arzberger et al. 2013, Schludi, 
May et al. 2015). DPRs predominantly accumulate in cytoplasmic aggregates. Thereby, Poly-
GA, Poly-GP, and Poly-GR are shown to be far more abundant than Poly-PR and Poly-PA 
(Gendron, Bieniek et al. 2013, Mori, Weng et al. 2013). The role of DPRs in the 
pathophysiology in patients with C9ORF72-HRE mutation is yet unclear since it was shown 
that the anatomical distribution of DPR inclusions does not correlate with neurodegeneration 
measured by classical neuropathology techniques as well as TDP43 aggregation (Mackenzie, 
Arzberger et al. 2013).  
DPR positive inclusions were shown to be positive for ubiquitin and p62 but negative for 
TDP43, which makes them a unique characteristic of C9ORF72-ALS (Ash, Bieniek et al. , 
Mackenzie, Arzberger et al. 2013, Mori, Arzberger et al. , Schludi, May et al. 2015). 
Nevertheless, TDP43-positive ubiquitinated cytoplasmic inclusions are a hallmark pathology 
of ALS (Neumann, Sampathu et al. 2006, Mackenzie, Neumann et al. 2009) and are also found 
in neurons and glial cells of almost all C9ORF72-HRE carriers (Zu, Liu et al. 2013, Gendron, 
Belzil et al. 2014, Mann 2015). In contrast to DPR positive inclusions, TDP43 positive 
aggregates are most abundant in spinal MNs and are found to lesser extent in cortical regions. 
This TDP43 pattern much better correlates with neurodegeneration in these ALS patients. 
(Mackenzie, Arzberger et al. 2013). Cytoplasmic mislocalization and aggregation of TDP43 
are, moreover, associated with the nuclear clearance of the protein (Lee, Lee et al. 2011) 
(Neumann, Sampathu et al. 2006).  
In summary, the accumulation of DPRs is a characteristic pathology in C9ORF72-
associated disease. Overexpression in vitro models show a DPR-induced toxicity while its role 
in human neuropathophysiology is still unclear, since only the aggregation formation of TDP43 
in C9ORF72-HRE carriers is correlated with motor neuron degeneration not DPR 
accumulation. As post-mortem tissue only recapitulates the end-stage of the disease and 
overexpression models possibly accelerate phenotypes, in vitro models are needed that 
express endogenous levels of C9ORF72-HRE.  
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1.3.2 DNA damage 
The human genome is constantly modified by endogenous (e.g. mitochondrial respiratory 
metabolites) and exogenous/environmental factors (e.g. air pollutants, chemicals, UV light) 
(Lindahl 1993). It is estimated that, in a mammalian genome, each day ~105 DNA lesions are 
produced due to spontaneous decay, replication errors, and cellular metabolism (Hoeijmakers 
2009). Persisting DNA damage can cause mutagenesis and can further lead to cell death 
(Iyama and Wilson 2013). To avoid this, cells evolved multiple DNA damage repair (DDR) 
pathways to maintain their genome integrity. 
Different types of DNA damage can occur,  including double strand breaks (DSBs), single 
strand breaks (SSBs), DNA-protein cross-links, or insertion/deletion mismatches (Rao 1993), 
each repaired by specialized DDR pathways. DSBs are the most deleterious form of DNA 
damage, as they promote genome instability and cell death if unrepaired (Jackson and Bartek 
2009, Bohgaki, Bohgaki et al. 2010). DSBs are repaired via two major pathways: homologous 
recombination (HR) or non-homologous end joining (NHEJ) (Iyama and Wilson 2013). HR is 
considered to be error-free and acts in particular in dividing cells, as it requires a sister 
chromatid for repair (Rulten and Grundy 2017). NHEJ is considered an error-prone pathway, 
because it directly ligates broken ends and does not require a template as replication-
dependent HR (Madabhushi, Pan et al. 2014). NHEJ is independent of cell cycle and can act 
in dividing and non-dividing cells. 
This difference is of note, because the human body consists of various cell types which are 
either in a dividing or non-dividing state (Iyama and Wilson 2013). Most cells in the body are 
in a non-dividing state, e.g. terminally differentiated such as neurons. They are post-mitotic 
cells that under physiological conditions do not re-enter cell cycle. This makes them highly 
vulnerable to DNA damage (Penndorf, Witte et al. 2018) and makes DNA damage a crucial 
pathomechanism causing neurodegenerative disease and particularly ALS (Coppede 2011, 
Madabhushi, Pan et al. 2014, Coppede and Migliore 2015).  
The investigation of DNA damage as a possible pathomechanism underlying ALS is a very 
wide field itself. The analyzed cell type (proliferative or post-mitotic), the type of DNA damage 
(SSB, DSB, etc.), and responsible DDR pathways need to be taken into account. Further 
research is needed to determine precise mechanisms of how DNA damage causes 
neurodegeneration and if it is cause or consequence of ALS-associated mutations. 
1.3.2.1 FUS 
Wild type (WT) FUS was shown to play an active role in DDR (Wang, Pan et al. 2013). FUS 
is recruited to laser-induced DNA damage sites (Mastrocola, Kim et al. 2013, Naumann, Pal 
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et al. 2018) and binds to DSBs marked by γH2AX   staining (Mastrocola, Kim et al. 2013, 
Wang, Pan et al. 2013). Similar to C9of72-HRE mutant cells, ALS-associated FUS mutations 
lead to increased DNA damage in patient-specific spinal MNs (Higelin, Demestre et al. 2016, 
Naumann, Pal et al. 2018). There as well, an accumulation of DNA damage could only be 
observed in post-mitotic neurons, but not in iPSCs (Higelin, Demestre et al. 2016). Moreover, 
Qiu et al. could show increased DNA damage in mouse primary cortical neurons 
overexpressing mutant FUS as well as in human cortical postmortem tissue (Qiu, Lee et al. 
2014). Wang et al. further showed increased γH2AX levels in transgenic mice spinal cord and 
cortex (Wang, Pan et al. 2013).  
1.3.2.2 C9ORF72 
The exact underlying mechanisms of how C9ORF72-HRE causes ALS is still unclear but 
various studies implicate a role of DNA damage in C9ORF72-ALS pathology (Konopka and 
Atkin 2018). Elevated levels of DNA damage were reported in C9ORF72-HRE mutant 
postmortem tissue as well as in iPSC-derived motor neurons (Lopez-Gonzalez, Lu et al. 2016, 
Farg, Konopka et al. 2017, Walker, Herranz-Martin et al. 2017, Higelin, Catanese et al. 2018). 
. Farg and colleagues found increased DNA damage levels in lumbar MNs from C9ORF72-
ALS patients (Farg, Konopka et al. 2017). Further they showed, that overexpression of DPRs 
in mouse primary cortical neurons and in human neuroblastoma cells induced accumulation of 
DNA damage. Higelin and colleagues could show that patient-specific iPSC-derived spinal 
MNs, but not induced pluripotent stem cells (iPSCs), show increased DNA damage in HRE 
expressing cells (Higelin, Catanese et al. 2018), highlighting the vulnerability of neurons to 
mutation-mediated DNA damage or mutation-mediated insufficiency of DDR. C9ORF72 is not 
known to be directly involved in DDR pathway, however it was shown that accumulation 
together with defective ATM-signaling is a pathological consequence of C9ORF72-HRE 
(Walker, Herranz-Martin et al. 2017).  
1.3.3 Organelle trafficking 
With axons reaching over one meter in length, MNs are one of the most asymmetrical cell 
type in the human body (Millecamps and Julien 2013, Taylor, Brown et al. 2016). Due to these 
long cell processes, they rely on functional transport of various cellular organelles from the cell 
body (soma) to the distal axons and synapses. This includes for example the transport of 
mRNA, ribosomes, and translational factors for local protein synthesis at distal sites. Organelle 
trafficking also includes functional clearance of recycled or misfolded proteins. Two categories 
of axonal transport exits: fast axonal transport for membrane-bound organelles (vesicles and 
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mitochondria) and slow axonal transport of cytoplasmic and cytoskeletal proteins (Millecamps 
and Julien 2013).  
Various studies in recent years showed axonal trafficking defects in neurodegenerative 
diseases (Sheetz, Pfister et al. 1998, Millecamps and Julien 2013, Guo, Naujock et al. 2017, 
Hasegawa, Sugeno et al. 2017, Kreiter, Pal et al. 2018, Naumann, Pal et al. 2018).  In ALS 
models, mutations within TARDBP and SOD1 lead to impaired axonal organelle trafficking 
(Williamson and Cleveland 1999, Perlson, Jeong et al. 2009, Perrot and Julien 2009, Alami, 
Smith et al. 2014, Kreiter, Pal et al. 2018). In a SOD1 ALS model, axonal trafficking defects 
could be observed before onset of neurodegeneration.  
The same is true for the ALS-associated gene FUS. Severe distal axonal trafficking defects 
of mitochondria and lysosomes precede neurodegeneration in patient-specific FUS mutant MN 
cultures (Naumann, Pal et al. 2018). In this context, Guo and colleagues could show 
progressive axonal transport defect, accumulating during aging of patient-specific MN cultures 
(Guo, Naujock et al. 2017). 
With regard to C9ORF72, the protein was found to regulate endosomal trafficking and 
possibly affect trafficking in ALS patients (Farg, Sundaramoorthy et al. 2014). Aoki et al. found 
an interaction between C9ORF72 and RAB7L1 which is disrupted in presence of HRE mutation 
due to downregulation of C9ORF72. This disrupted interaction results further in defect 
intracellular and extracellular trafficking (Aoki, Manzano et al. 2017).Impaired axonal trafficking 
is thought to be a key pathological event causing ALS. However, how exactly defects in 
organelle trafficking cause neurodegeneration is still under debate. 
1.4 ALS disease modeling 
1.4.1 Animal models 
Various model systems exist in ALS research. Rodent models (mouse and rat) have been 
the gold standard to investigate ALS disease pathology for decades (Van Damme, Robberecht 
et al. 2017). Due to their high homology to humans, rodent models allow detailed mechanistic 
studies with relevance to human physiology. The first ALS mouse model, overexpressing 
human mutant SOD1, came up in 1994 and was intensively investigated since then (Gurney, 
Pu et al. 1994). Even though there are new rodent models existing for ALS-associated proteins 
such as SOD1, TDP43, FUS, and C9ORF72 (Turner and Talbot , Gendron and Petrucelli , 
Philips and Rothstein , Nolan, Talbot et al.), much of our current understanding  of disease 
mechanisms is still based on this first SOD1 model (Gurney, Pu et al. 1994). Rodent models 
are expensive to maintain, complicated to generate, and do not allow to test for multiple 
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hypotheses at the same time (Van Damme, Robberecht et al. 2017). Therefore, model systems 
are needed that are easier to access. 
Small animal models are the second model system important in ALS research. The 
generation of transgenic strains is fast and cheap, and various tools for genomic modification 
exist (Van Damme, Robberecht et al. 2017). The most widely used small animal model in ALS 
research is Drosophila melanogaster, followed by Ceanorhabditis elegans and Danio rerio.  All 
three possess a rapid life cycle and are well-suited for high throughput analysis, e.g. for drug 
testing screens. However, small animal models lack the complex interplay between MNs and 
their environment as it is found in rodents or even human beings. It is also of note that many 
small animal models, as well as rodent models, most often use overexpression of mutant 
proteins to mimic human disease. Furthermore, treatments developed in both, small animal 
and rodent models, never lead to effective therapeutics in human trials (Swarup and Julien 
2011, Van Damme, Robberecht et al. 2017). To overcome these issues, cellular patient-
derived models have been upcoming in recent years to investigate disease mechanisms in 
vitro on a patient-specific basis.  
1.4.2 Patient-specific models 
The breakthrough discovery to reprogram human somatic cells to an embryonic-like state 
has been of great interest for the medical and scientific communities. So called induced 
pluripotent stem cells (iPSCs) can be derived by the overexpression of pluripotency genes in 
human somatic cells such as fibroblasts (Takahashi, Tanabe et al. 2007, Yu, Vodyanik et al. 
2007). The pluripotent nature of iPSCs allows them to become any cell type of the adult human 
body. This is of great interest for scientific investigations, because iPSCs can be differentiated 
into any cell type of interest including MNs to study ALS pathology in vitro (Burkhardt, Martinez 
et al. 2013, Matus, Medinas et al. 2014, Maury, Come et al. 2015, Sances, Bruijn et al. 2016). 
As shown in Figure 1.5, many aspects of ALS neuropathology could be recapitulated and 
putative underlying mechanisms have already been determined by the use of patient-specific 
iPSC-derived MNs.  
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Figure 1.5 Discovery of molecular mechanisms underlying ALS pathology using patient-specific 
iPSC-derived motor neurons. 
Fibroblast, derived from humans, can be used to generate iPSCs by the overexpression of pluripotency 
genes. iPSCs can be used further for differentiation into motor neurons, which are affected in ALS 
pathology. Recent studies using human motor neuron cultures from ALS patients with distinct genetic 
mutations have identified transversal pathological mechanisms, including abnormal protein and RNA 
aggregation, hyperexcitability, morphological alterations, and cell death. The illustration was adopted 
from Matus et al. 2014.   
Various protocols exist for the differentiation of iPSCs into spinal and cortical MNs 
(Burkhardt, Martinez et al. 2013, Reinhardt, Glatza et al. 2013, Sances, Bruijn et al. 2016). 
Most studies in recent years concentrated on the investigation of spinal MNs, for which many 
protocols exist which result in a good MN outcome. Spinal MNs can be differentiated using 
iPSC-derived neural progenitor cells (NPCs) (Reinhardt, Glatza et al. 2013). This makes them 
relatively easily accessible, because once patient-specific NPCs are generated, they can be 
expanded in culture or frozen away if not needed. Furthermore, fully mature spinal MNs can 
be derived already after 2 to 3 weeks of differentiation. The modeling of ALS in cortical MNs 
(also upper MNs) is not this straightforward. The cerebral cortex consists of various types of 
projection neurons, from which upper MNs are only a relatively rare subtype (Molyneaux, 
Arlotta et al. 2007, Sances, Bruijn et al. 2016). Furthermore, the generation of cortical neurons 
is more complex due to long differentiation times (2 to 4 months) and the need to use iPSCs 
(not NPCs) as starting cell type (Mariani, Simonini et al. 2012, Shi, Kirwan et al. 2012, Shi, 
Kirwan et al. 2012, Burkhardt, Martinez et al. 2013). This makes the evaluation of cortical 
neurons in ALS research rare, until now. Nevertheless, the use of patient-specific iPSCs is 
nowadays an important tool for modeling disease because they can be generated relatively 
easy and provide a good balance between throughput and relevance to human disease 
(Matus, Medinas et al. 2014). 
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1.4.3 CRISPR/Cas9 gene editing 
One challenge remains if patient-specific iPSC models are used to study disease-
associated pathology: the patient’s genetic background. For scientific investigation it is state-
of–the-art to compare several iPSC lines derived from different healthy individuals and different 
diseased patients. As abovementioned, pathological phenotypes associated with ALS-causing 
mutations highly depend on the underlying mutation. Some mutations might only cause a 
subtle phenotype. Due to that, sometimes it could be difficult to determine if such a phenotype 
is caused by the mutation itself or by the genetic background of the patient. To overcome this 
problem, the use of isogenic iPSC lines is recently becoming a crucial tool in ALS research 
and disease modeling systems altogether (Higelin, Demestre et al. 2016, Marrone, Poser et 
al. 2018, Naumann, Pal et al. 2018). An isogenic line is a cell line that has been generated 
from a parental line in which a gene modification was introduced (either induction of mutation 
or correction of mutation) (StemCell 2018). The generated modified iPSC line and the 
unmodified parental line can be easily compared with each other because both lines possess 
the same genetic background (=isogenic). Thus, phenotypes observed in experimental 
approaches most likely represent the result from the genotype and not the patient’s genetic 
background. 
Only recently, a new versatile and robust tool for targeted gene editing was established to 
easily generate isogenic iPSC lines: the Clustered Regularly Interspaced Short Palindromic 
Repeat (CRISPR)-associated 9 system (short CRISPR/Cas9). Cas9 nuclease, derived from 
Streptococcus pyogenes, can be directed by single guide RNAs (sgRNA) to any genomic locus 
of interest (Deveau, Garneau et al. 2010, Deltcheva, Chylinski et al. 2011, Jinek, Chylinski et 
al. 2012, Hsu, Scott et al. 2013, Ran, Hsu et al. 2013)(Figure 1.6). To improve specificity of 
Cas9-mediated gene editing, the D10A mutant nickase version of Cas9 (Cas9n) can be used 
(Gasiunas, Barrangou et al. 2012, Jinek, Chylinski et al. 2012, Cong, Ran et al. 2013, Ran, 
Hsu et al. 2013) (Figure 1.7). By nicking both DNA strands at the target site by a pair of sgRNA-
Cas9n complexes, the introduction of DSBs can be mimicked which triggers DDR pathways 
such as NHEJ and HR. This, in turn, can be used to correct disease-causing gene mutations 
or to generate ALS-associated mutations in WT iPSC lines to generate isogenic lines (Kiskinis, 
Sandoe et al. 2014, Sances, Bruijn et al. 2016).  
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Figure 1.6 CRISPR/Cas9-mediated gene editing. 
Single guide RNA (sgRNA) can be designed to specifically target the genomic locus of interest. sgRNAs 
recognize the genomic sequence followed by a PAM sequence, which recruits Cas9 endonuclease to 
the target site. Cas9 then introduces DSBs that are either repaired by NHEJ or HDR. NHEJ is error-
prone and can results in the formation of indels that disrupt the gene. HDR, in the presence of a donor 
constructs, can be used to introduce aimed genomic modifications as it needs a template for DSB repair. 
The illustration was adopted from Cribbs and Perera 2017.  
 
 
Figure 1.7 D10A mutant nickase version of Cas9 (Cas9n). 
By the use of Cas9n, specificity of Cas9-mediated gene editing can be improved because two individual 
sgRNAs are used to guide two Cas9n enzymes to the target site. By the nicking of both DNA strands 
by a pair of Cas9 nickases, site-specific DSBs can be mimicked further triggering HDR (Ran, Hsu et al. 
2013). The illustration was adopted from GenScript website (GenScript 2019).  
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1.5 Objective of the thesis 
Overall aim of this thesis work is the modeling of FUS- and C9ORF72-associated ALS in a 
disease-related in vitro model of particularly cortical neuropathology using patient-derived 
iPSCs.  
 
Specific questions of this thesis are: 
 Can hallmark neuropathology of FUS- and C9ORF72-associated ALS be 
recapitulated in patient-specific iPSC-derived cortical neurons and astrocytes? 
 Are there differential cell type dependent phenotypes between cortical neurons vs. 
astrocytes and cortical vs. spinal neurons? 
 
To achieve abovementioned aim, human iPSCs derived from healthy controls and ALS 
patients carrying mutations within FUS or C9ORF72 were used for directed cortical and spinal 
differentiation. Additionally, two new FUS-WT and FUS-P525L EGFP-tagged isogenic iPSC 
lines were generated by CRISPR/Cas9n gene editing. To analyze disease-related phenotypes 
in patient-specific in vitro cultures, immunofluorescence staining followed by fluorescence 
microscopy were conducted. Analysis included the evaluation of cortical differentiation 
potential, DNA damage markers γH2AX and 53BP1, FUS-EGFP cellular localization, and 
aggregation of C9ORF72-associated DPRs and TDP43. Live cell imaging approaches were 
used to analyze DNA damage in the context of FUS mutation by the analysis of FUS-EGFP 
recruitment to laser-induced DNA damage sites. Moreover, compartmentalized culture 
systems were used to evaluate motility parameters of axonal organelle trafficking by live 
imaging of lysosomes and mitochondria.  
The results of these experiments should help to augment knowledge on cortical 
neuropathology in ALS and highlighting differences and importance of the herein analyzed cell 
types. Using patient-specific iPSCs, disease-related phenotypes can be analyzed on 
physiological conditions without any need of overexpression or knockdown of ALS-associated 
proteins. Therewith, the presented thesis work is the first to use patient-specific iPSCs to model 
in particular cortical neuropathology of FUS- and C9rof72-associated ALS.  
 
Materials and methods 
28 / 163 
2 Materials and methods 
2.1 Materials 
2.1.1 Instruments 
Table 2.1 Instruments 
Instrument Company 
Analytical Balance - CP225D-0CE Satorius AG, Göttingen, GER 
Balance - SBA 52 Scaltec Instruments GmbH, Heiligenstadt, GER 
Cell culture Microscope – Axiovert 35 Carl Zeiss, Jena, GER 
Centrifuge – 5403 Eppendorf, Hamburg, GER 
Centrifuge - Biofuge Pico Thermo Fisher Scientific, Massachusetts, USA 
Centrifuge - Biofuge Primo Thermo Fisher Scientific, Massachusetts, USA 
Centrifuge - MiniSpinPlus Eppendorf, Hamburg, GER 
Fluorescence Microscope - AFLX6000 TIRF Leica Camera, Wetzlar, GER 
Fluorescence Microscope – Axiovert 200M Carl Zeiss, Jena, GER 
Fluorescence Microscope - Observer.Z1 Carl Zeiss, Jena, GER 
Gel documentation - Dunkelhaube D4 Biostep GmbH, Burkhardtsdorf, GER 
Gel electrophoresis - E865 Consort, Turnhout, BEL 
Gel electrophoresis PSU - EPS 600 Pfizer, New York, USA  
Hemocytometer - Neubauer improved Paul Marienfeld GmbH Co. KG, Lauda-
Königshofen, GER 
Hybridization oven - HB-1000  UVP, Upland, CAN 
Hyvridization oven - OV3 Biometra GmbH, Göttingen, GER 
Imager - LAS3000 Fujifilm, Tokyo, JPN 
Incubator - Heracell 150 Thermo Fisher Scientific, Massachusetts, USA 
Incubator - Heracell 150i Thermo Fisher Scientific, Massachusetts, USA 
Laminar Flow hood - Clean Wizard V 100 Kojair Tech Oy, Vilppula, FIN 
Laminar Flow hood – Herasafe HS Thermo Fisher Scientific, Massachusetts, USA 
Multichannel multistep pipette-Transferpipette-8 Brand GmbH & Co. KG, Wertheim, GER 
PCR cycler – Mastercycler gradient Eppendorf, Hamburg, GER 
pH meter - inoLab ph 720 Wtw GmbH, Weilheim, GER 
Photometer - Biophotometer Eppendorf, Hamburg, GER 
Real time PCR cycler - MX3000P  Agilent, Santa Clara, USA 
Shaker – incubating orbital shaker 3500l VWR International, Radnor Township, USA 
Shaker – RotaMax 150 Heidolph, Schwabach, GER 
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Stereo preparation microscope - Stemi 
DV4SteREO CL 1500 ECO 
Carl Zeiss, Jena, GER 
Thermomixer – Thermomixer 5436 Eppendorf, Hamburg, GER 
Thermomixer – Thermomixer Comfort Eppendorf, Hamburg, GER 
Transiluminator – BioView UST 30M-8R Biostep GmbH, Burkhardtsdorf, GER 
Water bath  Memmert GmbH & Co. KG, Schwabach, GER 
Water bath - Julambo SW22  JULAMBO Labortechnik GmbH, Seelbach, GER 
Water purification system - GenePure Thermo Fisher Scientific, Massachusetts, USA 
Qubit Fluorometer  Thermo Fisher Scientific, Massachusetts, USA 
 
2.1.2 Chemicals and reagents 
Table 2.2 Chemicals and reagents 
Chemical Manufacturer 
Agarose Biozym Biotech Trading GmbH, Oldendorf, GER 
Ampicillin Carl Roth GmbH & Co. KG, Karlsruhe, GER 
BSA Fraction V Thermo Fisher Scientific, Massachusetts, USA 
Collagenase Type IV Thermo Fisher Scientific, Massachusetts, USA 
DMSO Sigma Aldrich, St. Louis, USA 
DNA ladder Thermo Fisher Scientific, Massachusetts, USA 
Donkey Serum Jackson ImmunoResearch Laboratories Inc.,  
West Grove, USA 
Ethanol VWR International GmbH, Dresden, GER 
Fetal bovine serum Sigma Aldrich, St. Louis, USA 
Fetal calf serum Merck Group, Darmstadt, GER 
Fluoromount SouthernBiotech, Birmingham, USA 
FuGene® HD Promega, Madison, USA 
Gelatine Sigma Aldrich, St. Louis, USA 
Glycerol MP biomedicals, Santa Ana, USA 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, GER 
Isopropanol VWR International GmbH, Darmstadt, GER 
Kanamycin Carl Roth GmbH & Co. KG, Karlsruhe, GER 
Laminin Roche Holding AG, Basel, CHE 
Laminin Sigma Aldrich, St. Louis, USA 
LB Medium Thermo Fisher Scientific, Massachusetts, USA 
Matrigel BD Bioscience, Bedford, USA (556320) 
Mikrozid Schülke&Mayr, Norderstedt, GER 
Midori Green Advance DNA stain Nippon Genetics Europe GmbH, Dueren, GER 
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NaCl Merck Group, Darmstadt, GER 
PBS Thermo Fisher Scientific, Massachusetts, USA 
Paraformaldehyde 4% solution Seipt, Klinikapotheke UKD, 
Poly-L-orthnitine Sigma Aldrich, St. Louis, USA 
Protamin Sulfat Sigma Aldrich, St. Louis, USA 
Penicillin and streptomycin Thermo Fisher Scientific, Massachusetts, USA 
Penicillin, streptomycin, glutamine Thermo Fisher Scientific, Massachusetts, USA 
Sterile RNase-free  water Thermo Fisher Scientific, Massachusetts, USA 
Tris-HCL Carl Roth GmbH & Co. KG, Karlsruhe, GER 
TritonX-100 Thermo Fisher Scientific, Massachusetts, USA 
Tween 20 Serva Elektrophoresis GmbH, Heidelberg, GER 
 
2.1.3 Commercial available kits 
Table 2.3 Commercial available kits 
 
2.1.4 Enzymes 
Table 2.4 Enzymes for cell culture 
 
Table 2.5 Restriction enzymes for cloning 
 
Name Company 
DNeasy Blood & Tissue Kit Qiagen, Hilden, GER 
QIAquick® Gel Extraction Kit Qiagen, Hilden, GER 
QubitTM dsDNA BR Assay Kit Thermo Fisher Scientific, Massachusetts, USA 
ZR Plasmid Miniprep Kit Zymo Research, Irvine, USA 
Name Company 
Accutase Sigma Aldrich, St. Louis, USA 
Dispase Thermo Fisher Scientific, Massachusetts, USA 
Trypsin Thermo Fisher Scientific, Massachusetts, USA 
Name Company 
FastDigest Bpil Thermo Fisher Scientific, Massachusetts, USA 
FastDigest Lgul Thermo Fisher Scientific, Massachusetts, USA 
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2.1.5 Antibodies 
Table 2.6 Primary antibodies 
 
Table 2.7 Secondary antibodies 
Antibody Host & reactive species Dilution Company Reference 
Number 
Alexa Fluor 488 donkey anti mouse IgG 1:500 Molecular Probes A21202 
Alexa Fluor 555  donkey anti mouse IgG 1:500 Molecular Probes A31570 
Alexa Fluor 647 donkey anti mouse IgG 1:500 Molecular Probes A31571 
Alexa Fluor 488 donkey anti rabbit IgG 1:500 Molecular Probes A21206 
Alexa Fluor 555 donkey anti rabbit IgG 1:500 Molecular Probes A31572 
Alexa Fluor 594 donkey anti rabbit IgG 1:500 Molecular Probes A21207 
Alexa Fluor 488 goat anti-chicken IgG 1:500 Molecular Probes A11039 
Alexa Fluor 647 donkey anti-Chicken IgY 1:500 Dianova 703295155 
Alexa Fluor 488 donkey anti rat IgG 1:500 Dianova 703605155 
Alexa Fluor 594 donkey anti rat IgG 1:500 Molecular Probes A21208 
Alexa Fluor 647 goat anti-rat IgG 1:500 Dianova 712165150 
Antibody Host Dilution Company Reference Number 
53BP1 Rabbit 1:1000 Novusbio NB100-304 
CTIP2 Rat 1:1000 Abcam ab18465 
FUS Mouse 1:3000 Sigma AMAB90549-100UL 
GATA4 Rabbit 1:500 Abcam ab61170 
GFAP chicken 1:1000 Abcam ab46674 
GFAP Rabbit 1:1000 Abcam ab33922 
MAP2 Chicken 1:2000 Abcam ab5392 
OCT4 Rabbit 1:500 Abcam ab19857 
phHistone H2A.X(Ser139) Mouse 1:500 Millipore #05-636 
Poly-GA (IAI2) Mouse 1:500 Provided by  Prof. Dr. D. Edbauer 
Poly-GP (18H8) Rat 1:1000 Provided by  Prof. Dr. D. Edbauer 
Poly-GR (5H9) Rat 1:1000 Provided by  Prof. Dr. D. Edbauer 
SATB2 Mouse 1:600 Abcam ab51502 
SMA Mouse 1:100 Dako M0851 
SMI32 Chicken 1:10,000 Covance PCK-592P 
SOX2 Mouse 1:200 Millipore MAB4343 
SSEA4 Mouse 1:500 Abcam ab16287 
TARDBP Rabbit 1:300 Abcam ab41972 
TBR1 Rabbit 1:3000 Abcam ab31940 
TRA-1-60 Mouse 1:500 Abcam ab16288 
TUJ1 Mouse 1:1000 Covnce MMS-435P 
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Table 2.8 Fluorescence reporters 
 
2.1.6 Primer 
Table 2.9 List of primer 
2.1.7 Plasmids 
Table 2.10 List of plasmids 
 
Name Dilution Manufacturer (catalog number) 
LysoTracker Red (L7528) 1:20000 Thermo Fisher Scientific, Massachusetts, USA   
MitoTracker DeepRed (M22426) 1:20000 Thermo Fisher Scientific, Massachusetts, USA  
Hoechst33342 (H3570) 1:1333 Thermo Fisher Scientific, Massachusetts, USA  
Primer Name Forward/ 
Reverse 
Sequence (5’-3’) Used for… 
pX335_seq_R Reverse GGAAAGTCCCTATTGGCGTT Sequencing (2.2.1.3) 
FUS-1.3-F Forward CTTGCCTATTCCCCATCGCT Screening PCR (2.2.4.2) 
EGFP Rev 1 Reverse CGGTGGTGCAGATGAACTT Screening PCR (2.2.4.2) 
and Sequencing (2.2.5.1) 
FUS-2.1-F Forward CAGTTGAACAGAGGCCATAGG Genotyping PCR (2.2.4.3) 
FUS-2.1-R Reverse CTCTCTACCTTCCTGATCGGG Genotyping PCR (2.2.4.3) 
FUS-seq-R Reverse TGGGTGATCAGGAATTGGAAGG Sequencing (2.2.5.1) 
Plasmid name Description Source 
pX335B_hCas9_2x sgRNA Cas9n plasmid w/o sgRNAs Dr. Boris Greber (Max Planck 
Institute for Molecular 
Biomedicine, 48149 Münster, 
GER) 
pX335B_FUS_T1+T2 Cas9n plasmid containing 
sgRNA for FUS targeting 
Cloned as part of this thesis 
work 
pEX-K4-FUS-WT-EGFP Plasmid containing template 
for FUS modification 
Synthesized de novo by 
Eurofins Genomics 
pEX-K4-FUS-P525L-EGFP Plasmid containing template 
for FUS modification 
Synthesized de novo by 
Eurofins Genomics 
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2.1.8 Cell culture media, supplements, and consumables 
Table 2.11 Cell culture media and supplements 
 
Table 2.12 Growth factors and small molecules 
 
Table 2.13 Consumables 
Material  Company 
BD Falcon™ Round-Bottom Tube BD Bioscience, New Jersy, USA 
Bottle-top vacuum filters Corning Inc., Corning, USA 
Cell culture Dishes 
(4-,6-,12-,24-,96-well) 
Corning Inc., Corning, USA 
Thermo Fisher Scientific, Massachusetts, USA 
Sarstedt AG & Co., Nümbrecht, GER 
Name Company 
B27-Supplement w/o Vitamin A Thermo Fisher Scientific, Massachusetts, USA 
β-Mercaptoethanol Thermo Fisher Scientific, Massachusetts, USA 
DMEM Thermo Fisher Scientific, Massachusetts, USA 
DMEM F12 Thermo Fisher Scientific, Massachusetts, USA 
Etoposide Sigma Aldrich, St. Louis, USA 
GlutaMAX Thermo Fisher Scientific, Massachusetts, USA 
mTeSR1 Stemcell Technologies, Vancouver, CAN 
N2-Supplement Thermo Fisher Scientific, Massachusetts, USA 
Non Essential Amino Acids Thermo Fisher Scientific, Massachusetts, USA 
Neurobasal Thermo Fisher Scientific, Massachusetts, USA 
ReLeSR Stemcell Technologies, Vancouver, CAN 
TeSR-E8 Stemcell Technologies, Vancouver, CAN 
Name Company 
Activin A Biomol GmbH, Hamburg, GER 
Ascorbic Acid Sigma Aldrich, St. Louis, USA 
BDNF Promega, Madison, USA 
cAMP Sigma Aldrich, St. Louis, USA 
CHIR 99021 Cayman chemical company, Ann Arbor, USA 
Dorsomorphin Tocris Bioscience, Bristol, UK 
GNDF Sigma Aldrich, St. Louis, USA 
Insulin Sigma Aldrich, St. Louis, USA 
PMA Cayman chemical company, Ann Arbor, USA 
ROCK Inhibitor Y-27632 Abcam, Cambridge, United Kingdom 
SAG Cayman chemical company, Ann Arbor, USA 
SB431542 Tocris Bioscience, Bristol, UK 
TGFβ-3 Peprotech, London, UK 
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TPP Techno Plastic Products AG, Trasadingen, CHE 
Cell culture Flasks Corning Inc., Corning, USA 
Cell scraper Carl Roth, Karslruhe, GER 
TPP Techno Plastic Products AG, Trasadingen, CHE 
Centrifuge tubes Greiner Bio-One GmbH, Kremsmünster, AUT 
Costar® Stripette® Corning Inc., Corning, USA 
Cryo preservation tubes, 2 ml Greiner Bio-One GmbH, Kremsmünster, AUT 
Eppendorf tubes 1.5 ml, 2 ml Eppendorf, Hamburg, GER 
Glass Cover Slips Thermo Fisher Scientific, Massachusetts, USA   
Microscope slide glass Thermo Fisher Scientific, Massachusetts, USA   
Microfluidic chambers  Xona Microfluidics LLC, Temecula, USA 
Millex HV low binding PVDV 
membrane filters 0.45 μm 
Merck Millipore, Billerica, USA 
Nalgene® Mr. Frosty Freezing 
Container 
Sigma Aldrich, St. Louis, USA 
Nunc™ glass base dish, 27mm Thermo Fisher Scientific, Massachusetts, USA   
Pipette tips (w & w/o filter) Sarstedt AG & Co., Nümbrecht, GER 
 Biozym Scientific, Hessisch Oldendorf, GER 
 Corning Inc., Corning, USA 
Pipettes Gilson Inc., Middleton, USA 
Eppendorf, Hamburg, GER 
VWR International, Radnor Township, USA 
SafeSeal reaction tubes Sarstedt AG & Co., Nümbrecht, GER 
Serological pipette 5, 10, 25 and 
50ml 
Greiner Bio-One GmbH, Kremsmünster, AUT 
Surgery cap Barrier® Mönlycke Health Care, Erkrath-Unterfeldhaus, GER 
Surgical mask Paul Hartmann AG, Heidenheim, 
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2.1.9 Software 
Table 2.14 Software 
 
2.1.10 Cell lines 
Cell lines used in this thesis work were either generated previously by members of the group 
or obtained from collaborators. All iPSC lines were already fully established and the generation 
and basic characterization was not topic of this theses. An exception from this are the lines 
FUS-WT and FUS-P525L, which were generated as a part of this thesis work. Non-isogenic 
cell lines as well as isogenic once were used to analyze disease-associated phenotypes. The 
study was approved by the local ethics committee (EK45022009).  
Software Type Company 
CellProfiler 2.2.0 Image analysis Open Source (Carpenter, Jones et al. 
2006) 
FIJI 1.48a and 1.52b Image and video analysis Open Source (Schindelin, Arganda-
Carreras et al. 2012)  
GraphPad Prism 7 Statistics GraphPad Software Inc., La Jolla, USA 
KNIME 3.1.2 Data mining and organization KNIME.COM AG, Zurich, CHE 
Photoshop CS6 Image processing Adobe Systems, San Jose, USA 
Photoshop Illustrator CS6 Graphics design Adobe Systems, San Jose, USA 
SerialCloner 2.6.1 Sequence design Open Source 
Snap Gene Viewer 4.0.7 Plasmid design and maps GSL Biotech, Chicago, USA  
Zen 2011 Image acquisition Carl Zeiss AG, Oberkochen, GER 
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Table 2.15 Cell lines 
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2.2 Molecular biology 
2.2.1 Plasmid design and generation for CRISPR/Cas9n-mediated gene editing 
of FUS 
For CRISPR/Cas9n-mediated genome editing an approach described by Ran et al. (2013) 
was used. The CRISPR vector pX335B_hCas9_2x sgRNA (short pX335B) containing the 
D10A mutant nickase version of Cas9 (Cas9n) and a pair of sgRNA was used to create a 
double strand break (DSB) at the target site (Ran, Hsu et al. 2013). The pX335B vector was 
kindly provided by the laboratory of Dr. Boris Greber (Table 2.10). 
2.2.1.1 Design of sgRNA sequences 
Single-guide RNAs were manually selected by screening of the coding strand of FUS for 
suitable sgRNA target sequences upstream of FUS-R521C mutation site (Figure 2.1). DNA 
motifs screened for were CCN(N)19C for target one (T1) and G(N)20NGG for target two (T2). 
Target specific sgRNAs listed in Table 2.16 were selected for CRISPR/Cas9n-mediated gene 
editing of FUS. Each guide consisted of annealed pairs of forward and reverse 
oligonucleotides. Specific 5’-overhanging sequences (CACC- and AAC-) were introduced in 
each oligo to enable successful cloning within pX335B. The PAM sequence is not part of the 
designed sgRNAs.  
 
Table 2.16 Target specific sgRNA sequences for FUS gene editing 
 
Target Target sequence on + 
strand (PAM) 
sgRNA sequence 
5'3'  
Forward 
Oligo (a) 
Reverse Oligo 
(b) 
T1 CCCACTTGAGATAAGATAC
TCGC 
gcgagtatcttatctcaagt CACCgcgagt
atcttatctcaagt 
AAACacttgagata
agatactcgc 
T2 GTTAGGTAGGAGGGGCAG
ATAGG 
gttaggtaggaggggcag
at 
CACCgttaggt
aggaggggcag
at 
AACatctgcccctcc
tacctaac 
Materials and methods 
38 / 163 
 
Figure 2.1 Design of sgRNAs targeting FUS. 
“FUS coding strand” shows part of the WT sequence of FUS. sgRNA sequences were manually 
designed by screening the coding strand of FUS for the motifs CCN(N)19C for target 1 (T1) and 
G(N)20NGG for target 2 (T2). Each sgRNA is assembled from two complementary DNA 
oligonucleotides (“a” & “b”) containing a distinct 4bp-overhang at the 5’-end to allow ligation into the 
expression vector. The PAM sequence is not part of the sgRNA.  
2.2.1.2 Screening for CRISPR/Cas9n-related Off-targets 
A theoretical approach was used in order to screen for any possible off-target effects of 
Cas9n for target specific sgRNAs (T1 and T2, see Table 2.16). In this thesis work two different 
online tools were used for screening (seeTable 2.17).  
 
Table 2.17 Online tools for Off-target detection 
 
Online Tool Reference 
CRISPR Design (Zhang laboratory) http://crispr.mit.edu 
Off-spotter Pliatsika et al., 2015 
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2.2.1.3 Cloning of DNA oligos into the pX335B plasmid 
Target specific sgRNAs (T1and T2) were cloned into the pX335B_hCas9_2x sgRNA vector 
(short pX335B) vector in two cloning steps. To linearize the plasmid, it was digested with BbsI 
(BpiI) for 30 min at 37°C (see Table 2.19). In parallel, the sgRNA specific oligos “a” and “b” 
(Table 2.16) were phosphorylated by T4 Polynucleotide kinase for 30 min at 37°C (Table 2.20). 
The phosphorylated oligo mixture was directly used for annealing at 95°C for 5 min with 
subsequent cooling to 25°C at a cooling rate of 5°C/min. Annealed Oligos and linearized vector 
were then ligated using QuickLigase (NEB) for 20 min at RT (Table 2.21). Finally, unspecific 
recombination products were degraded via Plasmid-SafeTm DNase. 
 
Table 2.18 Materials for cloning 
 
Table 2.19 Mixture for restriction digestion 
 
Table 2.20 Mixture for annealing of oligos 
 
Name Company 
10x T4 DNA Ligase Buffer with 10 mM ATP NEB, Massachusetts, USA 
T4 Polynucleotide Kinase NEB, Massachusetts, USA 
10x T4 Polynucleotide kinase Buffer NEB, Massachusetts, USA 
2x Quick Ligase Reaction Buffer NEB, Massachusetts, USA 
ATP Solution 25 mM Epicentre, Wisconsin, USA 
10x Plasmid-SafeTM Buffer Epicentre, Wisconsin, USA 
Plasmid-SafeTM ATP-dependentDNase 1000U Epicentre, Wisconsin, USA 
1 µq pX335B_hCas9_2x sgRNA plasmid 
1 µl FastDigest  BbsI (BpiI) or SapI (LguI) 
1 µl 10x FastDigest Buffer 
X µl H2O 
20 µl Total 
1 µl Oligo “a” (10 µM) 
1 µl Oligo “b” (10 µM) 
1 µl 10x T4 Ligation Buffer 
0.5 µl T4 PNK 
6.5 µl H2O 
10 µl Total 
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Table 2.21 Mixture for ligation 
 
Table 2.22 Mixture for degradation of unspecific recombination products 
 
Ligated plasmids were transformed into JM109 competent E.coli (see section 2.2.2.1). After 
each ligation and transformation step, successfully cloned vectors were identified via colony 
PCR (see section 2.2.4.1). In order to put the second sgRNA for T2 into pX335B plasmid, the 
procedure was repeated with the obtained plasmid (containing sgRNA for T1). The second 
round SapI (LguI) was used for restriction digestion (see Table 2.19). Positive clones, 
containing both target sgRNAs, were amplified, sequenced using pX335_seq_R primer (Table 
2.9). Successful sequenced clones were used for targeting of h-iPSC (see section 2.3.5.1). 
2.2.1.4 Design & Generation of FUS correction plasmids 
The FUS genomic DNA sequence of the iPSC line FUS-R521C was aimed to be modified 
(Table 2.15). The FUS correction sequences were designed according to the WT sequence of 
FUS (NCBI Ref. Seq. NC_000016.10). Homology arms covering the FUS-R521C mutation site 
of the parental cell line (AA position 521), and in a size of 500 bp upstream and 400 bp 
downstream of the induced DSB, were used. The EGFP-Tag was added to the last exon of 
FUS with a 12 bp linker-DNA sequence (5‘-GCCGCCAAATTC-3’). In the FUS-WT-EGFP 
correction construct, the codon at AA position 521 coding for R521C mutation (Tgc) was 
replaced with its WT counterpart (Cgc). In the FUS-P525L-EGFP correction construct, the 
codon at AA position 521 coding for R521C mutation (Tgc) was replaced with its WT 
counterpart (Cgc) and the codon at AA position 525 coding for WT sequence (cCg) was 
replaced with its mutant counterpart (cTg). For detailed sequences used for correction see 
below. Synthesis of FUS-EGFP correction constructs was outsourced to Eurofins Genomics 
1 µl Annealed Oligo dilution (1:200) 
x µl Digested pX335B (50 ng) 
5 µl 10x T4 Ligation Buffer 
1 µl T4 QuickLigase 
X µl H2O 
11 µl Total 
11 µl Ligation reaction from Table 2.21 
1.5 µl 10x Plasmid-SafeTM Buffer 
1 µl 25 mM ATP 
1 µl Plasmid-SafeTM Exonuclease 
14.5 µl Total 
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(Table 2.10). The sequences for FUS-WT-EGFP and FUS-P525L-EGFP were synthesized de 
novo and cloned into the pEX-K4 backbone by the company.  
 
FUS-WT-EGFP 
TCCTTAGCACCTGTGAGAATATGAACTTCTCTTGGAGGAATGAATGCAACCAGTGTAAGGCC
CCTAAACCAGATGGCCCAGGAGGGGGACCAGGTGGCTCTCACATGGGTAAGAAAGGCAGACC
TGGTGCTAGGGAGCTGGGACCAAAGAATCCTTAATTTTTCAGCGGGGAGGCTCGGGGAACATAG
GGGAATGGGAATATGATAGATCTTGTTTCTTTTGTCCTAGGGGGTAACTACGGGGATGATCGTC
GTGGTGGCAGAGGAGGCTATGATCGAGGCGGCTACCGGGGCCGCGGCGGGGACCGTGGAGG
CTTCCGAGGGGGCCGGGGTGGTGGGGACAGAGGTGGCTTTGGCCCTGGCAAGATGGATTCCA
GGTAAGACTTTAAATCAGAATAAAAAAGTAGAGCAGTTGAACAGAGGCCATAGGATAACAGGGTT
TTGTTGAGAAAGTGGTTTCATTTTGAGGGCTAGGTGGAAAGACCTGAGGTTGTAACCAGTAGTGG
AGAGGGAAGGAAAATTAACTCAGGGGGAGTGAATCTGTAGACCCACTTGAGATAAGATACTCGCT
GGGTTAGGTAGGAGGGGCAGATAGGATATCTAGGCTTGGAGAGGCTGGTAACTCAAATATAATG
GATACTTAATTTTTTTTTTTTTTTTTGCAGGGGTGAGCACAGACAGGATCGCAGGGAGAGGCCGT
ATGCCGCCAAATTCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGG
TCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGAT
GCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGG
CCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGA
AGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTT
CAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAA
CCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGA
GTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTG
AACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGA
ACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG
CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCG
CCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATTAGCCTGGCTCCCCAGGTTCTGGAA
CAGCTTTTTGTCCTGTACCCAGTGTTACCCTCGTTATTTTGTAACCTTCCAATTCCTGATCACCCA
AGGGTTTTTTTGTGTCGGACTATGTAATTGTAACTATACCTCTGGTTCCCATTAAAAGTGACCATTT
TAGTTAAATTTTGTTCCTCTTCCCCCTTTTCACTTTCCTGGAAGATCGATGTCCCGATCAGGAAGG
TAGAGAGTTTTCCTGTTCAGATTACCCTGCCCAGCAGGA 
Legend: Intron (FUS), Exon (FUS), UTR (FUS), EGFP, Linker DNA, Stop, Codon AA 
position 521, Codon AA position 525 
 
FUS-P525L-EGFP 
CTCCTTAGCACCTGTGAGAATATGAACTTCTCTTGGAGGAATGAATGCAACCAGTGTAAGGC
CCCTAAACCAGATGGCCCAGGAGGGGGACCAGGTGGCTCTCACATGGGTAAGAAAGGCAGAC
CTGGTGCTAGGGAGCTGGGACCAAAGAATCCTTAATTTTTCAGCGGGGAGGCTCGGGGAACATA
GGGGAATGGGAATATGATAGATCTTGTTTCTTTTGTCCTAGGGGGTAACTACGGGGATGATCGT
CGTGGTGGCAGAGGAGGCTATGATCGAGGCGGCTACCGGGGCCGCGGCGGGGACCGTGGAG
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GCTTCCGAGGGGGCCGGGGTGGTGGGGACAGAGGTGGCTTTGGCCCTGGCAAGATGGATTCC
AGGTAAGACTTTAAATCAGAATAAAAAAGTAGAGCAGTTGAACAGAGGCCATAGGATAACAGGGT
TTTGTTGAGAAAGTGGTTTCATTTTGAGGGCTAGGTGGAAAGACCTGAGGTTGTAACCAGTAGTG
GAGAGGGAAGGAAAATTAACTCAGGGGGAGTGAATCTGTAGACCCACTTGAGATAAGATACTCG
CTGGGTTAGGTAGGAGGGGCAGATAGGATATCTAGGCTTGGAGAGGCTGGTAACTCAAATATAA
TGGATACTTAATTTTTTTTTTTTTTTTTGCAGGGGTGAGCACAGACAGGATCGCAGGGAGAGGCT
GTATGCCGCCAAATTCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCG
ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTG
GCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATG
AAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCT
TCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGA
ACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGG
AGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCA
GAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTC
CGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATTAGCCTGGCTCCCCAGGTTCTGG
AACAGCTTTTTGTCCTGTACCCAGTGTTACCCTCGTTATTTTGTAACCTTCCAATTCCTGATCACC
CAAGGGTTTTTTTGTGTCGGACTATGTAATTGTAACTATACCTCTGGTTCCCATTAAAAGTGACCA
TTTTAGTTAAATTTTGTTCCTCTTCCCCCTTTTCACTTTCCTGGAAGATCGATGTCCCGATCAGGAA
GGTAGAGAGTTTTCCTGTTCAGATTACCCTGCCCAGCAGGA 
Legend: Intron (FUS), Exon (FUS), UTR (FUS), EGFP, Linker DNA, Stop, Codon AA 
position 521, Codon AA position 525 
2.2.2 Plasmid preparation 
2.2.2.1 Transformation  
Chemical competent E.coli JM109 (Promega) were thawed on ice. To transform, 50 µl of 
bacteria were aliquoted into 1.5 ml tube and 0.4 µl β-Mercaptoethanol were added. E.coli were 
incubated on ice for 10 min and swirled every 2 min. Then, 50 ng plasmid DNA were added 
and incubated on ice for 30 min. Heat shock was applied at 42°C for 45 sec after which tubes 
were immediately placed on ice for 2 min. 500 µl S.O.C medium was added to the tubes which 
were then incubated at 37°C, 300 rpm for 60 min in thermomixer. Bacteria transformed with 
plasmid were plated on agar plates containing appropriate antibiotics (Ampicillin or Kanamycin) 
and incubated at 37°C overnight. 
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2.2.2.2 Mini-culture and plasmid preparation  
E.coli colonies on agar plates were picked (5 to 10 colonies) and directly added into a 
conical flask (one colony per flask) containing 15 ml LB medium with appropriate antibiotics 
and cultured overnight at 37°C, 210rpm.  
The ZR Plasmid Miniprep kit was used for plasmid purification following manufacturer’s 
protocol. Obtained plasmid were either used for further cloning (see section 2.2.1.3) or for 
transfection (see section 2.3.5.1), after successful confirmation via sequencing (see section 
2.2.5). 
2.2.3 Isolation of genomic DNA 
For the isolation of genomic DNA (gDNA), cells were grown on 1w/6w format. Cells were 
washed once with DPBS and 1 ml fresh DPBS was added to the cells. Using a cell scraper 
cells were detached from the plate and transferred to 1.5 ml tube. The cells were centrifuged 
down and supernatant was removed. The cell pellet was either directly used for gDNA isolation 
or stored at -20°C for later extraction. To isolate gDNA, the DNeasy Blood & Tissue Kit (Table 
2.3) was used and gDNA was isolated according to manufacturer’s instructions. 
2.2.4 Polymerase chain reaction (PCR) 
2.2.4.1 Colony PCR 
Positive clones of pX335B plasmid, containing sgRNAs for T1 and T2, were identified by 
colony PCR using the respective “a”-oligo as forward primer and pX335_seq_R as reverse 
primer (Table 2.9 and Table 2.16). 
Bacterial colonies were resuspended in 30µl of H2O and, simultaneously, a backup-plate 
for eventual inoculation was prepared. Cells were lysed at 95°C for 5 min and 3µl of the lysate 
were used as template for the PCR reaction (see Table 2.23 and Table 2.24). After 
amplification, 10µl of the PCR were analyzed on a 1% agarose gel for 20min at 120V (see 
section 2.2.6). 
 
Materials and methods 
44 / 163 
Table 2.23 Mixture for Colony PCR 
 
Table 2.24 Program for Colony PCR 
 
2.2.4.2 Screening PCR for FUS-EGFP 
To confirm the presence of the EGFP-Tag within the genomic sequence of FUS, genomic 
DNA of previously picked clones (see section 2.3.5.2) was analyzed. A forward primer (FUS-
1.3-F) targeting FUS upstream of the used homology arms was used and a reverse primer 
(EGFP Rev 1) targeting EGFP (Table 2.9), resulting in amplification of a 909 bp long PCR 
fragment. After amplification, 10µl of the PCR were analyzed on a 1% agarose gel (see section 
2.2.6). 
 
Table 2.25 Mixture for Screening PCR 
 
Component 25 µl reaction Final conc. 
OneTaq 2x Master Mix with Standard Buffer 12.5 µl 1X 
10µM Forward Primer 0.5 µl 0.2 µM 
10µM Reverse Primer 0.5 µl 0.2 µM 
Template DNA 3 µl <1 ng 
Nuclease-Free Water 8.5 µl  
Step Temp Time 
Initial Denaturation 94°C 1 min 
30x cycles 
94°C 
64°C 
68°C 
30 sec 
30 sec 
30 sec 
Final Extension 68°C 5 min 
Hold 4°C  
Component 25 µl reaction Final conc. 
10x Pfx Amplification Buffer 3.75 µl 1.5X 
dNTPs 2 µl 0.8 mM 
MgSO4 0.5 µl 1 mM 
10µM Forward Primer 1.25 µl 12.5 pmol 
10µM Reverse Primer 1.25 µl 12.5 pmol 
Template DNA 1.5 µl >40 ng 
PlatinumTM Pfx Polymerase 0.2 µl 0.5 U 
Nuclease-Free Water 14.55 µl  
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Table 2.26 Program for Screening PCR 
 
2.2.4.3 Genotyping PCR of FUS-EGFP positive clones 
To determine the genotype of FUS-EGFP positive iPSC clones, genomic DNA was 
amplified using the primer pair FUS-2.1-F/-R (Table 2.9) resulting in the generation of three 
possible PCR product combinations (Table 2.27). 
 
Table 2.27 Possible PCR products of FUS-EGFP Genotyping PCR 
 
Table 2.28 Mixture for Genotyping PCR 
 
Table 2.29 Program for Genotyping PCR 
Step Temp Time 
Initial Denaturation 94°C 5 min 
30x cycles 
94°C 
58°C 
68°C 
15 sec 
30 sec 
1 min 45 sec 
Step Temp Time 
Initial Denaturation 94°C 5 min 
30x cycles 
94°C 
58°C 
68°C 
15 sec 
30 sec 
45 sec 
Final Extension 68°C 5 min 
Hold 4°C  
Genotype WT allele CRISPR allele 
heterozygous 528 bp 1257 bp 
homozygous / 1257 bp 
homozygous 528 bp / 
Component 25 µl reaction Final conc. 
10x Pfx Amplification Buffer 3.75 µl 1.5X 
dNTPs 2 µl 0.8 mM 
MgSO4 0.5 µl 1 mM 
10µM Forward Primer 1.25 µl 12.5 pmol 
10µM Reverse Primer 1.25 µl 12.5 pmol 
Template DNA 1 µl >40 ng 
PlatinumTM Pfx Polymerase 0.3 µl 0.75 U 
Nuclease-Free Water 14.95 µl  
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Final Extension 68°C 5 min 
Hold 4°C  
 
2.2.5 Sequencing 
Purified plasmids or PCR fragments were analyzed via Sanger sequencing method. For 
that, 5 µl template DNA and 5 µl primer (5 pmol/µl) were mixed in a 1.5 ml tube. The tube was 
labled and send to GATC Biotech (Konstanz, GER) for LIGHTrun sequencing. Returned 
sequences were analyzed with SnapGene Viewer software and NCBI nucleotide blast. 
2.2.5.1 Sequencing of FUS-EGFP positive iPSC clones 
In order to confirm successful CRISPR/Cas9n-mediated gene editing, a genotyping PCR 
with 50 µl reaction mixture was run (section 2.2.4.3). After amplification, the complete reaction 
mixture was run on a 1% agarose gel (section 2.2.6) and extracted from it (section 2.2.7). The 
extracted PCR fragments were send to sequencing. The Primer FUS-seq-R (Table 2.9) was 
used to sequence PCR fragments representing the WT allele of FUS. To sequence PCR 
fragments representing the CRISPR (FUS-EGFP) allele the primer EGFP Rev 1 was used 
(Table 2.9). 
2.2.6 Agarose gel electrophoresis  
Analysis of PCR products was performed using agarose gel electrophoresis. To prepare 
1% gel (w/v), 0.5 g agarose and 50 ml 1xTAE buffer were mixed in a conical flask and heated 
in microwave until the agarose dissolved. Agarose solution was briefly cooled to which 2.5 µl 
Midori Green was added and mixture was swirled to distribute evenly. The gel was filled into 
chamber fitted with 1.5 mm comb and air-bubble free gel was the allowed to polymerize at RT. 
Gel was then placed in electrophoresis chamber and covered with 1xTAE buffer. 2 µl of 6 x 
loading buffer was added to 10 µl of sample and filled into wells of the gel. All gel 
electrophoresis were performed at 70 mAmps, 120V. Bands were detected and imaged using 
UV transilluminator and biostep argus X1 software, respectively. 
2.2.7 Gel extraction of PCR fragments 
To extract PCR fragments, the fragments of interest were cut out from the agarose gel and 
transferred to a 1.5 ml tube. The QIAquick® Gel Extraction Kit (Table 2.3) was used to isolate 
PCR product from an agarose gel according to manufacturer’s instructions. 
Materials and methods 
47 / 163 
2.3 Cell culture 
All cells used in this work were cultivated at 37°C in a tissue culture incubator maintaining 
a stable content of 21 % O2 and 5 % CO2.  Cell culture procedures described in this chapter 
were all performed under a sterile biosafety cabinet. All media and solutions used, were 
prewarmed in a 37°C water bath prior to use unless described otherwise.  
2.3.1 Cell culture media 
Culture media and additives for culturing eukaryotic cells were applied as sterile solution. 
Media supplement working stocks were stored as aliquots at -20°C. In order to avoid multiple 
freeze and thaw cycles, aliquots of freshly prepared media were stored at 4°C, if not indicated 
otherwise by the manufacturer. Growth factors were always added prior to use of pre-warmed 
media.  
 
iPSC freezing medium 
 TeSR-E8 or mTeSR1      90 % (v/v) 
 DMSO        10 % (v/v) 
 Y-27632        10 µM 
 
Neural Differentiation Medium (NDM) (Burkhardt, Martinez et al. 2013) 
 DEMEM/F-12       47.6 % (v/v) 
 Neurobasal       47.6 % (v/v) 
 GlutaMAX-Supplement (100x)    1% (v/v) 
Penicillin-Streptomycin (100x)    1% (v/v) 
MEM Non-essential Amino Acids (100x)   1% (v/v) 
N2-Supplement (100x)     0.5% (v/v) 
B27-Supplement without Vitamin A (50x)   0.5% (v/v) 
β – mercaptoethanol (50 mM)    100 µM 
Insulin        5 µg/ml 
 
EB medium for ectodermal differentiation 
DMEM/F-12       48.6% (v/v) 
Neurobasal       48.6% (v/v) 
N2-Supplement (100x)     1% (v/v) 
B27-Supplement without Vitamin A (50x)   0.5% (v/v) 
Penicillin-Streptomycin-Glutamine (100x)   1% (v/v) 
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2-Mercaptoethanol (50 nM)      0.1% (v/v) 
BSA Fraction V 7.5%      0.2% (v/v) 
 
EB medium for endodermal and mesodermal differentiation  
DMEM (Hi-glucose)     76.9% (v/v) 
Fetal Calf Serum (FCS)     20% (v/v) 
Penicillin-Streptomycin-Glutamine (100x)   1% (v/v) 
MEM Non-Essential Amino Acids (100x)    1% (v/v) 
2-Mercaptoethanol (50 nM)      0.1% (v/v) 
1-Thioglycerol (0.04 M stock solution)    1% (v/v) 
 
N2B27 medium 
DMEM/F12       48.75% (v/v) 
Neurobasal       48.75% (v/v) 
N2-Supplement (100x)     0.5% (v/v) 
B27-Supplement without Vitamin A (50x)   1% (v/v) 
Penicillin-Streptomycin-Glutamine (100x)    1% (v/v) 
 
N2B27 freezing medium 
 N2B27 medium      90% (v/v) 
 DMSO        10% (v/v) 
2.3.2 Coatings 
The following coatings were used to allow cell attachment and growth of monolayer cell 
cultures. The volume used for the following coating procedures was 250µl per well of a 4-well 
plate. For coating of 12-well and 6-well plates the amount used was increased twofold and 
fourfold respectively. 10 cm cell culture dishes were coated with 5 - 7 ml of coating solution. 
2.3.2.1 MatrigelTM coating 
MatrigelTM was pre-diluted 1:5 in DMEM/F12 and working aliquots were stored at -20°C. For 
coating, pre-diluted MatrigelTM was thawed at RT and further diluted 1:20 in cold DMEM/F12.  
Unused working aliquots were immediately stored at -20°C after use, to prevent 
polymerization. Culture plates were coated with MatrigelTM solution and incubated at 37°C for 
15-30 minutes. Plates could be directly used. Coated plates also could be stored for up to two 
weeks at 4°C. Cold plates (4°C) were allowed to equilibrate to RT for at least 30 minutes prior 
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to use. MatrigelTM solution was then removed and cells were plated on the coated culture 
vessels without any further washing steps.  
2.3.2.2 Poly-L-ornithine/ Laminin coating 
Neural precursor cells (NPCs) and cortical cultures were differentiated on Poly-L-ornithine 
(PLO)/ Laminin coated culture vessels. PLO-solution was diluted in DPBS to a total amount of 
15% (v/v). Culture plates were coated with 15% PLO-solution and incubated overnight at 37°C. 
The next day, plates were washed three times with DPBS and shortly dried at RT. Dried PLO 
pre-coated plates were incubated with 1% (v/v) Laminin (Sigma-Aldrich) solution in DPBS 
overnight at 37°C. Prior to use, plates were washed three times with DPBS. PLO/Laminin 
coated plates could be stored at 4°C in DPBS for up to four weeks or used directly.  
Microfluidic chamber (MFC) systems were assembled as previously established in our 
group (Naumann, Pal et al. 2018). In brief, NuncTM glass bottom dishes were coated with 30% 
(v/v) PLO in DPBS at 37°C overnight. Xona silicon MFC units were stored in 70% (v/v) ethanol 
in water for sterilization. PLO pre-coated dishes were washed three times with sterile water. 
Dishes and silicon chambers were dried for ~30 min under UV light under the laminar flow 
bench. Dried silicon chambers were carefully attached to the dry PLO-coated glass bottom 
dishes. The system was perfused with 2% (v/v) Laminin (Roche) in DPBS. Assembled and 
perfused MFCs were incubated overnight at 37°C. Prior to use, MFCs were washed once with 
corresponding medium.  
2.3.3 Cell count 
To plate cells at a defined density, cells needed to be count. For that, cells were detached 
from culture vessels using accutase as described under 2.3.7.4. The cell pellet was 
resuspended in 1 ml culture medium. For better counting, a dilution of this cell suspension was 
prepared. Most often, a 1:100 dilution was prepared by adding 1 µl of cell suspension to 99 µl 
medium.  
Cells were counted using a hemocytometer. 10 µl of diluted cell suspension were given to 
the hemocytometer and cells were counted with an inverted microscope under 10 x 
magnification. Cells within each of the four corner squares were count and the average value 
was calculated. Thereafter, the cell number could be calculated by using the following formula: 
 
Average value x dilution factor x 10,000 cell/ml = total cells/ml 
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Finally, the needed dilution factor of the current cell suspension for plating could be 
calculated by using the following formula: 
 
Measured cells concentration / desired cell concentration= dilution factor 
2.3.4 Cultivation of human induced pluripotent stem cells 
2.3.4.1 Expansion and maintenance of human iPSCs 
Human iPSCs were cultured on matrigel and maintained in feeder-free, animal component-
free culture medium. In general, iPSCs used for gene editing or simple expansion culture were 
maintained in TeSR-E8. iPSCs needed for neural differentiation were cultured in mTeSR1. 
Expansion cultures were cultured in 12-well or 6-well format. Medium was changed every day, 
except on weekends/holidays on which iPSCs were double fed (e.g. from Friday to Sunday).  
Cells typically were passaged when they reached 70-90% confluence (usually once a week) 
in a splitting ratio 1:10 to 1:50. Prior to splitting, matrigel coated plates were prepared (see 
section 2.3.2.1) and medium containing 10 µM of the ROCK inhibitor Y-27632 (ROCKi) was 
pre-warmed. iPSC were splitted using ReLeSR. For that, culture medium was removed and 
ReLeSR was added (500 µl per 1w/6w, 250 µl per 1w/12w). Cells were briefly rocked back 
and forth with the solution for 30 sec. Then ReLeSR was removed  and iPSC were incubated 
without any solution for 5 min at RT. After incubation, feeder-free medium containing Y-27632 
was added to the cells. iPSC colonies were detached by holding the plate with one hand and 
using the other hand to firmly tap the side of the plate for approximately 30 - 60 seconds. 
Detached cells were transferred in the respective splitting ratio onto a new plate containing 
pre-warmed feeder-free medium containing Y-27632. The following day, medium was replaced 
by feeder-free medium without Y-27632. 
2.3.4.2 Freezing and thawing of iPSCs 
In order to freeze iPSCs, colonies were detached and collected as described in  
Section 2.3.4.1. Colonies were then resuspended in feeder-free medium containing 10% 
DMSO and 10 µM Y-27632. iPSC were then immediately placed at -80°C using a NalgeneTM 
Cryo freezing container which ensures a cooling rate of 1°C/min. For long term storage, iPSCs 
were kept in a liquid nitrogen tank. As a rule, one confluent well of a 6-well plate was frozen 
down into 1 to 4 cryovial using 1 ml of freezing media. 
To thaw iPSCs, 1 to 6 wells of a 6-well plates were prepared with matrigel as described 
above. The iPSCs were then partially thawed at 37°C. Colonies were resuspended in 5 ml cold 
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feeder-free media, collected in a 15 ml falcon tube and centrifuged at 1200 rpm for 1 minute. 
Supernatant was removed, cells were resuspended in 1 ml warm feeder-free medium 
containing Y-27632 and evenly distributed throughout the well. The next day, medium was 
replaced by feeder-free medium without Y-27632 and iPSCs were maintained as described 
under section 2.3.4.1. 
2.3.5 CRISPR/Cas9n-mediated gene editing of iPSCs 
For gene targeting of iPSCs, feeder-free iPSCs cultured in TeSR-E8 medium were co-
transfected with pX335B vector (containing the Cas9n cassette, two sgRNAs and a puromycin 
selection cassette) and pEX-K4 vector (containing the FUS-WT-EGFP or FUS-P525L-EGFP 
sequence) using FuGENE HD transfection reagent (see 2.3.5.1). 24 h after transfection, cells 
containing the pX335B vector were selected by treatment with 0.4 µg/µl Puromycin (InvivoGen) 
for another 16h to 24h. Following selection, cells were allowed to recover for 3-7 days in TeSR-
E8 with daily medium changes. After recovery, iPSCs were passaged onto a new 6-well plate 
in a clonal dilution (2000 cells per 6-well) in Y-27632-containing medium. After 10-14 days 
EGFP-positive clones were picked as described in section 2.3.5.2 and further cultured for 
characterization.  
2.3.5.1 Transfection of feeder-free iPSCs 
The day before transfection 175,000 iPSC were plated onto 1w/6w into TeSR-E8 + Y-
27632. Prior to transfection, transfection reagent Fugene HD ® was allowed to adapt to RT 
and iPSC medium was replaced with fresh TeSR-E8 + Y-27632 (2 ml per 1w/6w). Then 
transfection mixture was prepared. For that, 200 µl OptiMEM were mixed with 2 µg plasmid 
DNA (1 µg pX335B and 1 µg correction plasmid) in a 1.5 ml tube and vortexted. Then, 7 µl 
Fugene HD ® were added to the mixture and vortexed immediately. Transfection mixture was 
incubated for 15 min at RT. Then the mixture was added dropwise to the iPSC and cells were 
incubated overnight. After 24h, transfection medium was replaced with new TeSR-E8 or 
selection medium. 
2.3.5.2 Single colony selection  
 Prior to picking iPSC colonies, matrigel coated 12-well plates were prepared (2.3.2.1). At 
least two plates were prepared per cell line. TeSR-E8 medium containing Y-27632 was pre-
warmed at 37°C water bath. Shortly before picking, matrigel solution was exchanged by the 
pre-warmed medium. Under a fluorescence microscope EGFP-positive iPSC colonies were 
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detected and marked on the plates. The EGFP-positive colonies were then picked under an 
inverted bright-field microscope as described below. 
Using 10 µl pipette tips, previously marked colonies were carefully detached using the tip 
of 10 µl pipette tips. Floating colonies were collected with the 10 µl pipette tip directly plated 
into one well of 12-well plate (one colony per well). About 12-24 colonies were picked per cell 
line. Colonies were titrated using 1 ml pipette tips about 2-4 times within the wells.  
 The next day medium was replaced with TeSR-E8 without Y-27632. Colonies were allowed 
to grow for 3-7 days with daily medium changes. iPSCs were splitted as described in section 
2.3.4.1 onto new wells of 12-well plate for further expansion and characterization. 
2.3.6 Differentiation of human iPSCs into three germ layer 
Three germ layer formation of human iPSCs was obtained via embryoid body (EB) 
differentiation. iPSCs were cultured as described under 2.3.4. For EB formation, iPSCs were 
expanded on 2w/6w or 3w/6w format. When colonies reached 70 to 90 % confluency, iPSCs 
were washed once with DPBS and 1mg/ml dispase diluted in iPSC medium was added to the 
cells. iPSCs were incubated with the enzyme for 30 to 45 min. Every 10 min iPSCs were 
checked for detachment. Once colonies detached completely, they were collected in a 15 ml 
falcon and centrifuged for 10 sec at 1200 rpm. For all following pipetting steps the cells were 
pipetted carefully and not titrated because the colonies were aimed to be collected as a whole 
(not as small fragments). The supernatant was removed and the cells were additionally 
washed twice with DMEM/F12 to further dilute remaining dispase. The cell pellet was then 
resuspended carefully in 6 ml DMEM/F12 and iPSCs were split 1/3 and 2/3 into two 15 ml 
falcons. Cells were again centrifuged for 10 sec at 1200 rpm and the supernatant was 
removed. 
For ectodermal differentiation, 1/3 of the cells were resuspended in mTeSR1 supplemented 
with 5 µM Y-27632, 10 µM SB431542, and 1 µM Dorsomorphin plated. For meso-/endodermal 
differentiation, 2/3 of the cells were resuspended in mTeSR1 supplemented with only 5 µM Y-
27632. Colonies were plated onto two 6 cm dishes. Two days later, medium was changed to 
same condition but without Y-27632. Another 2 days later, EBs were collected and centrifuged 
for 10 sec at 1200 rpm and supernatant was removed. EBs were resuspended in ectodermal 
differentiation medium and plated on Matrigel coated 4-well plate (). For meso- and 
endodermal differentiation, EBs were resuspended in meso-/endodermal differentiation 
medium and plated on gelatine coated 4-well plate (). Medium was changed every other day 
for 14 days. At day 14, cells were fixed for immunocytochemical analysis.  
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2.3.7 Differentiation of human iPSCs into spinal and cortical neural cell types 
2.3.7.1 Expansion of human small molecule neuronal precursor cells 
Supplements for NPC expansion: 
CHIR  3 µM  
AA   150 µM 
PMA   0.5 µM 
 
Expansion and differentiation of small molecule neuronal precursor cells (smNPCs) is 
basing on protocols established by Dr. Peter Reinhardt (Reinhardt, Glatza et al. 2013).The 
smNPCs were grown on matrigel coated plates in N2B27 media supplemented with 3μM 
CHIR99021 (CHIR), 150μM ascorbic acid (AA) and 0.5μM purmorphamine (PMA). Medium 
was changed every other day during expansion phase. NPCs were passaged once a week or 
when they reached 70-90% confluence. For passaging, cells were splitted using accutase (see 
section 2.3.7.4). NPCs were plated onto new matrigel coated plates in fresh N2B27 media 
supplemented with growth factors. 
2.3.7.2 Differentiation of human smNPCs into spinal motor neurons 
Supplements for differentiation induction: 
BDNF  1 ng/ml 
AA   0.2 mM 
RA   1 µM 
GDNF  1 ng/ml 
SAG   0.5 µM 
 
Supplements for maturation: 
Activin A  5 ng/ml (just the first day) 
cAMP  0.1 mM 
BDNF  2 ng/ml 
TGFβ-3  1 ng/ml 
GDNF  2 ng/ml 
 
To induce differentiation into spinal MNs, smNPCs were splitted in a 1:10 ratio (see section 
2.3.7.4) onto new matrigel coated plates (day 0 of differentiation process). Figure 2.2 shows a 
schematic overview of the differentiation steps. NPCs were plated in N2B27 medium 
containing growth factors for differentiation induction (see above). In differentiation phase (day 
0 to 5), medium was changed every other day. On day 6, medium for differentiation induction 
was changed to N2B27 medium containing factors for maturation (see above). Only on the first 
day of medium change to maturation (day 6 to 7) Activin A was added. On day 7 medium was 
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changed to N2B27 maturation medium without Activin A. On day 8 to 10, cells were then 
splitted into their desired format onto POL/Laminin coated plates (see section 2.3.2.2). Cells 
were split using accutase (see section 2.3.7.4). Prior to seeding, cells were counted (see 
section 2.3.3) and plated into N2B27 maturation medium at the following densities: 1x106 
cells/6 well, 4x104 cells/4 well, and 10µl of 30x106 concentrated cell suspension  per MFC. 
Spinal MNs were allowed to further mature/age from this time point on with medium changes 
every other day. 
 
 
Figure 2.2 Workflow chart of smNPC differentiation into spinal MNs. 
Differentiation of human smNPCs was induced by BDNF, AA, RA, GDNF, and SAG. After 6 days of 
differentiation spinal MN maturation was promoted by cAMP, BDNF, TGFβ-3, and GDNF. On day 8 to 
10 spinal MNs were re-plated onto their final format for further maturation and aging. © Julia Japtok 
2.3.7.3 Differentiation of human iPSCs into cortical neurons and astrocytes 
Supplements for neural induction: 
Dorsomorphin  1.5 µM 
SB431542   10 µM  
 
Supplements for neural maintenance:      
BDNF   2 ng/ml 
GDNF   2 ng/ml 
RA                0.05 µM 
 
Supplements for neural maintenance in MFC: 
 Seeding site (proximal):      
RA  0.05 µM 
 Exit site (proximal):      
BDNF  2 ng/ml 
GDNF  2 ng/ml 
Retinoic acid 0.05 µM 
 
Human iPSCs were split using ReLeSR (see section 2.3.4.1) and plated at a high density 
on matrigel coated 6-well plates in mTeSR1 containing 10 µM Y-27632. IPSCs were cultured 
for another 3 to 5 days in mTeSR1 without Y-27632 to obtain confluent cell layer for neural 
induction, with medium changes every day. When iPSCs reached a confluence of 80 to 90 %, 
differentiation into cortical lineage was induced by changing the medium to neural 
differentiation medium (NDM, see section 2.3.1) containing factors Dorsomorphin and 
SB431542 for neural induction (day 0 of differentiation process). Figure 2.3 shows a schematic 
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overview of the differentiation steps. Cells were differentiated for 10 days in NDM induction 
medium. From day 11 to 14 the thereby derived neuroepithelial cells/ neural progenitor cells 
(NPCs) were fed with NDM only (not containing any growth factors). From days 15 to 19 NDM 
was supplemented with 0.05 µM retinoic acid (RA). From day 0 to 20 medium was changed 
daily, supplemented with the respective growth factors.  
At day 20 cultures were dissociated using accutase (see section 2.3.7.4). The cells were 
replated at a density of 19.2x104  cells per cm2 onto PLO/Laminin coated cell culture 6-well 
plates in NDM maintenance medium containing BDNF, GDNF, and RA. For splitting, 10 µM Y-
27632 were added to the medium only for one day. Differentiating NPCs were cultured from 
day 21 to 45 in NDM supplemented with growth factors for neural maintenance. Medium was 
changed every other day.  
At day 40 to 45, cells were passaged into their final format for experimental analysis onto 
new PLO/Laminin coated plates (see section 2.3.2.2). Prior to seeding, cells were counted 
(see section 2.3.3) and plated into NDM maintenance medium supplemented with 10 µM Y-
27632 at the following densities: 30.000 cells/cm2 for immunostaining approaches and laser 
cutter experiments. For axonal trafficking analysis 10µl of 30x106 concentrated cell suspension 
per MFC were plated. For protein-dependent approaches (e.g. ELISA) 60.000 cells/cm2 cells 
were plated. The next day, Y-27632 was removed and cortical culture were allowed to further 
mature and age from this time point on. For cortical MFC cultures, on the seeding site 
(proximal) 50 µl medium per well were applied while on the exit sites (distal) 100 µl medium 
per well were added. NDM maintenance medium was changed 2 to 3 times a week.  
In general, cortical neurons are already detectable from day 20 to 30 on, mainly consisting 
of lower layer neurons. Upper layer cortical neurons can be detected between day 40 to 50 
earliest. To obtain astrocytes, cortical cultures need to be matured for at least 70 to 80 days. 
Therefore, all experimental analysis was implemented between maturation day 80 to 150, if 
not stated otherwise. 
 
 
Figure 2.3 Workflow chart of iPSC differentiation intro cortical cells. 
Differentiation of human iPSCs was induced by SB431542 (SB) and Dorsomophin (D) for 10 days. On 
days 11 to 15 RA was applied. Differentiating cells were re-plated on day 20 and further cultured in 
neural maintenance medium supplied with RA, BDNF, and GDNF. On day 45, cortical cells were re-
plated onto their final format for further maturation and aging. © Julia Japtok 
2.3.7.4 Splitting of NPCs, spinal MNs, and cortical cells using accutase 
To obtain a single cell suspension, as for instance required for cell counting, cells were split 
using accutase. To detach cells, culture medium was replaced by accutase solution. In general 
Materials and methods 
56 / 163 
0.5 ml were used to detach cells from 1w/6w format. Cell were incubated for 10 minutes at 
37°C with accutase solution. Cells thereafter were dissociated into single cells clumps by 
pipetting up and down 6 to 10 time in accutase solution. The solution containing the cells, was 
than transferred to 15 ml falcon and diluted with 4 volumes of pre-warmed medium. Cells were 
centrifuged for 2 minutes at 160xg. Supernatant was discarded and cells were resuspended 
in the required amount of pre-warmed culture medium for plating onto new plates. 
2.4 Microscopy 
2.4.1 Immunofluorescence staining 
Blocking solution (in DPBS) 
 BSA   1% 
 Donkey serum  5% 
 Glycine   0.3M  
 Triton-X   0.02% 
 
The following specifications refer to one well of a 4-well plate. Prior staining, cells needed 
to be fixed. For that, media was removed, cells were washed twice with DPBS and fixed with 
4% PFA for 10 min at RT. PFA was aspirated and cells were washed three times with DPBS. 
Fixed cells could be stored in DPBS at 4°C for up to one week or stained directly. 
Fixed cells were first permeabilised for 10 minutes in 250 µl 0.2 % Triton X solution. Cells 
then were incubated for 1 hour at RT in 250 µl blocking solution. Following blocking, primary 
antibodies (Table 2.6) were diluted in blocking solution and cells were incubated with 250 µl 
primary antibody solution overnight at 4°C. The next day, cells were washed 4 to 5 times for 5 
minutes in DPBS. Secondary antibodies (Table 2.7) were diluted in blocking solution and cells 
were incubated for 1 hour at RT in 250µl secondary antibody solution. Secondary antibody 
solution was aspirated and samples were washed three times for 5 min in DPBS. During all 
steps involving secondary antibodies, the sample was protected from light. Nuclei from cells 
were stained using Hoechst (Table 2.8). 0.75 µl of Hoechst solution were mixed with 1 ml 
DPBS and cells were incubated in 250 µl Hoechst solution for 5 minutes at RT. Cells were 
washed three times with PBS. Cells were finally covert with a glass coverslip. For that 1 to 2 
drops of mounting medium were given to the cells and a coverslip was carefully mounted onto 
the cells. In contrast, cells that were already grown on coverslips were mounted onto glass 
slides. One drop of mounting medium was put onto a glass slide for each coverslip with stained 
cells and coverslips were carefully removed from the wells and mounted onto the glass slide. 
Covert cells were sealed with nail polish the next day. Immunofluorescence stained cells were 
stored at 4°C.  
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2.4.2 Fluorescence microscopy 
Images of immunofluorescence staining or in vitro fluorescence for qualitative analysis were 
obtained with the fluorescence microscope Observer.Z1. Images of cortical marker (Figure 
3.2), FUS-EGFP expression in iPSCs (Figure 3.4), pluripotency marker (Figure 3.5), and germ 
layer marker (Figure 3.6), and distal axonal outgrowth (Figure 3.33) were taken with this 
microscope. 
For quantitative analyses (including DNA damage, C9-HRE associated DPRs, FUS-EGFP 
expression in cortical cultures, and TDP43), images were obtained using the fluorescence 
microscope Axiovert 200M from Light Microscopy Facility (a Core Facility of the CMCB 
Technology Platform at TU Dresden). Apotome microscopy was conducted using either a 63x 
oil or 40x air objective. If not stated otherwise, 5x Apotome projection images per channel were 
taken to obtain one optical-sectioned image. Randomly assigned images of different 
experiments were evaluated either qualitative or quantitative using CellProfiler image analysis 
software (Table 2.14).  
2.4.3 Live cell imaging 
Live cell imaging approaches were conducted for the analysis of organelle trafficking in 
MFC cultures (see section 2.5.2) and laser cut assays of FUS-EGFP expressing iPSCs and 
cortical neurons (see section 2.5.1.2). Dr. Arun Pal. implemented all live cell imaging 
microscopy. Both approaches, live cell imaging of compartmentalized cultures and DNA 
damage laser cut assay, were implemented as published by Naumann and Pal, 2018 
(Naumann, Pal et al. 2018).  
2.5 Investigation of patient-specific in vitro cultures 
The characterization of human iPSCs, spinal MNs, and cortical cells was performed on 24-
well plates with glass coverslips for immunofluorescence staining. For axonal trafficking 
analysis, cortical cultures were grown in MFC culture system. Laser cut live cell imaging was 
implemented with cells gown on Nunc glass bottom dishes. Cells required for isolation of 
protein or DNA were cultured on 6-well plates. For cell densities plated see sections 2.3.7.2 
and 2.3.7.3.  
2.5.1 DNA damage analysis 
DNA damage within patient-specific in vitro cultures was assessed by immunofluorescence 
staining for γH2AX or 53BP1 and by laser cut live cell imaging approach.  
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2.5.1.1 Analysis of γH2AX and 53BP1 
Phosphorylated H2A.X (γH2AX) and 53BP1 can be used to detect DSBs via 
immunofluorescence staining. Once the cell detects DSBs, DDR signaling is initiated including 
the phosphorylation of serine 139 of histone H2A.X (Kinner, Wu et al. 2008, Grabarz, Barascu 
et al. 2012). This is followed by the recruitment of 53BP1. The amount of nuclear DNA damage 
within neurons and astrocytes was assessed by the evaluation of immunofluorescence 
images.  
As a DNA damage positive control, cells were treated with 2 µM etoposide for 1h to induce 
DNA damage. To assess whether cells are able to recover after DNA damage induction, 
etoposide was removed from the medium and cells were allowed to recover for 24h prior to 
fixation.  
Neurons and astrocytes were stained using antibodies against MAP2 or GFAP (Table 2.6).  
DSBs were detected by staining against γH2AX or 53BP1 (Table 2.6). Both marker can be 
visualized as nuclear foci in immunofluorescence staining. Apotome microscopy using a 63x 
oil objective was conducted to obtain images of one focal plane for analysis (see section 2.4.2). 
To identify and quantify DSBs, a semi-automated workflow using CellProfiler image analysis 
software was used (Table 2.14). Analysis pipeline was designed as follows: 
1. For Apotome images stained for four markers (e.g. γH2AX / 53BP1/ MAP2/ 
Hoechst): 
a. Loading of images in czi- or tif-format  
b. Extract metadata  
c. Split channels into greyscale components  
2. Identify nuclei automatically via Hoechst staining 
3. Identify MAP2 region automatically via MAP2 staining 
4. Overlay MAP2 and Heochst channels with detected outlines in point 2 and 3 
5. Manually select nuclei positive for MAP2, using overlay created in point 4 
6. Mask γH2AX channel with manually selected MAP2 positive nuclei (point 5) 
7. Mask 53BP1 channel with manually selected MAP2 positive nuclei (point 5) 
8. Identify γH2AX foci within MAP2 positive nuclei automatically (point 6), by using a 
robust background tresholding within each assigned nuclei 
9. Identify 53BP1 foci within MAP2 positive nuclei automatically (point 7), by using a 
robust background tresholding within each assigned nuclei 
10. Measure object size, shape, and number of identified γH2AX foci (point 8), 53BP1 
foci (point 9), and MAP2 region (point 3) 
11. Relate identified objects 
a. γH2AX foci (point 8) and MAP2 positive nuclei (point 5) 
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b. 53BP1 foci (point 9) and MAP2 positive nuclei (point 5) 
12. Overlay outlines of identified object to create merged images (e.g. overlay γH2AX   
and MAP2 channel with outlines detected in point 8 and 5) 
13. Save images of interest 
14. Export measurements as excel spreadsheets 
Results derived from semi-automated CellProfiler analysis were assembled and post-
filtered in KNIME (Table 2.14). Further, the foci numbers per nuclei and normalized values 
were calculated using KNIME and exported as excel spreadsheets. Those results were further 
loaded in Graphpad PRISM 7 for creation of graphs and statistical analysis (see section 2.6).  
2.5.1.2 DNA damage laser cut assay 
Another approach used in this work was the DNA damage laser cut assay, in which nuclear 
DNA damage at defined positions within nuclei was induced. FUS, as an ALS-associated 
protein (Kwiatkowski, Bosco et al. 2009, Vance, Rogelj et al. 2009) and known to be involved 
in DDR (Mastrocola, Kim et al. 2013, Wang, Pan et al. 2013, Qiu, Lee et al. 2014, Rulten, 
Rotheray et al. 2014, Naumann, Pal et al. 2018), was tagged with EGFP using CRISPR/Cas9n 
gene editing technique. The generation of EGFP-tagged FUS-WT and FUS-P525L iPSC lines 
(see section 2.3.5) enabled, concomitant, the live cell imaging of FUS recruitment to DNA 
damage sites (see section 2.4.3).  Aim was to analyze the effect of FUS mutation on 
recruitment in iPSCs and cortical neurons. The UV laser cutter experimental setup was 
implemented as previously published by our group (Naumann, Pal et al. 2018). Dr. Arun Pal 
implemented imaging and data evaluation shown in Figure 3.31.  
2.5.2 Axonal organelle trafficking analysis 
In order to analyze the motility of mitochondria and lysosomes in distal vs. proximal axonal 
parts, cortical neurons were cultured in compartmentalized microfluidic chambers (MFCs) 
(Figure 2.4). In general, the experimental set up, including MFC preparation, live cell imaging, 
and track analysis, was implemented as previously established by our group (Naumann, Pal 
et al. 2018, Pal, Glass et al. 2018).  
Cortical cultures were splitted as described under 2.3.7.4 and plated on one site only of 
PLO/Laminin-coated MFCs (see section 2.3.2.2). Only neuronal axons can grow through the 
900 µm long micro channels, allowing the separation of distal vs. proximal axons for organelle 
trafficking analysis.  To visualize mitochondria and lysosomes, cell cultures were incubated 
with 50 nM Mito- and Lysotracker in double for 1 h at 37°C, prior to imaging. Live cell imaging 
was performed without any further washing steps as described in section 2.4.3. Post-imaging, 
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medium was changed to normal NDM maintenance medium and cell could be further cultivated 
if needed.  
Movie acquisitions was performed at strictly standardized readout positions (Figure 2.4). 
The readout windows were located either adjacent to the micro channels exits (distal) or the 
channel entries (proximal). Movies were analyzed with FIJI software using the TrackMate 
v2.7.4 plugin for object (lysosomes and mitochondria) recognition and tracking. Video 
properties were as shown in Table 2.30. Settings for TrackMate plugin are shown in Fehler! 
Verweisquelle konnte nicht gefunden werden.. A minimum of 5 movies showing 2 micro 
channels each was analyzed at each readout positions (distal vs. proximal) per cell line. 
Typically, 200–500 tracks per movie were obtained and analyzed with respect to track 
displacement (measure for processive, i.e. straight, motility as opposed to undirected random 
walks) and mean speed. Results were assembled and post-filtered (threshold for track 
displacement ≥1.2 µm) in KNIME and batch results were saved as MS Excel files. The bulk 
statistics were analyzed and displayed as box plots using GraphPad Prism 7 software (see 
section 2.6).   
 
Table 2.30 Video properties for TrackMate analysis 
 
Table 2.31 Settings for TrackMate Plugin. 
Detector DoG detector 
Diameter (DoG detector) 1.6 
Threshold (DoG detector) 45 
Median filter No 
Subpixel localization Yes 
Initial tresholding 45 
View HyperStack Displayer 
Filters on spot None 
Tracker Linear mition LAP tracker (Kalam tracker) 
Global Yes 
Channels (c) 1 
Slices (z) 1 
Frames (f) 400 
Unit of length Micron 
Pixel width 0.23 
Pixel high 0.23 
Voxel depth 1 
Frame interval 0.3 sec 
Origin (pixel) 0.0 
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Initial search radius 2.0 
Search radius 1.25 
Max frame gap 2 
Filters on track Yes 
Duration of track 3 sec 
 
 
 
Figure 2.4 Overview of MFC culture system for axonal organelle trafficking analysis.  
iPSC-derived neurons are plated on only one side of the microfluidic chambers (MFCs). Axons grow 
from the seeding site through 900 µm long micochannels. To distinguish between distal and proximal 
axonal parts, live cell imaging was implemented on defined readout positions as marked by red boxes. 
The illustration was adopted from Pal et al. 2018. 
2.5.3 FUS-EGFP localization 
The cellular localization of endogenously expressed FUS was aimed to be analyzed. For 
that isogenic iPSC lines FUS-WT and FUS-P525L, expressing EGFP-tagged FUS, were 
differentiated into cortical neurons and astrocytes and stained for either neuron marker MAP2 
or astrocyte marker GFAP (Table 2.6). Apotome microscopy using a 63x oil objective was 
conducted to obtain Z-stack images (see section 2.4.2). A Z-stack of 7 images in 1 µm steps 
was acquired. A semi-automated workflow, using CellProfiler image analysis software (Table 
2.14), was established to measure and quantify FUS-EGFP intensity within cytoplasm and 
nuclei of cortical neurons and astrocytes. Analysis pipeline was designed as follows: 
1. For Apotome images stained for three markers (e.g. FUS-EGFP/ MAP2/ Hoechst) 
a. Loading of maximum intensity projection images in czi- or tif-format  
b. Extract metadata  
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c. Split channels into its greyscale components  
2. Identify nuclei automatically via Hoechst staining 
3. Mask MAP2/GFAP channel with automatically detected nuclei from point 2 
4. Identify MAP2/GFAP region automatically via MAP2/GFAP staining, excluding 
nuclei as masked in point 3 
5. Mask FUS-EGFP channel with automatically detected MAP2/GFAP area from point 
4 
6. Overlay MAP2 and Hoechst channels with detected outlines in point 2 and 4 
7. Manually select nuclei positive for MAP2/GFAP, using overlay created in point 6 
8. Measure object intensity of MAP2/GFAP area excluding nuclei (point 4) and marker 
positive nuclei (point 7) 
9. Overlay outlines of identified object to create merged images (e.g. overlay MAP2 
area and MAP2 positive nuclei with outlines detected in point 4 and 7) 
10. Save images of interest 
11. Export measurements as excel spreadsheets 
Results derived from semi-automated CellProfiler analysis were assembled and post-
filtered in KNIME (Table 2.14). To determine the cytoplasmic shift of FUS-EGFP amount, the 
ratio of nucleus/cytoplasm was calculated using KNIME and exported as excel spreadsheets. 
Those results were further loaded in Graphpad PRISM 7 for creation of graphs and statistical 
analysis (see section 2.6). 
2.5.4 Evaluation of C9ORF72-associated DPRs 
In collaboration with Dr. Carina Schludi and Prof. Dr. Dieter Edbauer (DZNE Munich) three 
monoclonal antibodies were evaluated in iPSC-derived cortical neurons by ELISA and 
immunofluorescence staining. All three antibodies were generated individually by collaborators 
and shown to specifically detect DRPs in previous publications (Table 2.32). In this thesis work, 
partially different clones as published were used. According to Edbauer lab, used clones 
exposed to work best in ELISA and immunofluorescence staining of cell cultures.  
 
Table 2.32 DPR antibodies 
 
Antibody Clone used Clone published Reference  
Poly-GA  IAI2 5E9 + 5F2 (Mackenzie, Arzberger et al. 2013, Schludi, 
May et al. 2015) 
Poly-GP 18H8 7A5 (Schludi, May et al. 2015) 
Poly-GR 5H9 5H9 + 7H1 (Mori, Arzberger et al. 2013, Schludi, May et 
al. 2015) 
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For ELISA experiments, iPSCs were differentiated into cortical cells and cell pellets were 
collected at different maturations stages. To obtain pellets, 2w/6w or 3w/6w of cortical cells 
were washed once with DPBS, scraped off in DPBS, and collected in a 15 ml falcon. Cells 
were centrifuged briefly at full speed to collect pellet at the bottom of the tube. Supernatant 
was removed and cell pellets were directly frozen at -80°C. Frozen cell pellet were send to Dr. 
Carina Schludi, who implemented protein extraction and ELISA experiments. Results received 
from Dr. C. Schludi were further loaded into Graphpad PRISM 7 for creation of graphs and 
statistical analysis (see section 2.6). 
 
For immunofluorescence analysis, cortical cultures were co-stained with one of the three 
DPR antibodies and neurons marker MAP2 (Table 2.6). Apotome microscopy using a 63x oil 
objective was conducted to obtain images of one focal plane for analysis (see section 2.4.2). 
To identify and quantify cytoplasmic DPR granules, an automated workflow using CellProfiler 
image analysis software was established (Table 2.14). Analysis pipeline was designed as 
follows: 
1. For Apotome images stained for three markers (e.g. Poly-GP/ MAP2/ Hoechst) 
a. Loading of images in czi- or tif-format  
b. Extract metadata  
c. Split channels into its greyscale components  
2. Identify nuclei automatically via Hoechst staining 
3. Mask MAP2 channel with automatically detected nuclei from point 2 
4. Identify MAP2 region automatically via MAP2 staining, excluding nuclei as masked 
in point 3 
5. Mask Poly-GP/Poly-GA channel with automatically detected MAP2 area from point 
4 
6. Identify cytoplasmic Poly-GP/Poly-GA granules within MAP2 area (point 5) 
automatically by using a robust background tresholding within each assigned object 
(point 4) 
7. Measure object size, shape, and number of identified Poly-GP/Poly-GA granules 
(point 6) and MAP2 region (point 4) 
8. Relate identified objects: Poly-GP/Poly-GA granules (point 6) and MAP2 region 
(point 4) 
9. Overlay outlines of identified object to create merged images (e.g. overlay MAP2 
area and MAP2 positive nuclei with outlines detected in point 4 and 7) 
10. Save images of interest 
11. Export measurements as excel spreadsheets 
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Results derived from CellProfiler analysis were assembled and post-filtered in KNIME 
(Table 2.14). Further, the granule numbers per MAP2 area were calculated using KNIME and 
exported as excel spreadsheets. Those results were further loaded in Graphpad PRISM 7 for 
creation of graphs and statistical analysis (see section 2.6).  
2.6 Quantifications and Statistics 
Randomly assigned images of independent experiments were used for quantitative 
analysis. Independent experiments base on different (independent) differentiation pipelines 
and are depicted as sample size (n) in the main text and/ or figure legends.  
Statistical analysis was performed using Graphpad/ PRISM 7 (Table 2.14). Graphs that are 
separated by dotted line always show: left non-isogenic lines and right isogenic ones.  
Statistica analysis was performed as follows: T-test was conducted to analyze experiments 
with one independent variable and two groups only. Experimental setups with one independent 
variable but more than two groups were analyzed using a One-way ANOVA. Experimental set 
ups with two independent variables and more than two groups were analyzed by Two-way 
ANOVA. Tukey’s post-hoc test was used if every mean was compared with every other mean. 
Dunnett’s post-hoc test was used if every mean was compared to one control mean. Sidak 
post-hoc test was used if a selected set of means was compared. The individually used 
significance tests and post-hoc tests are indicated in the respective figure legends of results. 
Present statistical significances according to the adjustments are indicated in each graph and 
Figure legend. *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001 were considered as significant.  
If not stated otherwise, the mean ± SD of independent experiments was calculated, as 
represented in the main text or by bar/ line graphs and aligned dot plots. Error bars are only 
shown for data obtained from n≥3 experiments. Data obtained from n≤2 experiments is 
depicted without error bars. Box plots represent batch results (plotted raw data of individual 
detected objects) with following settings: whiskers from 1–99%, outliers as dots, boxes from 
25–75 percentile, median as horizontal center line, mean as cross. Other settings are indicated 
in the legend of the individual Figure. 
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3 Results 
3.1 Cortical differentiation of patient-specific iPSCs  
The main focus of this thesis work was the analysis of disease-related pathologies within 
corticospinal motor neurons of cortical layer 5 and projection neurons of cortical layer 1/2 – 3 
that are specifically affected in ALS and FTLD, respectively.  Moreover, cortical astrocytes 
were aimed to be analyzed to compare their phenotypical characteristics to that of neurons. 
For this purpose, a differentiation protocol was used which recapitulates human neurogenesis 
(Burkhardt, Martinez et al. 2013), resulting in the derivation of heterogeneous cultures 
consisting of all cortical neuronal and glial cell types (Molyneaux, Arlotta et al. 2007). The 
protocol used was already established in the lab by me in a previous study, which showed that 
FUS-NLS mutant iPSCs are able to successfully differentiate into cortical neurons and 
astrocytes (Japtok, Lojewski et al. 2015).  
Patient-specific iPSCs were used as starting material for neural differentiation (see section 
2.3.7.3). After 70 to 120 day of maturation, cortical cells were ready for analysis. Altogether, 
eleven different control and mutant iPSC lines (C9ORF72 and FUS), including non-isogenic 
and isogenic ones, were used for in-depth characterization of disease-associated phenotypes. 
Following is an overview of non-isogenic and isogenic lines (for details see Table 2.15): 
 
 Non-isogenic control lines: 
o Ctrl 1 
o Ctrl 2 
o Ctrl 3 
o Ctrl 4 
 Non-isogenic C9ORF72 mutant lines: 
o C9-HRE 1 
o C9-HRE 3 
 Isogenic C9ORF72 lines: 
o C9-WT 
o C9-HRE 2 
 Isogenic FUS lines: 
o FUS-WT (with EGFP-Tag) 
o FUS-R521C (without EGFP-Tag) 
o FUS-P525L (with EGFP-Tag) 
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In order to proof the neural differentiation capacity of control and mutant iPSC lines, the 
neuron types and cell morphologies were analyzed. For that, patient-specific iPSCs were 
differentiated and matured for at least 70 days after neural induction. Cortical neurons were 
then detected by immunofluorescence staining against microtubule-associated protein 2 
(MAP2). Astrocytes were detected by staining against glial fibrillary acid protein (GFAP). Figure 
3.1 shows that control as well as mutant lines were able to differentiate into cortical neurons 
and astrocytes. Representative images of only control cell lines (Ctrl 1, C9-WT) and mutant 
line C9-HRE 2 are shown as FUS lines were already published in Japtok et al. (2015). No 
gross morphological differences were observed between control and mutant neurons (Figure 
3.1 A) and astrocytes (Figure 3.1 C) after 100 days maturation. Even though there was an 
effect of the cell line on neuron number in the determination of living MAP2 positive neurons, 
statistical post-hoc testing revealed that these differences were not statistically significant 
between the tested lines (Figure 3.1 B; P=0.031, F(6, 12) = 3.48, n=1-3, one-way ANOVA with 
Tukey’s post-hoc test). Quantification of astrocytes was not possible due to cell morphology. 
Astrocytes can show star-like shape or spongiform morphology, while possessing long main 
processes in differentiation stage and acquiring complex morphologies at more mature stage 
(Schiweck, Eickholt et al. 2018, Zhou, Zuo et al. 2019). Moreover, they do not possess such a 
clear “cell body” surrounding the nucleus as observed in neurons (also called soma). Thus, 
nuclei positive for GFAP could not be determined with certainty. Furthermore, fragmented and 
pyknotic nuclei (independent of MAP2 staining) were counted in order to determine cell death 
in cortical cultures. Quantification revealed an effect of cell line on number of pyknotic nuclei 
However, statistical post-hoc testing revealed that these differences were not statistically 
significant between the tested lines (Figure 3.1 B; P=0.049, F(7, 12) = 2.94, n=1-3, one-way 
ANOVA with Tukey’s post-hoc test). 
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Figure 3.1 Derivation of patient-specific cortical neurons and astrocytes. 
The differentiation protocol used in this study results in the derivation of cortical neurons (A) and 
astrocytes (B). A Neurons (MAP2) matured for 100 days show no morphological differences between 
controls and mutants. B Quantification of total MAP2 positive neuron soma from total living cell number 
(intact Hoechst) in % showed an effect of cell line (P=0.031, F(6, 12) = 3.48, n=1-3). However, C9ORF72 
(red) and FUS (green) mutants show no significant differences compared to controls (black and grey). 
C Cortical astrocytes (GFAP) at maturation day 100 show now morphological differences between 
controls and mutants. D Quantification of fragmented nuclei from total nuclei number (living and dead) 
in % showed an effect of cell line (P=0.049, F(7, 12) = 2.94, n=1-3). However, C9ORF72 (red) and FUS 
(green) mutants show no significant differences compared to controls (black and grey). The effect of cell 
line in B+D was calculated by One-way ANOVA with Tukey’s post-hoc test (n=1-3). Representative 
images of control cell lines (Ctrl 1, C9-WT) and mutant line C9-HRE 2 are shown (A+C). Nuclei were 
stained with Hoechst. Scale bars: 25 µm. 
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Figure 3.2 Derivation of patient-specific neurons from all cortical layers. 
A The differentiation protocol results in the derivation of various neuronal cell types from all cortical 
layers. Upper layer neurons can be detected by SATB2 (layer 1/2-3), while deep layer neurons can be 
detected by CTIP2 (layer V) or TBR1 (layer VI). B Neurons stain positive for upper and lower neuron 
marker. Images display sections of 40x magnification. Scale bars: 10 µm. C Control as well as mutant 
iPSC lines successfully differentiate into neurons of all cortical layers. Images display sections of 20x 
magnification. Scale bars: 25 µm. Representative images of controls (Ctrl 1, C9-WT) and mutant C9-
HRE 2 are shown (B-C). Nuclei were stained with Hoechst. 
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Cortical neurons of different laminar fates and projection types can be identified by 
analyzing expression of subtype specific markers (Molyneaux, Arlotta et al. 2007, Shi, Kirwan 
et al. 2012, Shi, Kirwan et al. 2012). Accordingly, immunofluorescence staining with different 
antibodies was used to detect distinct cerebral neuronal subtypes, including neurons of layer 
6 (TBR1), layer 5 (CTIP2), and upper layer 1/2-3 (SATB2) (schematic overview: Figure 3.2 A). 
Figure 3.2 B+C shows that neurons positive for marker proteins of all cortical layers were 
detected, indicating that control as well as mutant lines were able to successfully differentiate 
into mixed cultures of the main cortical neuronal subtypes. 
In summary, control and mutant iPSC lines showed similar capacities to differentiate into all 
cortical cell types that are of interest for further disease modeling purposes. Of note, a cell line 
dependent difference in neuron number was not observed. The absence of morphological 
pathologies at the analyzed time point for cortical neurons and astrocytes was verified for all 
control and mutant cultures. Thus a pathological action of FUS or C9ORF72 mutation to 
cortical culture derivation/differentiation could be excluded. 
3.2 CRISPR/Cas9n-mediated gene editing of FUS 
3.2.1 Generation of isogenic WT and P525L FUS-EGFP iPSC lines 
One aim of this thesis work was generation of isogenic FUS-EGFP lines for the study of 
FUS-related neuropathology in iPSC in vitro models. Two isogenic iPSC lines, FUS-WT and 
FUS-P525L were generated. As a parental line for gene editing, a patient-derived iPSC clone 
from a female patient carrying a heterozygous FUS-R521C mutation was used (see section 
2.1.9). The patient-specific FUS sequence was corrected/ modified at its mutation site and 
simultaneously an EGFP sequence was introduced by CRISPR/Cas9n-mediated genome 
editing (Ran, Hsu et al. 2013) (Figure 3.3 A).  
First, sgRNA for FUS targeting were designed and cloned into pX335B vector (see section 
2.2.1.1 and 2.2.1.3). Next, using the CRISPR vector pX335B containing Cas9n and two 
sgRNAs, a DSB at the target site was introduced to trigger homology directed repair (HDR) 
(Figure 3.3 B). As a HDR template, a plasmid (pEX-K4) containing the FUS correction 
sequence (WT or P525L) plus EGFP-Tag was used. For codon specification that were 
modified see Table 3.1. The correction plasmids for CRISPR/Cas9n-mediated FUS editing 
were designed and generated as described under section 2.2.1.4.  
For gene targeting, human iPSCs were transiently co-transfected with pX335B and pEX-K4 
plasmids (either WT or P525L) (Figure 3.3 C)(see section 2.3.5). Successfully transfected cells 
were selected by Puromycin treatment. After 3-7 days of recovery, iPSCs were split on new 
plates in a single cell dilution. After another 7-14 days, EGFP-positive colonies were picked 
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and further expanded. Such single-cell-derived clones were then characterized and 
successfully gene edited clones were used for disease-modeling experiments. 
 
Table 3.1 Codon specifications for gene editing of FUS 
 WT codon Mutant codon 
R521C Cgc Tgc 
P525L cCg cTg 
 
 
 
Figure 3.3 Generation of gene edited FUS-EGFP iPSC lines. 
A Schematic representation of FUS before and after gene editing showing the Cas9n cut site and the 
mutation site of the parental line (upper panel). The native R521C mutation was corrected to WT or 
P525L coding sequence of FUS and C-terminally tagged with EGFP (lower panel). The illustration was 
adopted by Marrone et al. 2018 and modified by the author of this study. B Plasmid maps of 
CRISPR/Cas9n plasmid pX335B containing Cas9 nickase and 2x guide RNAS and pEX-K4 correction 
plasmid containing HDR template for FUS editing. C Workflow chart of CRISPR/Cas9n-mediated 
genome editing of human iPSCs. © Julia Japtok 
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3.2.2 Characterization of isogenic WT and P525L FUS-EGFP iPSC lines 
3.2.2.1 Screening and Genotyping of isogenic FUS-EGFP iPSCs 
 The CRISPR/Cas9n-mediated gene editing of FUS resulted in generation of mixed cell 
population in which iPSCs that underwent gene editing were expressing EGFP-tagged FUS. 
This criterion was used for a first screening of single-cell-derived clones. Using widefield 
fluorescence microscopy 12-24 clones were examined for homogenous expression of FUS-
EGFP. Figure 3.4 A shows representative clones for FUS-WT and FUS-P525L iPSCs which 
show an uniform expression of FUS-EGFP in all cells. The clones FUS-WT C4 and FUS-
P525L-C21 were selected for further characterization.  
By using CRISPR/Cas9n gene editing method described by Ran and colleagues, the risk 
of targeting unwanted genomic sites is reduced to a minimum (Ran, Hsu et al. 2013). 
Nevertheless, proper integration of EGFP into the targeted site of FUS needed to be confirmed 
on genomic DNA level. The presence of the EGFP-Tag within the genomic sequence of FUS 
was confirmed by Screening-PCR (Figure 3.4 B, lane 1+2). For this a forward primer (FUS-
1.3-F) targeting FUS upstream of the used homology arms and a reverse primer (EGFP Rev 
1) targeting EGFP were used (Table 2.9). The 909 bp amplified PCR product confirmed that 
integration of EGFP occurred on the targeted site of FUS.  
After successful Screening-PCR the genotype of selected clones was determined by PCR 
and sequencing (see section 2.2.4.3). For the genotyping PCR, the primer pair FUS-2.1-F/-R 
was used targeting FUS up- and downstream of EGFP sequence, including the mutation site 
of the parental line. In this setup amplification should result in two PCR products (1257 bp for 
FUS-EGFP and 528 bp for untagged, endogenous FUS), if cells are heterozygous for the 
introduced modification. Figure 3.4 B (lane 2+4) shows that both selected clones, FUS-WT C4 
and FUS-P525L C21, are heterozygous for the introduced genomic modification. To confirm 
the genotype by sequencing, PCR products were analyzed on a 1% agarose gel and the two 
different sized bands were purified from the gel (see section 2.2.7). In order to identify if 
correction of FUS occurred on the originally mutated allele and not on the WT allele of the 
parental line, both purified PCR products were sequenced (Figure 3.4 C, see section 2.2.5.1). 
The PCR products containing FUS with EGFP (FUS-EGFP Allele) were sequenced using the 
reverse primer (EGFP Rev 1). The smaller PCR products containing FUS without EGFP (WT 
Allele) were sequenced using the reverse primer (FUS-seq-R).  The original genotype of the 
used patient-derived iPSC line was FUS-R521C/FUS-WT. The genotype of successfully 
modified clones FUS-WT C4 and FUS-P525L C21 was  FUS-WT-EGFP/FUS-WT and FUS-
P525L-EGFP/FUS-WT respectively, as confirmed by sequencing. Both clones were chosen 
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for in-depth characterization of pluripotency and are further referred to as FUS-WT and FUS-
P525L. 
 
 
Figure 3.4 Screening and genotyping of FUS-EGFP positive clones. 
A FUS-EGFP expression in WT and P525L clones after CRISPR/Cas9n-mediated gene editing. Nuclei 
are counter stained with Hoechst. Scale bars: 50μm. B Screening-PCR (lane 1+3) and Genotyping-PCR 
(lane 2+4). C-D In order to verify that correction of mutant FUS-R521C cell line (Table 2.15) was 
successful, the genotype of the derived isogenic cell lines was determined by Sanger sequencing. 
Shown are the reverse strands of both alleles. C Sequencing results of FUS-WT C4. The FUS-EGFP 
allele shows that FUS mutation at amino acid position 521 (light green box) is corrected to WT sequence 
and EGFP sequence is present (dark green box). The WT allele shows FUS-WT sequence at the same 
position (blue box). D. Sequencing results of FUS-P525L C21. The FUS-EGFP allele confirms presence 
of EGFP sequence (dark green box) and possesses the mutant sequence coding for P525L mutation at 
amino acid position 525 (red box) while the parental FUS-R521C mutation was corrected to WT 
sequence (light green box). The WT allele shows FUS-WT sequences (blue boxes) at both positions of 
interest. 
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3.2.2.2 Pluripotency of isogenic FUS-EGFP iPSCs 
The parental line FUS-R521C which was used for CRISPR/Cas9n-mediated gene editing 
was previously characterized and published (Japtok, Lojewski et al. 2015). However, even 
though the introduced genomic modification is specific for the target site within FUS, there is 
still a possibility of off-targets that might affect pluripotency of generated iPSCs. Therefore, the 
confirmation of pluripotent state of the generated iPSC lines was necessary. Standard 
procedures for verification of pluripotency include immunofluorescence staining for known 
marker proteins and differentiation into the three germ layers, namely meso-, endo- and 
ectoderm. 
To confirm pluripotency, iPSC clones were stained for proteins which are known to be 
expressed in pluripotent ESCs: OCT4, SOX2, TRA-1-60, and SSEA4. Figure 3.5 shows that 
both isogenic iPSC clones were stained positive for the pluripotency markers.  
 
 
Figure 3.5 Isogenic WT and P525L iPSCs are positive for markers of pluripotency. 
Isogenic WT and P525L iPSC clones show positive staining for pluripotency markers OCT4, SOX2, 
TRA-1-60, and SSEA4. Representative images in 40x magnification are shown. Nuclei are counter 
stained with Hoechst. Scale bars: 50µm. 
Next, embryoid bodies (EBs) were formed from both iPSC clones. EBs were spontaneously 
differentiated into three germ layers for two weeks (see section 2.3.6). Figure 3.6 shows 
positive staining of iPSC clones for known marker proteins of mesoderm (alpha-smooth muscle 
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actin (SMA)), endoderm (GATA Binding Protein 4 (GATA4)), and ectoderm (neuron-specific 
class III beta-tubulin (TUJ1)), which further confirmed their pluripotent nature.  
 
 
Figure 3.6 Isogenic WT and P525L iPSCs can differentiate into cells of all three germ layer. 
Isogenic WT and P525L iPSC clones were spontaneously differentiated into cell types of the three germ 
layer to confirm pluripotent state of gene edited iPSCs. Both clones show positive staining for endoderm 
marker GATA, mesoderm marker SMA, and ectoderm marker TUJ1. Nuclei are counter stained with 
Hoechst. Scale bars: 50µm. 
Taken together, the pluripotent state and successful recombination, as shown by 
genotyping and sequencing, were confirmed for both gene edited clones. In conclusion, the 
isogenic pair (FUS-WT and FUS-P525L) can be used for neural differentiation and disease-
related experiments. 
3.2.2.3 Off-targets 
The CRISPR/Cas9n-mediated gene editing approach via double nicking is a powerful 
system to target precisely and reduce unintended interactions (off-targets) to a minimum. 
Nevertheless, cooperative nicking at off-target sites or individual off-target single-stranded 
nicks might still occur. Consequently, a computational approach was used to evaluate the 
likelihood of off-target sites for the given pair of sgRNAs. 
To screen for possible off-target effects of Cas9n both target specific sgRNAs (T1 and T2, 
see Table 2.16) were checked via the “CRISPR Design” online tool from Zhang laboratory 
(http://crispr.mit.edu) and the “Off-spotter” tool from Pliatsika et al. (Pliatsika and Rigoutsos 
2015). Both online tools confirmed that there are no genomic off-targets that are targeted from 
both sgRNAs in combination, which could result in the introduction of a DSB at any unintended 
site. Table 3.2 Table 3.3 and show possible off-target site of individual sgRNAs T1 and T2, 
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respectively, which could result in single-stranded nicks. The analysis of possible off-target 
site indicates a high specificity of the selected sgRNAs for FUS gene editing. 
 
Table 3.2 Possible Off-targets of sgRNA Target 1 (GCGAGTATCTTATCTCAAGT) 
Chr. Strand Position # of mis-
matches 
Gene Intron / 
Exon 
Tool 
7 - 82419483 3 PCLO Intron Off-spotter 
3 - 10226296 4 IRAK2 Intron Off-spotter 
20 - 34778913 4 EPB41L1 Intron Off-spotter 
4 + 4304528 4 ZBTB49 Exon Zhang Lab 
20 - 18467412 4 RBBP9 Exon Zhang Lab 
2 - 171249076 3 MYO3B Intron Zhang Lab 
4 - 124236784 4 SPATA5 Exon Zhang Lab 
8 - 14596389 4 SGCZ Intron Off-spotter 
X + 101979095 4 BHLHB9 Intron Off-spotter 
17 - 38548446 4 TOP2A Intron Zhang Lab 
 
Table 3.3 Possible Off-targets of sgRNA Target 2 (GTTAGGTAGGAGGGGCAGAT) 
Chr. Strand Position # of mis-
matches 
Gene Intron / 
Exon 
Tool 
2 + 241705216 4  KIF1A Intron Zhang Lab 
20 + 3016619 4 PTPRA Intron Zhang Lab 
16 - 2946266 4 FLYWCH2 Intron Zhang Lab 
11 - 16883955 4 PLEKHA7 Intron Off-spotter 
3 + 123823364 4 KALRN Intron Off-spotter 
2 + 218750868 4 TNS1 Intron Zhang Lab 
15 + 91003806 3 IQGAP1 Intron Off-spotter 
6 + 152016039 3 ESR1 Intron Off-spotter 
7 - 154375887 3 DPP6 Intron Off-spotter 
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15 + 93480077 4 CHD2 Intron Off-spotter 
9 - 35496488 4 RUSC2 Intron Off-spotter 
11 - 8909439 4 ST5 Intron Off-spotter 
3 - 67492286 4 SUCLG2 Intron Off-spotter 
15 - 45544391 4 SLC28A2 Intron Zhang Lab 
11 + 32457461 4  WT1-AS Intron Zhang Lab 
 
3.3 Analysis disease-associated proteins 
3.3.1 FUS-EGFP localization in cortical neurons and astrocytes 
Mutations within the NLS of FUS are known to lead to a cytoplasmic mislocalization of FUS 
protein (Vance, Rogelj et al. 2009, Bosco, Lemay et al. 2010, Dormann, Rodde et al. 2010, 
Gal, Zhang et al. 2011, Kino, Washizu et al. 2011, Zhang and Chook 2012, Vance, Scotter et 
al. 2013, Wang, Pan et al. 2013). Previously, it could be shown that FUS mislocalization 
depends on aging and the severity of mutation in mutant cortical neurons (Japtok, Lojewski et 
al. 2015).Furthermore, our group showed that FUS-P525L mutation leads to a severe shift of 
FUS from the nucleus to cytoplasm in spinal MNs (Naumann, Pal et al. 2018). In this thesis 
work, the same isogenic FUS-EGFP iPSC lines were used to analyze FUS-EGFP cellular 
localization in iPSC-derived cortical neurons and astrocytes.   
Cortical cultures derived from isogenic iPSC lines FUS-WT and FUS-P525L were matured 
for 100 days and stained for either neuron marker MAP2 or astrocyte marker GFAP. In both 
lines, a nuclear as well as cytoplasmic expression of FUS-EGFP could be observed. However, 
cytoplasmic mislocalization of FUS-EGFP seemed to be more severe in few FUS-P525L 
mutant neurons, but not astrocytes, compared to FUS-WT (Figure 3.7 A). To determine 
quantitative FUS-EGFP amounts, signals were semi-automatically detected using CellProfiler 
Software (see section 2.5.3). In brief, MAP2 or GFAP area was automatically detected and 
marker positive nuclei were manually selected. FUS-EGFP integrated intensity was measured 
within MAP2 or GFAP positive area (excluding nuclei) and within marker positive nuclei. To 
determine the cytoplasmic shift of FUS-EGFP amount the ratio of nucleus/cytoplasm was 
calculated. Figure 3.7 B shows that FUS-P525L mutant neurons showed a tendency of 
increased nuclear to cytoplasmic shift of FUS-EGFP amounts compared to FUS-WT. This was 
not observed in astrocytes. These results show that FUS-NLS mutation seems to specifically 
affect FUS cellular localization in neurons but not astrocytes.  
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Figure 3.7 Analysis of FUS-EGFP cellular distribution in cortical neurons and astrocytes. 
A Cortical cultures at maturation day 100 were stained for MAP2 or GFAP. FUS-EGFP was detected in 
nucleus and cytoplasm of both isogenic lines (FUS-WT and FUS-P525L). Nuclei were stained with 
Hoechst. Scale bars: 10 µm. B FUS-EGFP integrated intensity was semi-automatically measured in 
cytoplasm and nuclei of either MAP2 or GFAP positive cells. FUS-P525L mutant neurons but not 
astrocytes showed a decreased FUS-EGFP amount compared to isogenic control. The ratio of FUS-
EGFP integrated intensity nuclear/cytoplasmic in marker positive cells was calculated. Data is depicted 
relative to isogenic FUS-WT cell line. 
3.3.2 Characterization of C9ORF72-associated DPRs 
Aim of this thesis work was the recapitulation of C9ORF72-HRE-associated pathologies in 
the here used patient-specific in vitro model, using iPSC-derived cortical neurons. The 
accumulation of DPRs is a characteristic pathology in C9ORF72-associated disease. Studies 
using post mortem tissue of C9ORF72-HRE carriers showed, that DPRs are predominantly  
detectable within cortical region (Ash, Bieniek et al. 2013, Mackenzie, Arzberger et al. 2013, 
Schludi, May et al. 2015) and that the DPR species Poly-GA, Poly-GP, and Poly-GR are most 
abundant (Gendron, Bieniek et al. 2013, Mori, Weng et al. 2013). For that reason Poly-GA, 
Poly-GP, and Poly-GR were chosen to be analyzed. In collaboration with Dr. Carina Schludi 
and Prof. Dr. Dieter Edbauer (DZNE Munich) three monoclonal antibodies, which were already 
shown to specifically detect DRPs in various models (Mackenzie, Arzberger et al. 2013, Mori, 
Results 
78 / 163 
Arzberger et al. 2013, Schludi, May et al. 2015), were evaluated in iPSC-derived cortical 
neurons. 
3.3.2.1 ELISA for Poly-GP  
First, endogenous DPR levels of Poly-GP were determined utilizing enzyme linked 
immunosorbent assay (ELISA). Various control and C9ORF72-HRE mutant cell lines were 
differentiated into cortical cells. After 80 and 120 days of maturation whole cell lysates where 
collected for ELISA analysis. Analysis of the data showed that there seems to be no effect of 
aging on Poly-GP production (Figure 3.8). Also, there seemed to be no differences between 
distinct cell lines (Figure 3.8), although C9ORF72-HRE mutant lines showed a slightly higher 
Poly-GP production compared to controls (for descriptive statistics see Supplemental Table S 
7). Non-isogenic mutants (C9-HRE 1+3) showed very low DPR amount, which can be 
expected to be non-pathogenic as it is comparable to control levels (below 400 arbitrary units). 
Moreover, those data is comparable to Poly-GP ELISA results obtained from control sMN 
cultures (Abo-Rady 2018). In contrast, C9-HRE 2 cell line showed much higher Poly-GP levels 
compared to its isogenic control. This data is comparable to data obtained from sMN cultures 
in which the same isogenic pair was used (Abo-Rady 2018). Overall, ELISA quantification does 
not show a clear C9ORF72-HRE caused effect on Poly-GP production but did confirm previous 
findings of excessive Poly-GP production in only one out of three C9ORF72-HRE mutant lines. 
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Figure 3.8 Production of Poly-GP in cortical cells is not affected by aging. 
Production of endogenous Poly-GP was quantified utilizing ELISA. Mature (D80) iPSC-derived cortical 
cells were compared with aged (D120) ones. No difference in Poly-GP production between D80 and 
D120 old cortical cells was observed. Poly-GP production tended to be higher in C9-HRE mutant lines 
compared to controls. For descriptive statistics see Supplemental Table S 7 (n=1-3). 
As already shown, the in vitro model used in this work results in the production of only 5-
20% neurons (Figure 3.1). The Poly-GP levels detected by ELISA do not distinguish between 
different cortical cell types. This could be a reason for the unexpected low DPR detection 
levels. To specifically detect DPRs within cortical neurons, Poly-GP, Poly-GA, and Poly-GR 
were analyzed using co-immunofluorescence staining with the neuron marker MAP2. Because 
ELISA results showed no effect of aging on DPR production, only one maturation time point 
(100 days) was chosen to be analyzed. 
3.3.2.2 Immunofluorescence staining for Poly-GP 
Poly-GP was analyzed first. Small dot-like granules could be detected in control as well as 
C9ORF72-HRE mutant lines (Figure 3.9). The granules were distributed in the cytoplasm and 
neurites of cortical neurons. Additionally a nuclear staining could be detected, which confirms 
previous findings (Schludi, May et al. 2015, Yamakawa, Ito et al. 2015).  Surprisingly, Poly-GP 
granules were also observable within control neurons as well. The qualitative analysis of the 
immunofluorescence staining revealed no clear difference between control and C9ORF72-
HRE mutants. To evaluate this further, CellProfiler image analysis software was used 
(Carpenter, Jones et al. 2006, Kamentsky, Jones et al. 2011). A pipeline was created to 
automatically detect Poly-GP granules within MAP2 positive area, excluding nuclear region 
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(see section 2.5.4). Detected granules were automatically counted and size was measured. 
Because the derivation of neurons, and thus MAP2 area, can vary between independent 
differentiations and cell lines, Poly-GP values were normalized to total MAP2 area per 
experiment.  
Figure 3.10 A shows that no difference was observed regarding the number of detected 
Poly-GP granules between control and C9ORF72-HRE mutant cortical neurons relative to 
MAP2 area (for descriptive statistics see Supplemental Table S 8). In contrast, the total area 
of detected Poly-GP was significantly increased in both C9ORF72-HRE mutant cell lines 
compared to controls (Figure 3.10 B). Analysis of individual Poly-GP granules plotted as box 
plots, showed that granule size (area and radius) is significantly increased in C9ORF72-HRE 
mutant cortical neurons compared to controls (Figure 3.10 C+D; for descriptive statistics see 
Supplemental Table S 10 and Supplemental Table S 11).Taken together, immunofluorescence 
staining analysis of size parameters of detected Poly-GP granules revealed that granule size 
is increased in C9ORF72-HRE mutant cell lines.  
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Figure 3.9 Detection of Poly-GP in cortical neurons. 
Representative images of cortical neurons at maturation day 100 and stained for neuron marker MAP2 
(red) and Poly-GP (green) are shown. Small cytoplasmic dot-like granules (white arrows) and nuclear 
staining were detected in non-isogenic (Ctrl 1 + C9-HRE 1) and isogenic lines (C9 WT + C9-HRE 2). 
Nuclei were stained with Hoechst. Scale bars: 10 µm. 
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Figure 3.10 Characterization of Poly-GP within cortical neurons. 
In cortical neurons matured for 100 days, Poly-GP granules were automatically detected within MAP2 
positive area and excluding nuclei using CellProfiler software. A No difference in Poly-GP granule 
number was observed between control and C9-HRE mutants (Supplemental Table S 8). B Total Poly-
GP area is significantly increased in C9-HRE mutants compared to controls (Supplemental Table S 9). 
Poly-GP measurements in A+B were normalized to MAP2 area. C-D The area (C) and radius (D) of 
individual Poly-GP granules is significantly increased in C9-HRE mutant cortical neurons compared to 
controls (Supplemental Table S 10+11). Values of individual detected Poly-GP granules are plotted. 
Box plots represent batch results merged from independent experiments. Statistics in A+B were 
calculated by One-way ANOVA with Tukey’s post-hoc test and in C+ D by Kruskal-Wallis test with 
Dunn’s post-hoc test (n=3-4). 
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3.3.2.3 Immunofluorescence staining for Poly-GA 
After evaluation of Poly-GP in cortical neurons, a monoclonal antibody was used to detect 
Poly-GA. The same experimental setup as used for Poly-GP immunofluorescence staining and 
analysis was implemented. Similar to Poly-GP, small cytoplasmic inclusions and nuclear 
staining were observed for Poly-GA (Figure 3.11). This is consistent with previous findings 
(Schludi, May et al. 2015).  
Software-based quantification of Poly-GA granule numbers revealed no difference between 
C9ORF72-HRE mutants and controls (Figure 3.12 A, for descriptive statistics see 
Supplemental Table S 12). Also for determination of total Poly-GA area, no difference between 
C9ORF72-HRE mutant and control cortical neurons was observed (Figure 3.12 B, for 
descriptive statistics see Supplemental Table S 13). Analysis of individual granule parameters 
showed varying results. Analyzing the non-isogenic cell lines, increased size of Poly-GA 
granule area was observed in C9-HRE 1 compared to Ctrl 2, but not to Ctrl 1 (Figure 3.12 C). 
Also, there was no difference in radius size (Figure 3.12 D). Overall, the results showed no 
differences in Poly-GA size parameters (area and radius) between C9-HRE 1 and Ctrl 1, which 
is in contrast to the results obtained previously for Poly-GP in the same cell lines. For 
descriptive statistics see Supplemental Table S 14 (area) and Supplemental Table S 15 
(radius). Analysis of single Poly-GA granules in isogenic cortical neurons revealed no 
difference of granule area between C9-HRE 2 and its isogenic control C9-WT (Figure 3.12 C,) 
but the radius was significantly increased in C9-HRE 2 compared to C9-WT (Figure 3.12 D). 
Additionally, C9-HRE 2 Poly-GA granules showed significantly increased area and radius 
compared to all other non-isogenic lines. Moreover, the granule area between the three control 
lines differed significantly from each other. Taken together, quantitative determination of Poly-
GA immunofluorescence staining revealed highly inconsistent results between non-isogenic 
and isogenic lines. No clear difference between C9ORF72-HRE mutants and controls was 
detected. 
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Figure 3.11 Detection of Poly-GA in cortical neurons. 
Representative images of cortical neurons at maturation day 100 and stained for neuron marker MAP2 
(red) and Poly-GA (green) are shown. Small cytoplasmic dot-like granules (white arrows) and nuclear 
staining were detected in non-isogenic (Ctrl 1 + C9-HRE 1) and isogenic lines (C9 WT + C9-HRE 2). 
Nuclei were stained with Hoechst. Scale bars: 10 µm. 
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Figure 3.12 Characterization of Poly-GA within cortical neurons. 
In cortical neurons matured for 100 days, Poly-GA granules were automatically detected within MAP2 
positive area and excluding nuclei using CellProfiler software. A-B No difference in Poly-GA granule 
count (A, Supplemental Table S 12) or total area (B, Supplemental Table S 13) was observed between 
control and C9-HRE cortical neurons. Poly-GA measurements were normalized to MAP2 area. C An 
increased area of individual Poly-GA granules is observable in non-isogenic C9-HRE 1 mutant 
compared to Ctrl 2 but not Ctrl 1. C9-HR 2 shows no increased granule area compared to its isogenic 
control C9-WT but to all other non-isogenic lines (Ctrl 2, Ctrl 1, C9-HRE 1). For descriptive statistics see 
Supplemental Table S 14. D Analysis of radius showed no difference for non-isogenic cortical neurons 
(Ctrl 1, Ctrl2, and C9-HRE1). The radius of single granules in C9-HRE2 mutants was increased 
compared to its isogenic control C9-WT and also to all other non-isogenic lines (Ctrl 2, Ctrl 1, C9-HRE 
1). For descriptive statistics see Supplemental Table S 15. In C+D, values of individual detected Poly-
GP granules are plotted. Box plots represent batch results merged from independent experiments. 
Statistics in A+B were calculated by One-way ANOVA with Tukey’s post-hoc test and in C+D by Kruskal-
Wallis test with Dunn’s post test (n=3-6).  
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3.3.2.4 Immunofluorescence staining for Poly-GR 
In addition to Poly-GP and Poly-GA, Poly-GR was also aimed to be analyzed. However, 
preliminary test staining revealed a contingent un-specificity of the used monoclonal antibody. 
A strong cytoplasmic accumulation of Poly-GR in neurons and non-neuronal cells could be 
observed (Figure 3.13). However, even in the control line severe cytoplasmic aggregates 
positive for Poly-GR were detectable. Therefore, no further quantitative analysis of Poly-GR in 
cortical neurons was implemented. 
 
 
Figure 3.13 Detection of Poly-GR in cortical neurons.  
Representative images of cortical neurons at maturation day 100 and stained for neuron marker MAP2 
(red) and Poly-GR (green) are shown. Big cytoplasmic aggregates (white arrows) were detected in non-
isogenic (Ctrl 2 + C9-HRE 1) neuronal and non-neuronal cells. Nuclei were stained with Hoechst. Scale 
bars: 10 µm. 
3.3.3 DPRs versus DNA damage 
DDR is shown to be induced by C9ORF72-HRE in ALS and by overexpression of DPRs in 
cellular models (Farg, Konopka et al. 2017). In this thesis work, it was aimed to analyze a 
possible correlation between DPRs and DSBs using patient-specific iPSC-derived cortical 
neurons endogenously expressing C9ORF72. For this purpose, cortical neurons matured for 
100 days were co-stained with either Poly-GP or Poly-GA antibody and the DSB marker 53BP1 
and qualitative analysis was done to detect a possible correlation. It was not possible to 
perform automated analysis, since Poly-GP granules are localized in the cytoplasm while 
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53BP1 foci are situated in the nucleus and this kind of setup was incompatible with an 
automated Fiji or CellProfiler workflow. 
No obvious correlation between Poly-GP nor Poly-GA and 53BP1 was observed. The 
formation of Poly-GP (Figure 3.14) and Poly-GA (Figure 3.15) granules was detected in both 
cortical neurons that showed nuclear 53BP1 foci (red arrows) as well as in neurons that did 
not show any DNA damage (white arrows). There was no clear difference in DPR levels 
between cells with high and low 53BP1 foci number. Thus, a direct correlation between DPR 
expression and DNA damage as shown by others could not be recapitulated in iPSC-derived 
cortical neurons carrying C9ORF72-HRE mutation.  
 
 
Figure 3.14 Poly-GP versus 53BP1. 
Representative images of cortical neurons at maturation day 100 and stained for Poly-GP (green), 
53BP1 (red) and neuron marker MAP2 (cyan) are shown. Small cytoplasmic Poly-GP granules could be 
detected in neurons without DNA damage (white arrows) and within neurons showing nuclear 53BP1 
foci (red arrows). Nuclei were stained with Hoechst. Scale bars: 10 µm.  
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Figure 3.15 Poly-GA versus 53BP1. 
Representative images of cortical neurons at maturation day 100 and stained for Poly-GA (green), 
53BP1 (red) and neuron marker MAP2 (cyan) are shown. Small cytoplasmic Poly-GA granules could be 
detected in neurons without DNA damage (white arrows) and within neurons showing nuclear 53BP1 
foci (red arrows). Nuclei were stained with Hoechst. Scale bars: 10 µm.  
3.3.4 TDP43 neuropathology in C9ORF72-HRE cortical cultures 
To evaluate potential TDP43 neuropathology within the here used patient-specific in vitro 
model, 100 day matured iPSC-derived cortical neurons from healthy and C9ORF72-ALS 
patients were stained for TDP43.  
No severe cytoplasmic accumulation of TDP43 was detectable. Only small cytoplasmic 
TDP43 granules were observed in control and in C9ORF72-HRE cortical neurons (Figure 
3.16). TDP43 granules in C9ORF72-HRE mutant cortical neurons partially seemed to be 
bigger compared to control. Those granules, furthermore, did not co-localize with Poly-GA. In 
addition, nuclear loss of TDP43 was observed in a small number of cells. Also in these cells 
small cytoplasmic TDP43 granules were detected. However, qualitative screening revealed 
that mainly non-neuronal cells (MAP2 negative) showed a loss of nuclear TDP43 (Figure 3.17 
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A). Neuronal nuclear loss of TDP43 seemed to be very rare and was seen in only a few single 
MAP2 positive cells for C9-HRE 1 cell line (Figure 3.17 A, last panel). To determine if loss of 
nuclear TDP43 is associated with C9ORF72-HRE mutation, Hoechst positive and TDP43 
negative nuclei were manually counted (independent of MAP2) and the percentages of cells 
with nuclear loss were determined. Quantification revealed that in C9ORF72-HRE mutant 
cortical cultures there were more cells with TDP43 negative nucleus compared to control 
(Figure 3.17).  Because the percentages of TDP43 negative cells were highly variable between 
experiments, further quantification of additional experiments and cell lines need to be 
conducted.  
Taken together, the detection of only small TDP43 granules in cortical neurons is consistent 
with previous reports which show that cytoplasmic TDP43 aggregation can be observed only 
at low amounts in cortical regions (Ash, Bieniek et al. 2013, Mackenzie, Arzberger et al. 2013, 
Mori, Arzberger et al. , Schludi, May et al. 2015). The nuclear clearance of TDP43 was 
accompanied by the cytoplasmic inclusion formation as previously shown (Neumann, 
Sampathu et al. 2006, Lee, Lee et al. 2011).  
 
 
Figure 3.16 Detection of TDP43 versus Poly-GA in cortical neurons. 
Representative images of cortical neurons at maturation day 100 and stained for Poly-GA (green), 
TDP43 (red) and MAP2 (cyan) are shown. Small cytoplasmic Poly-GA granules (green arrows) and 
TDP43 granules (red arrows) could be detected in non-isogenic (Ctrl 2 + C9-HRE 1) cortical neurons. 
Nuclei were stained with Hoechst. Scale bars: 5 µm. 
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Figure 3.17 Loss of TDP43 in C9ORF72-HRE cortical neurons.  
A Cortical neurons matured for 100 days were stained for TDP43 (red) and MAP2 (cyan). Depletion of 
nuclear TDP43 could be observed in control and C9ORF72-HRE mutant MAP2 negative cells (upper 
and middle panel) as well as in C9ORF72-HRE mutant MAP2 positive cells (lowest panel) as indicated 
by white arrows. Cell showing nuclear loss of TDP43 showed formation of cytoplasmic TDP43 granules 
(red arrows). Nuclei were stained with Hoechst. Scale bars: 10 µm. B Percentages of cells showing 
depletion of nuclear TDP43 were determined manually. C9-HRE 1 showed increased loss of nuclear 
TDP43 compared to Ctrl 2. 
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3.4 Analysis of DNA damage in patient-specific in vitro models of 
ALS 
3.4.1 Analysis of DNA damage marker γH2AX and 53BP1 
In order to detect DNA damage, patient-specific cultures were stained for DNA double 
strand break (DSB) marker proteins γH2AX and 53BP1. Aim was the comparison of DNA 
damage levels in neurons and astrocytes. Because the in vitro models used in this thesis work 
showed variable differentiation potential (see section 3.1), the iPSC-derived neural cells were 
stained for neuron marker MAP2 or astrocyte marker GFAP to determine DNA damage 
specifically within marker positive nuclei. To evaluate the effect of patient-specific C9ORF72 
and FUS mutations on the amount of DNA damage, γH2AX+ and 53BP1+ foci were 
determined at basal levels and using a pulse chase experiment after induction of DSBs by 
etoposide treatment and recovery. Cells were treated with 2 µM etoposide for 1h to induce 
DNA damage and either fixed directly after treatment or etoposide was removed for 24h from 
the medium for DNA damage recovery (Figure 3.18 A). Furthermore, isogenic as well as non-
isogenic lines were used. 
3.4.1.1 Evaluation of DSB markers in cells with C9ORF72-HRE mutation 
DSB markers γH2AX and 53BP1 were analyzed in control and C9ORF72-HRE mutant 
spinal MNs, cortical neurons, and cortical astrocytes. Both markers were detected as nuclear 
dot-like pattern (foci) in spinal MNs (Figure 3.18), cortical neurons (Figure 3.19), and cortical 
astrocytes (Figure 3.20) under all implemented conditions (untreated, Eto 0h Recovery, and 
Eto 24h Recovery). Immunofluorescence staining revealed no obvious difference between 
examined cell lines or cell types. Therefore, CellProfiler software was used to semi-
automatically detect and quantify nuclear foci (see section 2.5.1.1). In brief, MAP2 or GFAP 
positive nuclei were manually selected. Then, the software automatically detected nuclear 
γH2AX and 53BP1 foci within neurons or astrocytes, following the quantification of DSBs under 
untreated and etoposide treated conditions. 
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Figure 3.18 Detection of DSB markers in spinal MNs with C9ORF72-HRE mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. B Spinal MNs at 
maturation day 21 were stained for neuron marker MAP2 (cyan) and the two DSB markers γH2AX 
(green) and 53BP1 (red). DSBs were analyzed in untreated and etoposide treated cells without and 
after 24h recovery. Nuclear foci positive for both markers could be detected in all conditions and cell 
lines. Representative images of Ctrl 1 and C9-HRE1 are shown. Nuclei were stained with Hoechst. 
Scale bars: 10 µm. 
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Figure 3.19 Detection of DSB markers in cortical neurons with C9ORF72-HRE mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. B Cortical cultures 
at maturation day 100 were stained for neuron marker MAP2 (cyan) and the two DSB markers γH2AX 
(green) and 53BP1 (red). DSBs were analyzed in untreated and Etoposide treated cells without and 
after 24h recovery. Nuclear foci positive for both markers could be detected in all conditions and cell 
lines. Representative images of Ctrl 1 and C9-HRE1 are shown. Nuclei were stained with Hoechst. 
Scale bars: 10 µm. 
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Figure 3.20 Detection of DSBs in cortical astrocytes with C9ORF72-HRE mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. B Cortical cultures 
at maturation day 100 were stained for astrocyte marker GFAP (magenta) and the two DSB markers 
γH2AX (green) and 53BP1 (red). DSBs were analyzed in untreated and Etoposide treated cells without 
and after 24h recovery. Nuclear foci positive for both markers could be detected in all conditions and 
cell lines. Representative images of Ctrl 1 and C9-HRE1 are shown. Nuclei were stained with Hoechst. 
Scale bars: 10 µm. 
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First, DSB levels were quantified in spinal MN cultures. For that, the non-isogenic lines Ctrl 
1 and C9-HRE 1 were differentiated as described under section 2.3.7.2. Spinal MNs matured 
for 21 days were then stained for γH2AX and 53BP1. In spinal MNs no difference of DNA 
damage between control and mutant was observed (Figure 3.21, γH2AX: P=0.124, 53BP1: 
P=0.123, n=3, unpaired two-tailed t-test). This is contrast to previous findings which showed 
increased DSB levels in patient-specific spinal MNs with C9ORF72-HRE mutation (Higelin, 
Catanese et al. 2018) or in neuroblastoma cell and primary mouse neurons expressing 
C9ORF72-HRE (Farg, Konopka et al. 2017). 
 
 
Figure 3.21 Characterization of DSB markers in untreated spinal MNs with C9ORF72-HRE 
mutation. 
Nuclear foci of DSB markers γH2AX and 53BP1 were semi-automatically detected within MAP2 positive 
nuclei in 21 day matured spinal MNs. A-B No difference of γH2AX (A) or 53BP1 (B) foci number per 
MAP2+ nucleus was detected between control (Ctrl 1) and C9-HRE mutant (C9-HRE 1). Statistics were 
calculated by Unpaired two-tailed t-test (n=3). 
Next, DSB numbers were determined within cortical cells. Figure 3.22 A and B show the 
quantification of DSB markers γH2AX (A) and 53BP1 (B) in cortical neurons. An effect of cell 
line was observed on γH2AX foci number (P=0.013, F (4, 19) = 4.19, n=3-8, One-way ANOVA) 
but not on 53BP1 foci count (P=0.102, F (4, 16) = 2.31, n=3-6, One-way ANOVA).  In Figure 
3.22 C and D the quantification of γH2AX (C) and 53BP1 (D) in cortical astrocytes is 
demonstrated. The cell line showed an effect on both γH2AX (P=0.007, F(4,17)=5.18, n=3-7, 
One-way ANOVA) and 53BP1 (P<0.0001, F(4,17)=15.53, n=3-7, One-way ANOVA) foci 
numbers. Statistical post-hoc testing revealed no significant differences when C9ORF72-HRE 
mutants where compared to their corresponding non-isogenic or isogenic controls (C9-HRE 1 
vs. Ctrl 1+2 and C9-HRE 2 vs. C9-WT). Thus, C9ORF72-HRE mutation does not seem to drive 
the detected cell line effects. Taken together, it can be said, that no obvious effect of 
C9ORF72-HRE mutation on accumulation of DSBs in spinal or cortical neurons and astrocytes 
was observed. 
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Figure 3.22 Characterization of DSB markers in untreated cortical neurons and astrocytes with 
C9ORF72-HRE mutation. 
Nuclear foci of DSB markers γH2AX and 53BP1 were semi-automatically detected within MAP2 and 
GFAP positive cells in 100 day matured cortical cultures. A-B In MAP2+ nuclei the cell line had an effect 
on γH2AX foci number (A, P=0.013) but not on 53BP1 (B, P=0.102). C-D In GFAP+ nuclei the cell line 
had an effect on the foci number on both γH2AX (C, P=0.007) and 53BP1 (D, P<0.0001). Multiple 
comparison revealed no significant difference between mutants compared to their corresponding 
controls (C9-HRE 1 vs. Ctrl 1+2; C9-HRE 2 vs. C9-WT). Statistics were calculated by one-way ANOVA 
with Tukey’s post-hoc test (n=3-8).  
We next asked the question whether there are differences in occurrence of DNA damage 
in cortical vs. spinal neurons. The neuronal cell type indeed showed an effect on basal γH2AX 
(Figure 3.23 A, P=0.001, F (1, 12) = 19.55, n=3-6, Two-way ANOVA) and 53BP1 (Figure 3.23 
B, P<0.0001, F (1, 11) = 36.3, n=3-6, Two-way ANOVA) levels. Thus, spinal MNs show 
significantly more DSBs compared to cortical neurons. Next, DSB levels were compared in 
cortical neurons versus astrocytes. Here the cell type also showed a strong effect on DSB 
levels for both γH2AX (Figure 3.23 C, P<0.0001, F (1, 36) = 39.97, n=3-8, Two-way ANOVA) 
and 53BP1 (Figure 3.23 D, P<0.0001, F (1, 33) = 160.7, n=3-6, Two-way ANOVA). Neurons 
showed significantly less DNA damage than astrocytes in cortical cultures. Finally, the two 
DSB markers were compared amongst each other in cortical cells. In cortical neurons an effect 
of the marker on the foci number could not be detected (Figure 3.23 E, P=0.147, F (1, 35) = 
2.20, n=3-8, Two-way ANOVA). In contrast, in cortical astrocytes an effect of the marker was 
detectable (Figure 3.23 F, P<0.0001, F (1, 34) = 27.51, n=3-6, Two-way ANOVA). However, 
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only two control lines showed significantly increased 53BP1 foci number compared to γH2AX. 
In summary, spinal MNs showed significantly more basal DNA damage compared to cortical 
neurons while, in turn, cortical astrocytes presented significantly increased DSB levels 
compared to cortical neurons. Thus, the cell type showed a clear effect on basal DNA damage 
levels.  
 
 
Figure 3.23 Comparison of DSB markers in untreated neural cell types with C9ORF72-HRE 
mutation. 
After detection of nuclear foci of the DSB markers γH2AX and 53BP1 in untreated spinal MNs and 
cortical neurons and astrocytes, the detected foci numbers were compared among each other. A-B 
Spinal MNs showed significantly higher basal levels of DNA damage for both γH2AX (A) and 53BP1 (B) 
when compared to cortical neurons. C-D In cortical cultures, basal DNA damage levels for both γH2AX 
(C) and 53BP1 (D) were significantly higher in astrocytes compared to neurons. E-F DSB marker 53BP1 
showed similar basal levels of DNA damage in cortical neurons (E) and astrocytes (F) when compared 
to γH2AX. Only in astrocytes (F), increased foci numbers of 53BP1 could be detected for Ctrl2 and C9-
WT lines. Statistics were calculated by Two-way ANOVA with Sidak’s post-hoc test to compare cortical 
vs. sMN (A-B), MAP2 vs. GFAP (C-D), or γH2AX  vs. 53BP1 (E-F) (n=3-8). Asterix indicate post-hoc 
significances. 
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No clear effect of patient-specific C9ORF72-HRE mutation on DNA damage could be 
observed in unstressed conditions. Therefore, we next investigated whether induction of DNA 
damage differs in mutants and controls. Thus spinal and cortical cultures were treated with 
etoposide to analyze the effect of DNA damage induction in mutant cells. Etoposide (Eto) is 
an inhibitor of topoisomerase IIα which results in the formation and accumulation of DSBs as 
long as it is exposed to cell culture (Walker and Nitiss 2002). Spinal cultures at day 21 or 
cortical cultures at day 100 of maturation were treated with 2µM etoposide for 1h. Cells were 
either fixed directly after treatment or etoposide was removed to allow cells to recover for 24h 
(Figure 3.24 A). Aim was to evaluate if patient-specific cells react differentially to the treatment 
and if they are able to recover. 
First, etoposide treated spinal MNs were analyzed. DSB levels after etoposide treatment 
and recovery were normalized to untreated values. No effect of treatment was neither 
observed for γH2AX (Figure 3.24 B, P=0.079, F (2, 11) = 3.22, n=2-3, Two-way ANOVA) nor 
53BP1 (Figure 3.24 C, P=0.165, F (2, 11) = 2.136, n=2-3, Two-way ANOVA).  
 
 
Figure 3.24 Characterization of DSB markers in etoposide treated spinal MNs with C9ORF72-HRE 
mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. Spinal MNs matured 
for 21 days were treated with etoposide to induce DNA damage. Foci number of γH2AX and 53BP1 was 
determined in untreated, etoposide treated without recovery and etoposide treated with 24h recovery 
MAP2+ cells. B+C An effect of etoposide treatment on DSB foci levels could not be detected, neither 
for γH2AX (B, P=0.079) nor 53BP1 (C, P=0.165). Data is depicted relative to untreated cell line. 
Statistics were calculated by Two-way ANOVA with Dunnett’s post-hoc test to compare treatment effect 
with untreated condition (n=2-3). 
Next, etoposide treated cortical cultures were analyzed. Because non-isogenic controls Ctrl 
1 and Ctrl 2 did not significantly differ under untreated condition they were pooled for analysis. 
Evaluation of etoposide treatment and recovery was analyzed relative to untreated condition. 
In cortical neurons, etoposide treatment showed a strong effect on both γH2AX (Figure 3.25 
B, P<0.0001, F (2, 46) = 47.33, n=2-12, Two-way ANOVA) and 53BP1 (Figure 3.25 C, 
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P<0.0001, F (2, 43) = 16.02, n=2-10, Two-way ANOVA) foci number. Same in cortical 
astrocytes, a strong effect of treatment on γH2AX (Figure 3.25 D, P<0.0001, F (2, 46) = 23.97, 
n=2-11, Two-way ANOVA) and 53BP1 (Figure 3.25 E, P=0.0004, F (2, 46) = 9.183, n=2-11, 
Two-way ANOVA) was observed. All examined cell lines and cell types were able to recover. 
Of note, similar as observed in untreated conditions non-isogenic lines behaved slightly 
differently compared to isogenic ones. Non-isogenic controls (Ctrl 1+2) and C9-HRE 1 mutant 
showed a stronger increase of DNA damage after treatment than isogenic control C9-WT and 
C9-HRE 2 mutant. This, in turn, is contrary to untreated conditions, in which the two isogenic 
lines showed increased basal DSB levels compared to non-isogenic lines (Figure 3.22).  
 
 
Figure 3.25 Characterization of DSB markers in etoposide treated cortical cultures with 
C9ORF72-HRE mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. Cortical cultures 
matured for 100 days were treated with etoposide to induce DNA damage. Foci number of γH2AX and 
53BP1 was determined in untreated, etoposide treated without recovery, and etoposide treated with 24h 
recovery MAP2+ and GFAP+ cells. B-C Etoposide treatment showed an effect in cortical neurons for 
both DSB markers γH2AX (B, P<0.0001) and 53BP1 (C, P<0.0001). D-E An effect of treatment could 
also be detected in cortical astrocytes for both γH2AX (D, P<0.0001) and 53BP1 (E, P=0.0004). Non-
isogenic lines showed a stronger increase of DNA damage after etoposide treatment than isogenic lines. 
No difference between controls and C9-HRE mutants could be observed. All tested lines recover after 
DNA damage induction. Data is depicted relative to untreated cell line. Data of non-isogenic controls 
(Ctrl 1+2) were pooled. Statistics were calculated by Two-way ANOVA with Dunnett’s post-hoc test to 
compare treatment effect with untreated condition (n=2-12). Asterix indicate post-hoc significances.  
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Taken together, etoposide treatment and recovery showed an effect in cortical neurons and 
astrocytes but not in spinal MNs. Most importantly, there was no difference between control 
and mutant cells. Moreover, isogenic lines C9-WT and C9-HRE 2 showed a less strong 
increase of DSB number after treatment than non-isogenic lines. Both lines presented already 
higher DNA damage level in untreated condition in cortical cells. The same applies to spinal 
MNs, which showed increased DSB levels compared to cortical neurons. In conclusion, this 
implies that cells which already possess high basal levels of DNA damage, do not accumulate 
DSBs after etoposide treatment to the same extend as cells with lower basal DNA damage 
levels or cells with high basal DNA damage levels die of after treatment.  
3.4.1.2 Evaluation of DSB marker in cells with FUS-NLS mutation 
Increased levels of DNA damage, specifically DSBs, and increased vulnerability to DNA 
damage induction have been reported for various in vitro models carrying ALS-associated FUS 
mutations (Mastrocola, Kim et al. 2013, Qiu, Lee et al. 2014, Higelin, Demestre et al. 2016, 
Naumann, Pal et al. 2018). In our recent publication, using the same FUS lines as within this 
thesis work, we could show that FUS mutant NPCs and spinal MNs show higher DSB levels 
in untreated condition compared to control (Figure 3.26 A+B). However, nothing is yet known 
about cortical cells in FUS mutation carriers. Therefore, DSB levels were analyzed in FUS 
mutant cortical neurons and astrocytes under the same conditions as already described for 
C9ORF72-HRE mutant cells (see section 3.4.1.1). Only DSB marker 53BP1 was evaluated, 
as previous comparison of γH2AX and 53BP1 revealed no significant difference between both 
markers in controls and C9ORF72-HRE mutants (Figure 3.23 E+F). Further, isogenic control 
(FUS-WT) and mutants (FUS-R521C and FUS-P525L) were compared to non-isogenic 
controls (Ctrl 1 and Ctrl 2). As described in section 3.2, the patient-specific line FUS-R521C 
was used to generate EGFP-tagged lines FUS-WT and FUS-P525L. Thus, all three lines are 
isogenic to each other, however only two possess an EGFP-Tag. To exclude a possible 
influence of the EGFP-Tag on DNA damage levels, FUS-R521C line was additionally 
compared to non-isogenic control lines Ctrl 1 and Ctrl 2.  
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Figure 3.26 Characterization of DSB marker γH2AX and 53BP1 in spinal MNs with FUS mutation. 
A+B Both, FUS-NPCs (A) and mature sMNs (B) showed more DSBs per nucleus over controls (N = 3). 
C Untreated mature FUS-P525L (FUS) sMNs showed increased nuclear DSB foci over isogenic control 
cells, consistent with untagged FUS lines in B. 1 h etoposide treatment and 24 h withdrawal led to a 
similar response compared to control cells (i.e. transient increase of DSB foci and reversion to basal 
levels indicative of successful DSB repair). D Same as C but expressed as fold change over respective 
untreated control (N = 4). Statistics A-D: data are plotted as mean±SD, unpaired t-test (only A) or one-
way ANOVA (B-D) with post-hoc Bonferroni test. E Validation of the γH2AX antibody in FUS-P525L 
sMNs (without etoposide) by co-staining with 53BP1: Note the prominent colocalization (merge, yellow 
overlapping). The figure was adopted from Naumann & Pal 2018 and modified by the author of this 
study. 
 
Small nuclear 53BP1 foci could be detected in all cell lines in untressed (Figure 3.27 A) and 
etoposide treated conditions (images not shown). Quantification of 53BP1 foci numbers in 
untreated cells showed no effect of the cell line on DSB levels in cortical neurons (Figure 3.27 
B, P=0.865, F (4, 11) = 0.31, n=1-6, One-way ANOVA with Tukey’s post-hoc test). In contrast, 
an effect of cell line on foci numbers was observed in cortical astrocytes (Figure 3.27 C, 
P=0.047, F (4, 12) = 3.346, n=2-7, One-way ANOVA with Tukey’s post-hoc test). Statistical 
post-hoc testing, however, revealed no significant differences between FUS mutants and 
controls. Tis is different to spinal MNs, where FUS mutants showed significantly increased 
DSB levels compared to control (Figure 3.26 A-C). Furthermore, cortical astrocytes showed 
increased DSB levels in controls and FUS mutants when compared to cortical neurons (Figure 
3.27 D). Thus, the cell type had an effect on 53BP1 foci number (P<0.0001, F (1, 23) = 25.96, 
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n=1-7, One-way ANOVA), which is consistent to previous findings in C9ORF72-HRE mutant 
lines (Figure 3.23 C+D).  
 
 
Figure 3.27 Characterization of DSB marker 53BP1 in untreated cortical cells with FUS mutation. 
Cortical cultures at maturation day 100 were stained for DSB marker 53BP1 (red) and neuron marker 
MAP2 (cyan) or astrocyte marker GFAP (magenta). Nuclear foci were semi-automatically detected 
within MAP2 and GFAP positive nuclei. A Nuclear 53BP1 positive foci could be detected in all cell lines. 
Representative images of isogenic FUS control (FUS-WT) and mutant (FUS-R521C, FUS-P525L) lines 
are shown. Nuclei were stained with Hoechst. Scale bars: 10 µm. B-C The cell line had no effect on 
basal 53BP1 foci numbers in cortical neurons (B, P=0.865) but showed an effect in astrocytes (C, 
P=0.047). Effect of cell line on 53BP1 foci numbers was calculated by One-way ANOVA with Tukey’s 
post-hoc test (n=1-7). D The cell type had an effect on basal DSB levels (P<0.0001). The effect of cell 
type was calculated by Two-way ANOVA with Sidak’s post-hoc test to compare MAP2 vs. GFAP (n=1-
7). Asterix indicate post-hoc significances.  
Evaluation of DSB levels after DNA damage induction revealed an effect of etoposide 
treatment on 53BP1 foci numbers in both cortical neurons (Figure 3.28 B, P<0.0001, F (2, 33) 
= 18.96, n=1-10, Two-way ANOVA) and astrocytes (Figure 3.28 C, P<0.0001, F (2, 32) = 
76.54, , n=1-11, Two-way ANOVA). Controls as well as mutants showed increased DSB 
numbers after treatment. All cell lines were able to recover after DNA damage induction. No 
differences were found between control and mutant cortical cells. Those results are consistent 
with DNA damage induction data obtained from spinal MNs. Figure 3.26 C+D shows, that both 
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control and FUS mutant spinal MNs show increased DSB levels after etoposide treatment and 
that both are able to recover DNA damage after etoposide retrieval.  
 
 
Figure 3.28 Characterization of DSB marker 53BP1 in etoposide treated cortical cells with FUS 
mutation. 
A Workflow chart of etoposide (Eto) treatment conditions with and without recovery. Cortical cultures 
matured for 100 days were treated with etoposide to induce DNA damage. Foci number of 53BP1 was 
determined in untreated, etoposide treated without, and etoposide treated with 24h recovery MAP2+ 
and GFAP+ cells. B-C Etoposide treatment showed an effect on 53BP1 foci numbers in cortical neurons 
(B, P<0,0001) and astrocytes (C, P<0,0001). All tested lines recover after DNA damage induction. Data 
is depicted relative to untreated cell line. Data of non-isogenic controls (Ctrl 1+2) were pooled. Statistics 
were calculated by two-way ANOVA with Dunnett’s post-hoc test to compare treatment effect with 
untreated condition (n=1-11). Asterix indicate post-hoc significances. 
In summary, cortical cultures of FUS mutants show no increased accumulation of DNA 
damage in unstressed condition compared to controls, which is different to spinal MNs. 
Moreover, cortical astrocytes show increased basal levels of DNA damage compared to 
neurons. This results are consistent with aforementioned findings in C9ORF72-HRE mutant 
cortical cultures. Finally, cortical neurons and astrocytes are able to recover after DNA damage 
induction via etoposide, similar as observed in spinal MNs.  
3.4.1.3 Effect of etoposide on cell survival 
Previous findings showed that cortical neurons are able to recover DNA damage induced 
by etoposide (see section 3.4.1). However, single cells acquire different amounts of DSBs. 
Because neurons are supposed to be highly vulnerable to DSBs (Penndorf, Witte et al. 2018), 
cells with high DSB levels might rather die off instead of repairing the DNA damage. In turn, 
measured DSB levels after recovery might be related to cells that did not acquire high DSB 
levels after etoposide treatment. To validate this, fragmented nuclei were counted and MAP2 
positive nuclei numbers were determined in cortical cultures before and after etoposide 
treatment with 24h recovery phase. Quantification of fragmented nuclei revealed no effect of 
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etoposide treatment on cell death (Figure 3.29 A, P=0.094, F (1, 22) = 3.06, n=1-3, Two-way 
ANOVA). Etoposide neither had an effect on neuron numbers (Figure 3.29 B, P=0.133, F (1, 
22) = 2.44, n=1-3, Two-way ANOVA). Taken together, DNA damage induction via etoposide 
did not result in increased cell death or neuron loss. 
 
 
Figure 3.29 Effect of etoposide on cell survival. 
Cortical cultures matured for 100 days were treated with etoposide to induce DNA damage and allowed 
to recover for 24h. A-B The effect of etoposide treatment on cell survival was analyzed by determining 
the numbers of fragmented nuclei (A) and living MAP2 positive nuclei (B). Etoposide treatment showed 
neither effect on fragmented nuclei numbers (A, P=0.094) nor on MAP2 positive nuclei (B, P=0.1329). 
Data is depicted relative to untreated cell line. Statistics were calculated by Two-way ANOVA with 
Sidak’s post-hoc test to compare etoposide treated cells after recovery with untreated condition (n=1-
3). 
3.4.2 Analysis of laser-induced DNA damage 
FUS is known to be involved in DDR and mutations within FUS gene were shown to lead to 
an impaired recruitment of the protein to DNA damage sites (DDS) (Mastrocola, Kim et al. 
2013, Wang, Pan et al. 2013, Qiu, Lee et al. 2014, Rulten, Rotheray et al. 2014, Naumann, 
Pal et al. 2018). In particular, our group could show that P525L mutant FUS fails to be recruited 
to laser cut sites in spinal MNs (Figure 3.30)(Naumann, Pal et al. 2018). In this thesis work, 
the same isogenic WT and P525L EGFP-tagged FUS lines were used. Implementing the same 
UV laser-induced DNA damage, the recruitment of WT and P525L FUS-EGFP was analyzed 
in iPSCs and cortical neurons.  
Both cell types (iPSC and cortical neurons) showed FUS-EGFP recruitment to DDS in WT 
as well as in P525L mutants (Figure 3.31 A). Of note, P525L mutant FUS is recruited to laser 
cut, which is contrary to previous findings in spinal MNs (Figure 3.30)(Naumann, Pal et al. 
2018). Evaluation of FUS-EGFP fluorescence intensity on cutting site revealed, that P525L 
mutant cortical neurons showed delayed recruitment of FUS-EGFP and longer association to 
laser cut sites compared to controls (Figure 3.31 B, lower panel). This difference was not 
observed in iPSCs, in which control and P525L mutant cells show similar FUS-EGFP kinetics 
after laser irradiation (Figure 3.31 B, upper panel). In iPSCs, mutant FUS even seemed to be 
recruited slightly faster than WT FUS.  
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Figure 3.30 Recruitment of FUS-EGFP to laser-induced DNA damage sites in spinal MNs. 
A Mutant FUS-P525L failed to be recruited to DNA damage sites. Recruitment-withdrawal to Laser cuts 
in spinal MN nuclei (boxed area) expressing normal (WT) or mutant P525L (Mut) FUS-EGFP was 
imaged live at maturation day 21. B Quantification of A, FUS-EGFP at cut over time. The figure was 
adopted from Naumann & Pal 2018 and modified by the author of this study. 
 
 
 
Figure 3.31 Recruitment of FUS-EGFP to laser-induced DNA damage sites in cortical neurons. 
A Recruitment of WT or P525L FUS-EGFP to laser cut sites was analyzed in iPSCs and cortical neurons 
matured for 70-90 days. WT as well as P525L mutant cells showed recruitment of FUS-EGFP Scale 
bar: 10 µm (Supplementary movie S1).  B Graphic representation of A showed that FUS-EGFP 
recruitment of P525L mutant is delayed in cortical neurons compared to mutant iPSCs and compared 
to WT cortical neurons as well as iPSCs. Graphs represent FUS-EGFP signal at cut over time.  Data 
from n=3 independent experiments is plotted. Data obtained from individual cells was pooled per 
experiment.  
3.5 Axonal organelle trafficking analysis within patient-specific 
cortical neurons 
Axonal organelle trafficking is known to be impaired in ALS (Wang, Li et al. 2013, Xia, Wang 
et al. 2016, Guo, Naujock et al. 2017, Kreiter, Pal et al. 2018, Naumann, Pal et al. 2018). Using 
compartmentalized microfluidics chambers (MFCs) for directed axonal growth, previous 
findings of our group show that FUS mutations lead to trafficking defects in the distal axon of 
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spinal MNs (Figure 3.32)(Naumann, Pal et al. 2018). In this thesis work, the same FUS mutant 
iPSC line as included in the publication (FUS-R521C) and one additional FUS mutant line 
(FUS-P525L) were used to analyze axonal organelle trafficking in iPSC-derived cortical 
neurons. Mitochondria and lysosome were visualized by the life dye treatments with Mito- and 
Lysotracker of cortical neurons cultured in MFCs (Pal, Glass et al. 2018). Videos from the distal 
(away from the soma) and proximal (near the soma) part of neuron axon were taken to 
determine organelle motility (schematic overview: Figure 3.34 A). 
 
Figure 3.32 FUS mutant spinal MNs develop trafficking defects of mitochondria and lysosomes 
in distal axons. 
Organelle displacement (A) and mean speed (B) analyses as box plots, batch analysis of three non-
isogenic controls (Ctrl) and three FUS mutant (FUS) lines. The figure was adopted from Naumann & Pal 
2018 and modified by the author of this study. 
3.5.1 Directed axonal outgrowth of cortical neurons 
Cortical cultures were matured for 40-45 days and plated into MFCs (see section 2.3.7.3). 
In order to determine if cortical neurons successfully grow within MFCs, cells were observed 
over time after splitting into MFCs. Brightfield imaging showed that control as well as FUS 
mutant lines successfully grow through micro channels from proximal to distal site (Figure 3.33 
A, upper panel). Cortical astrocytes can also generate long cell processes that look similar to 
neuronal dendrites and axons (Figure 3.1 C, Figure 3.20). To verify that only neuronal axons 
grow through the micro channels and to distinguish neuronal and astrocytic cell processes, 
MFC cultures were stained for axon marker SMI32 (also known as neurofilament H) and 
astrocyte marker GFAP. SMI32 labels non-phosphorylated NF-H, including cell bodies, 
dendrites and subpopulation of pyramidal neurons in human and monkey neocortex (Campbell 
and Morrison 1989, Trapp, Peterson et al. 1998). Figure 3.33 A shows that only SMI32 positive 
axons grow through micro channel exit sites, while GFAP positive processes could not be 
observed.  
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Additionally, after splitting into MFCs the number of passed channel exits was counted 2 to 
3 times a week for the isogenic FUS lines. In Figure 3.33 B the data of two independent 
differentiations is plotted. For all three cell lines a highly inter-experimental variability was 
observed. As shown in the upper panel of Figure 3.33 B, FUS-R521C neurons need more time 
to fully grow through the micro channels in one experiment (Exp. 1) which is the other way 
around in the second experiment (Exp.2). In contrast, FUS-P525L as well as FUS-WT neurons 
need approximately the same time to grow through MFCs in both independent experiments. 
Nevertheless, the data showed no growth differences caused by FUS mutations (FUS-R521C 
and FUS-P525L) compared to their isogenic control (FUS-WT). Moreover, the data showed 
that cortical neurons need at least 30 days after splitting into MFCs to fully grow through 
channel exit sites. 
 
Figure 3.33 Characterization of distal axonal outgrowth of cortical neurons in MFCs. 
Cortical cells were split into MFCs at maturation day 40-45. A To fully grow through the micro channels 
exit sites, neurons needed to be matured for at least further 40 days as shown by brightfield imaging 
(upper panel). Staining of distal exit sites of MFCs for axon marker SMI32 (red) and astrocyte marker 
GFAP (green) confirmed that only neuronal axons grow though the micro channels and not astrocytic 
processes. Representative images of non-isogenic line Ctrl 2 and isogenic lines FUS-WT and FUS-
P525L are shown. Images display sections of 20x magnification. Scale bars: 25 µm. B Quantitative 
determination of number of passed channel exits over time after split into MFCs. No difference of axonal 
outgrowth between isogenic control (black lines) and FUS mutants (FUS-R521C: light green, upper 
panel; FUS-P525L: dark green, lower panel) was observed. Shown is data of two independent 
differentiations (Exp. 1 + 2). For each experiment, values of three technical replicates (MFCs) were 
pooled. 
3.5.2 Motility of mitochondria and lysosomes 
Previous findings of our group and others could show, that axonal organelle trafficking is 
impaired in mutant FUS (Guo, Naujock et al. 2017, Naumann, Pal et al. 2018)(Figure 3.32) 
and TDP43 (Kreiter, Pal et al. 2018) spinal MN cultures. To analyze organelle motility 
parameters in cortical cultures, mitochondria and lysosome were tracked with a live cell 
imaging approach (see section 2.4.3) and the mean speed and displacement (=extent of 
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movement radius) of tracked organelles was determined. Cortical MFC cultures were imaged 
earliest at maturation day 70 (~30 days after splitting into MFCs) to ensure that cortical neuron 
axons fully grow through micro channels. Latest imaging time point was 130 days after neural 
induction to ensure imaging before cortical neurons start to degenerate. Received data of the 
two isogenic FUS mutant lines FUS-R521C and FUS-P525L was pooled (FUSmt) and 
compared to pooled control data received from isogenic control FUS-WT and the non-isogenic 
control line Ctrl 2.  
Live cell imaging movies and maximum intensity projections of Mito- and Lysotracker 
showed no obvious differences between controls and mutants in cortical neurons cultured in 
MFCs (Figure 3.34 B+E, Supplemental Movie S2+3). Quantitative assessment of 
mitochondrial and lysosomal track displacement revealed a significant increased track 
displacement of mitochondria and lysosomes in distal and proximal axons of FUS mutants 
compared to controls (Figure 3.34 C+F, Supplemental Table S 1, Supplemental Table S 3). 
Calculation of mitochondrial and lysosomal mean speed revealed that both organelle types are 
significantly slowed down in distal and proximal axons of FUS mutant cortical neurons 
compared to controls (Figure 3.34 D+G, Supplemental Table S 2, Supplemental Table S 4). 
Taken together, an effect of FUS mutations on axonal trafficking of mitochondria and lysosome 
could be observed in cortical neurons. However, mutant FUS affects cortical axonal trafficking 
differently as observed in spinal MNs in which a dramatic if not complete loss of motility has 
been described (Guo, Naujock et al. 2017, Naumann, Pal et al. 2018).  
 
 
 
Figure 3.34 Live cell imaging analysis of mitochondrial and lysosomal motility. 
A Schematic demonstration of distal and proximal areas of a neuron axon. B+E Representative images 
taken from live cell imaging show Mitotracker (B) and Lysotracker (E) in 900 µm MFC cortical cultures 
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matured for over 70 days (for movies see supplementary Movies S2+3). Images represent maximum 
projection intensities of one passed channel and display sections from 100 x magnifications. Scale bars: 
10 µm. C Quantification of mitochondrial track displacement showed a significant increase of proximal 
and distal motility. D Quantification of mean speed revealed significantly decreased motility of 
mitochondria in proximal and distal axons. F Quantification of lysosomal track displacement showed a 
significant increase of proximal and distal motility. G Quantification of mean speed revealed significantly 
decreased lysosomal motility in both proximal and distal axons. Analysis as box plots. Control data was 
pooled from non-isogenic Ctrl 2 and isogenic FUS-WT. FUS mutant data was pooled from isogenic 
mutants FUS-R521C and FUS-P525L. For detailed statistics see Supplemental Table S 1-4. Statistics 
were calculated by Kolmogorov-Smirnov test (n=3-7 technical replicates from 2-4 independent 
differentiations). 
Not all of the detected organelles are considered to be moving. To calculate the 
percentages of moving mitochondria and lysosome the ratio of non-moving versus moving 
organelle counts was determined. Tracked organelles with a displacement ≥1.2 µm were 
considered as moving tracks. Everything below was considered to be a non-moving organelle. 
Figure 3.35 shows the comparison of total moving mitochondria and lysosomes in distal versus 
proximal cortical neuron axon.  
An effect of cell line on amount of moving mitochondria was neither detected for distal nor 
for proximal axon (Figure 3.35 A, Supplemental Table S 5). Similar amounts of moving 
mitochondria could be detected for mutants as well as controls with no detectable effect of 
FUS mutation. Consistent with this, no effect of cell line on amounts of moving lysosome in 
distal and proximal (Figure 3.35 B, Supplemental Table S 6) axon could be observed. Similar 
amounts of moving lysosomes were detected for both mutants and controls.  
In summary, on average 20.61 ± 6.56 % moving organelles were detected within cortical 
axons. An effect of FUS mutation on amounts of moving organelles could not be observed.  
 
 
Figure 3.35 Quantification of mitochondrial and lysosomal moving tracks. 
The amounts of moving organelles in distal and proximal parts of cortical neuron axon were determined 
by calculating the ratio of non-moving and moving tracks. Tracked organelles with a displacement ≥1.2 
µm were considered as moving tracks. No effect of cell line on amounts of moving mitochondria (A) or 
lysosomes (B) could be observed. The effect of the cell line on organelle motility was calculated by One-
way ANOVA with Tukey’s post-hoc test (n=3-7 technical replicates from ≥ 2 independent 
differentiations). See Supplemental Table S 5+6 for descriptive statistics.  
Discussion 
110 / 163 
4 Discussion 
The main subject of this thesis work is to model cortical neuropathology of FUS- and 
C9ORF72-associated ALS using patient-specific iPSCs. Thereby, this study concentrates on 
the importance of human cellular models and the consideration of the analyzed cell type. One 
issue in ALS research is still that our understanding of the disease is mainly based on human 
postmortem tissue, animal models, and overexpression model systems. Cellular models using 
heterologous expression in primary rodent cultures or human carcinoma-derived cell lines 
(HeLa, U2OS, NSC-34, etc.) are an important tool to decipher disease mechanism underlying 
disease, however they cannot fully represent physiological conditions. Moreover, in ALS 
specifically spinal and cortical motor neurons are affected by neurodegeneration (Van 
Langenhove, van der Zee et al. 2012) and also astrocytes have been proposed to contribute 
to disease (Di Giorgio, Carrasco et al. 2007, Marchetto, Muotri et al. 2008, Haidet-Phillips, 
Hester et al. 2011, Meyer, Ferraiuolo et al. 2014). Therefore, the analysis of those affected cell 
types is important to reveal mechanism causing particularly those cells to degenerate. Another 
issue in ALS research which is discussed in this thesis, is that various pathomechanisms have 
been proposed to cause ALS pathology and that those highly depend on the underlying gene 
mutation (Japtok, Lojewski et al. 2015, Higelin, Demestre et al. 2016, Pal, Glass et al. 2018). 
To gather a deeper insight into this set of issues, patient-specific iPSC lines were used, 
which allow the analysis of pathological effects caused by physiological expressed mutant 
proteins. Moreover, iPSC-derived neural cultures allowed the direct comparison of cortical 
neurons vs. astrocytes and cortical vs. spinal neurons of the same patient. The additional use 
of isogenic iPSC lines further allowed the analysis of mutation-caused effects independent of 
patient’s genetic background. To narrow down the many and various proposed cellular 
processes causing ALS, this thesis concentrated on the evaluation of cellular distribution of 
disease-associated proteins, DNA damage, and axonal organelle trafficking. Therewith and to 
the best of my knowledge, this study is the first to analyze iPSC-derived cortical cultures 
carrying either mutation within FUS or C9ORF72 and directly comparing neurons vs. 
astrocytes as well as spinal vs. cortical lineage. Previous studies concentrating on those two 
ALS-associated genes focus only on the analysis of iPSC-derived spinal MNs or use rodent 
primary cultures of cortical neurons. Thus, this thesis work will contribute new knowledge in 
the context of cortical neuropathology in FUS- and C9ORF72-ALS.  
Discussion 
111 / 163 
4.1 Control and mutant iPSCs differentiate into cortical neurons and 
astrocytes 
Patient-specific iPSCs derived from healthy controls and ALS patients with either FUS or 
C9ORF72 mutation successfully differentiate in various cortical cell types, including neurons 
of all cortical layers and astrocytes. The protocol used here resulted in the derivation of 
heterogeneous cultures including differentiation into cortical neurons and astrocytes 
(Burkhardt, Martinez et al. 2013). The advantage of this protocol is that different cortical neural 
cell types are co-cultured and can be monitored simultaneously, closely mimicking 
physiological conditions. Increased cell death or variances of neuron count as hint for 
neurodegeneration could not be detected. By this I found no hint for a difference of 
differentiation behavior in healthy vs. diseased lines indicating no neurodevelopmental 
phenotype. In this thesis work, marker positive cells of all cortical deep and upper layers 
neurons (Figure 3.2) could be detected as well as astrocytes (Figure 3.1).  This is consistent 
with a previously published study on FUS-NLS iPSC lines (Japtok, Lojewski et al. 2015).  
A significant drawback of the used protocol is the long differentiation time which further only 
results in the derivation of 5 to 20% neurons. Because iPSCs are used as starting material, 
the differentiation process becomes more complex and cells need to be differentiated for 2 to 
4 months to obtain fully mature cultures. However, fast protocols such as NGN2 driven cortical 
differentiation did no yield cortical subtype/layer subtype neurons (B. Szewczyk in our group, 
personal communication). In contrast to this, spinal MN protocols are easy to handle and highly 
efficient because NPCs can be used as starting material. The use of NPCs allows the 
derivation of greater than 90% of spinal MNs within 2 to 3 weeks of differentiation (Kreiter, Pal 
et al. 2018, Marrone, Poser et al. 2018). This may  explain why ALS research, as yet, 
concentrates on studying patient-specific cellular models of spinal MNs and only few studies 
on cortical neurons exist (Burkhardt, Martinez et al. 2013, Japtok, Lojewski et al. 2015, Birger, 
Ottolenghi et al. 2018). In conclusion, control as well as mutant iPSCs successfully differentiate 
into cortical neurons and astrocytes, however showing a high variability between experiments 
and cells lines. This highlights the importance to evaluate disease-related phenotypes in the 
context of marker positivity such as MAP2 for neurons and GFAP for astrocytes.  
4.2 Isogenic iPSC lines allow the analysis of mutation-dependent 
effects independent of patient’s genetic background 
In this study, non-isogenic patient-specific iPSC lines were used but also isogenic ones. All 
isogenic lines used, were generated using CRISPR/Cas9n technology for target gene editing. 
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As starting material for gene modification patient-derived iPSC lines with either FUS or 
C9ORF72 mutation were used. As part of this thesis work, two FUS EGFP-tagged cell lines 
were generated. Using a parental line with FUS-R521C mutation, both a wild type and a new 
FUS-P525L iPSC line carrying an additional C-terminal EGFP tag were generated (Figure 3.3 
A and Table 2.15). Two clones were selected for disease modeling purposes as they showed 
the intended genotypes (Figure 3.4) and pluripotency could be confirmed (Figure 3.5 and 
Figure 3.6). In addition to those FUS isogenic lines, C9ORF72 isogenic lines were used, which 
were kindly provided by the lab of Jared Sterneckert and generated by Dr. Masin Abo-Rady 
(Abo-Rady 2018). To derive the here used isogenic lines, a parental line with C9ORF72-HRE 
mutation was corrected to physiological repeat length (Table 2.15).  
The use of isogenic lines is an important aspect of this thesis work because it allows the 
analysis of disease associated phenotypes resulting from the genotype and not the patient’s 
genetic background. This is of great interest, as in ALS research it is already shown that 
pathological phenotypes depend on severity of underlying mutation (Huang, Zhou et al. 2011, 
Mitchell, McGoldrick et al. 2013, Japtok, Lojewski et al. 2015) and the gene affected (Pal, Glass 
et al. 2018). In this context, analyzed phenotypes can be very subtle or vary between non-
isogenic lines. As an example, FUS mislocalization in FUS-R521C mutants was only 
detectable in aging cortical neurons while more severe FUS-R495QfsX527 mutation led to 
mislocalization in all cells, independent of age and cell type (Japtok, Lojewski et al. 2015). 
Moreover, C9ORF72-HRE spinal MNs showed increased DNA damage compared to only one 
out of two non-isogenic controls (Higelin, Catanese et al. 2018). Therefore, one cannot rule 
out the possibility that such observations are putatively caused by the patient’s genetic 
background, especially if only subtle observed phenotypes are detected. In conclusion, this 
highlights the importance of isogenic lines to rule out possible effects of unintended genetic 
background.  
4.3 Disease-associated proteins 
4.3.1 Cytoplasmic mislocalization of mutant FUS depends on cell type 
Cytoplasmic mislocalization and aggregation of mutant FUS is a widely discussed disease 
mechanisms causing FUS pathology. In FUS-ALS, most disease-causing mutations cluster 
within the C-terminal part of the protein, which lead to a disrupted NLS and further resulting in 
nuclear to cytoplasmic shift of mutant FUS (Vance, Rogelj et al. 2009, Bosco, Lemay et al. 
2010, Dormann, Rodde et al. 2010, Gal, Zhang et al. 2011, Kino, Washizu et al. 2011, Zhang 
and Chook 2012, Vance, Scotter et al. 2013, Wang, Pan et al. 2013). In the present work, it 
could be shown that FUS-P525L mutant cortical neurons show a nuclear to cytoplasmic shift 
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of FUS-EGFP localization compared to FUS-WT cells, which is consistent with a previous 
study on spinal MNs using the same isogenic lines (Naumann, Pal et al. 2018). This shift was 
not observed in mutant cortical astrocytes when compared to control (Figure 3.7). Those 
results indicate that FUS cellular localization is not only affected by mutation but also 
dependent on the cell type. Indeed, a study by Andersson and colleagues showed cell type-
specific expression patterns of FUS by analyzing its cellular distribution in various organ 
tissues derived from healthy individuals (Andersson, Stahlberg et al. 2008). They found that 0 
% of glial cells but 2 to 25 % of neurons showed FUS cytoplasmic expression. In addition, in 
my Master thesis work on cortical in vitro cultures I could show different effects of FUS-R521C 
mutation on cytoplasmic mislocalization. Accordingly, the percentage of neurons showing a 
mislocalization was higher (>40 %) than those of non-neuronal cells (<20 %) (Japtok, Lojewski 
et al. 2015). Moreover, the extent of FUS cytoplasmic mislocalization and aggregation was 
shown to depend on age and severity of mutation in spinal MNs (Higelin, Demestre et al. 2016) 
as well as cortical neurons (Japtok, Lojewski et al. 2015).  
In conclusion, the present work and previous studies showed that FUS pathology in ALS is 
not simply caused by FUS mutation, but also depends on the severity of mutation, aging, and 
cell type. The precise underlying mechanism how FUS mislocalization and aggregation causes 
disease are still unclear. However, aforementioned factors seem to have a great influence on 
how underlying pathomechanism cause disease. Therefore, those factors need to be taken 
into account for future investigation.   
4.3.2 C9ORF72-associated DPR pathology can only be recapitulated partially 
within iPSC-derived cortical neurons 
 DPRs are a hallmark characteristic of C9ORF72-associated ALS. DPRs can be detected 
throughout the CNS of C9ORF72-ALS patients, while predominantly localizing to cortical 
regions and cerebellum (Ash, Bieniek et al. 2013, Mackenzie, Arzberger et al. 2013, Schludi, 
May et al. 2015). DPR-conferred toxicity was shown in various overexpression models (Wen, 
Tan et al. 2014, Freibaum, Lu et al. 2015, Ohki, Wenninger-Weinzierl et al. 2017). The problem 
with these models is that they lead to accelerated protein levels, incomparable to ALS patient’s 
pathology. Within this thesis work, immunocytochemistry assays were used to analyze whether 
endogenously expressed DPRs can be detected in iPSC-derived cortical neurons. Three 
monoclonal antibodies against Poly-GP, Poly-GA, and Poly-GR were evaluated in patient-
specific in vitro cultures.  
Poly-GA and Poly-GR antibodies were tested in immunofluorescence staining only. Staining 
for both antibodies reveal unexpected and possibly unspecific staining as also control lines 
show positive staining, which was unexpected. Quantitative analysis of Poly-GA revealed 
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highly inconsistent results between non-isogenic and isogenic lines and no clear effect of 
C9ORF72-HRE mutation was observed (Figure 3.12). Small cytoplasmic DPR granules as well 
as nuclear staining were detected in both control and C9ORF72-HRE mutant cortical neurons. 
In terms of Poly-GR antibody, a strong cytoplasmic accumulation in control and C9ORF72-
HRE mutant neuronal in non-neuronal cells was observed (Figure 3.13). Both antibodies were 
previously shown to specifically detect DPR aggregation in C9ORF72-ALS cases but not in 
healthy individuals (Mackenzie, Arzberger et al. 2013, Mori, Arzberger et al. 2013, Schludi, 
May et al. 2015). However, the specificity of the two generated antibodies was tested in 
immunoblots and IHC staining on postmortem tissue. Protocols for preparation of protein 
samples and staining of human tissue are highly different from protocols used for in vitro 
staining, as used within this thesis. Such protocols can affect the antigen detected. If antibodies 
are then developed according to such protocols, staining patterns can look differently because 
staining protocols for in vitro culture might affect the antigen differently. Moreover, the tissue 
used was obtained from different patients as the patient-derived iPSC lines in the present 
study. Thus, it is still possible that the antibodies reveal partially unspecific staining in cellular 
models expressing DPRs endogenously. Therefore, both antibodies were considered to be 
unspecific within the here used model system. Further evaluations would be needed to confirm 
specificity also in cellular models such as testing additional patient-derived iPSC lines or 
different protocols for staining. In the present study only one to two control and C9-HRE lines 
were tested. Further on, antibodies could be tested in overexpression cellular models. 
In contrast to Poly-GA and Poly-GR, Poly-GP antibody showed expected staining pattern 
(Figure 3.9). A diffuse staining with some nuclear enrichment and small cytoplasmic granules 
was observed, as previously published (Schludi, May et al. 2015, Yamakawa, Ito et al. 2015). 
Quantification of staining revealed that C9ORF72-HRE mutant cortical neurons did not show 
increased granule numbers, but size of granules was increased compared to controls (Figure 
3.10). This is partially consistent with previous findings, showing increased area but not 
number of aggregates in DPR expressing cells (Zhou, Lehmer et al. 2017). However, Zhou 
and colleagues could observe increased aggregation only for Poly-GA and Poly-PR but not for 
Poly-GP and used, different to this work, rodent and human overexpression models. In addition 
to staining, ELISA was utilized to analyze Poly-GP levels at different maturation stages in 
cortical cells. ELISA evaluation revealed neither effect of aging nor genotype (Figure 3.8). The 
control lines and two C9ORF72-HRE lines (out of three) showed no increased Poly-GP levels. 
The detected levels (below 500 arbitrary units) can be considered to be not pathological as 
they are comparable to Poly-GP levels detected in control spinal MNs (Abo-Rady 2018). Only 
one out of three C9ORF72-HRE lines showed increased levels of Poly-GP in cortical cells 
(2000 to 4000 arbitrary units). This confirms previous studies using the same line and antibody 
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that showed higher Poly-GP levels in spinal MN cultures at approximately same detected Poly-
GP levels (Abo-Rady 2018).  
Within the here established in vitro model, using iPSC-derived cortical neurons, the hallmark 
pathology of C9ORF72-ALS can be recapitulated only partially. Only one out of three 
C9ORF72-HRE lines showed elevated Poly-GP levels. Further, immunofluorescence staining 
revealed increased Poly-GP aggregation, however yet only small dot-like granules could be 
observed. No big cytoplasmic star-shaped aggregates were detected, as they are reported to 
occur in C9ORF72 cases (Mackenzie, Arzberger et al. 2013, Mori, Arzberger et al. 2013, 
Freibaum, Lu et al. 2015, Schludi, May et al. 2015). DPRs are also shown to be primarily 
detected within cortical regions of C9ORF72-ALS tissue (Mackenzie, Arzberger et al. 2013, 
Schludi, May et al. 2015). Therefore, it was unexpected that here no such aggregation could 
be detected. A possible explanation could be an age-dependent effect as also discussed below 
in terms of DNA damage and axonal trafficking. This is plausible also in this case, especially 
as I already could show in my master thesis study on FUS-ALS, that severe cytoplasmic 
aggregation occurred only after 160 days in vitro differentiation within cortical neurons (Japtok 
2014). However, no age-dependent effect between 80 and 120 days was observed. Yet, 40 
more days of in vitro cultivation is a long time to obtain 160 day aged cortical cultures. 
Furthermore, an age-dependency was only tested by ELISA but not by staining, in which 
specifically neurons are detected. Thus, additional staining experiments on cortical neurons 
aged for more than 120 days are need to clarify if the used models is able to fully recapitulate 
disease pathology. Finally, similar to Poly-GA and Poly-GR, Poly-GP showed possibly 
unspecific staining and detection in ELISA. Same as discussed above, also control cortical 
cells showed positive staining and/ or antigen is maybe differently affected by different staining 
protocols used. 
In conclusion, all three tested antibodies are possibly unspecific and results shown should 
be interpreted with care. Also not tested in this thesis is the influence of the C9RF72-HRE 
length on staining pattern and stability of repeat length. iPSC lines used in this study were 
genotyped once initially after reprogramming or gene modification but not after several 
passaging or differentiation. C9RF72-HRE length is thought to be unstable, meaning increase 
or decrease of size is possible. Reprogramming and differentiation was shown to affect repeat 
instability (Almeida, Gascon et al. 2013) and also repeat size can vary among neuronal and 
non-neuronal tissues of patients with C9ORF72-HRE (Nordin, Akimoto et al. 2015). Repeat 
length in cerebellum correlated with survival, disease onset, and progression (van Blitterswijk, 
DeJesus-Hernandez et al. 2013, Nordin, Akimoto et al. 2015), yet the exact relation between 
repeat length and phenotype is unclear (Rohrer, Isaacs et al. 2015). Thus future experiment 
might need to analyze repeat length on staining pattern and/ or also test exact repeat length 
on a regular basis.  
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4.3.3 DPR accumulation and DNA damage do not correlate in iPSC-derived 
cortical neurons 
Accumulation of DPRs as well as DNA damage are both linked to C9ORF72-ALS 
individually but also in correlation with each other (Lopez-Gonzalez, Lu et al. 2016, Farg, 
Konopka et al. 2017, Higelin, Catanese et al. 2018). In this thesis work, both DPR formation 
and DNA damage were analyzed in C9ORF72-ALS patient-specific in vitro model. Neither 
severe DPR accumulation nor increased DNA damage could be observed in C9ORF72-HRE 
mutant cortical neurons, as already discussed above. Qualitative assessment of both factors 
neither revealed a correlation between both. This is in contrast to previous findings that show 
that accumulation of DNA damage is conferred by DPR production (Lopez-Gonzalez, Lu et al. 
2016). Using C9ORF72-ALS patient-specific spinal MNs, Lopez-Gonzalez et al. could show 
that DPR production leads to mitochondrial dysfunction, which further results in increased 
oxidative stress and accumulation of DNA damage. However, they also showed that most 
severe DNA damage was only observed in 4-month-old cultures. This is even longer 
differentiation time than used in this thesis work. Thus, additional aging experiments would be 
needed to fully clarify if cortical neurons need more time to develop disease-associated 
phenotype or if underlying disease mechanism are different in spinal versus cortical neurons. 
Further, antibody specificity within the here used model is questionable.  
4.3.4 ALS-associated TDP43 pathology can be recapitulated partially within 
iPSC-derived cortical neurons 
Cytoplasmic aggregates containing non-mutated TDP43 are another hallmark in ALS 
(Neumann, Sampathu et al. 2006, Mackenzie, Bigio et al. 2007, Blokhuis, Groen et al. 2013). 
In terms of C9ORF72-ALS, neuronal and glial TDP43 positive inclusions can be observed in 
most cases (Mackenzie, Bigio et al. 2007, Rohrer, Isaacs et al. 2015). Within this thesis work, 
TDP43 was analyzed by immunofluorescence staining of control and C9ORF72-HRE mutant 
cortical neurons. Small cytoplasmic granules, which did not co-localize with Poly-GA, could be 
found in C9ORF72-HRE mutant cortical neurons (Figure 3.16). The missing co-localization is 
consistent with previous findings in human postmortem (Ash, Bieniek et al. , Mackenzie, 
Arzberger et al. 2013, Mori, Arzberger et al. , Schludi, May et al. 2015). However, also control 
cortical cells showed described pathology. TDP43 was shown to form beneficial and reversible 
aggregates under physiological condition in healthy muscle cells (Vogler, Wheeler et al. 2018). 
If cytoplasmic granules observed within healthy neurons possess beneficial effects needs to 
be proven.  Moreover, TDP43 granules seemed to be slightly bigger in C9ORF72-HRE mutant 
neurons. However, granule numbers and size were not quantified due to technical reasons. 
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Thus, further evaluation is required to verify if C9ORF72-HRE mutant cortical neurons show 
increased TDP43 aggregation. In addition, the nuclear clearance of TDP43 accompanied by 
the formation of small cytoplasmic inclusions was observed (Figure 3.17).  This is consistent 
with previous studies on TDP43 pathology in ALS (Neumann, Sampathu et al. 2006, 
Mackenzie, Bigio et al. 2007, Lee, Lee et al. 2011). In contrast to those findings is, that within 
this thesis work, TDP43 nuclear loss was mainly detected within MAP2 negative cells. Though 
glial inclusions formation and nuclear loss could already be shown in spinal cord postmortem 
tissue (Mackenzie, Bigio et al. 2007), it needs to be determined, yet, whether nuclear loss can 
be associated with astrocytes within iPSC-derived cortical cells. Furthermore, only two 
independent differentiations with high inter-experimental variability were analyzed. 
Accordingly, additional experiments will be needed to clarify if nuclear clearance of TDP43 is 
indeed increased in C9ORF72-HRE cortical cells within the here used model system.  
In conclusion, known ALS-associated TDP43 pathology could be partially recapitulated 
within the here used model system. Additional experiments to increase sample size as well as 
additional quantifications need to be implemented to confirm that observed pathology indeed 
can be associated with C9ORF72-ALS. 
4.4 Characterization of DNA damage 
4.4.1 C9ORF72-HRE and FUS-NLS mutations do not affect DSB levels in 
unstressed cortical neurons and astrocytes 
One aim of this study was the analysis of DSB markers γH2AX and 53BP1 in cortical 
neurons and astrocytes to determine the effects of ALS-associated mutations on DNA 
damage. Evaluation of immunofluorescence staining revealed no increased accumulation of 
DNA damage in mutant cell lines compared to their corresponding controls. This could be 
shown for mature cortical neurons and astrocytes (day 100) with either C9ORF72-HRE (Figure 
3.22) or FUS-NLS (Figure 3.27) mutation. In addition, young spinal MNs (day 21) did not 
showed an effect of C9ORF72-HRE mutation either (Figure 3.21). This is contradicting to 
published data for both ALS-associated genes. Both FUS and C9ORF72 have clearly been 
linked to DNA damage and DDR (Wang, Pan et al. 2013, Hill, Mordes et al. 2016, Farg, 
Konopka et al. 2017). Accordingly, it is shown that cortical and spinal MNs with either 
C9ORF72-HRE (Lopez-Gonzalez, Lu et al. 2016, Farg, Konopka et al. 2017, Higelin, Catanese 
et al. 2018) or FUS-NLS (Wang, Pan et al. 2013, Qiu, Lee et al. 2014, Higelin, Demestre et al. 
2016, Naumann, Pal et al. 2018) mutation show increased DSB levels. However, published 
date is either basing on h-iPSC-derived spinal MNs or primary mouse cortical neurons. None 
of them analyzed DNA damage in patient-specific iPSC-derived cortical cells. Following 
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paragraphs will give explanations for the differences between published and the here 
presented data. 
In the context of C9ORF72-HRE mutation, an effect of the cell line, independent of 
genotype, on DSB levels in cortical cultures could be shown. This means that no obvious 
influence of the mutation was detected, however the two isogenic cell lines (C9-WT and C9-
HRE 2) showed increased DNA damage levels compared to non-isogenic lines (Ctrl 1, Ctrl2, 
and C9-HRE 1). Overall the DSB levels between controls and mutants were rather similar. This 
fits together with data published by Higelin and colleagues (Higelin, Catanese et al. 2018). 
They could show significantly increased DSB levels within spinal MNs only between one 
analyzed C9ORF72-HRE patient-specific iPSC line compared to one out of two non-isogenic 
control lines. This indicates a potential participation of the patient’s genetic background on 
DNA damage levels. In isogenic lines the patient’s genetic background is the same and should 
not affect analyzed phenotypes. However, focusing only on isogenic iPSC lines used here, 
C9ORF72-HRE mutant cortical cultures did not show increased accumulation of DSBs 
compared to corresponding control either. This shows that in contrast to spinal MNs, DDR 
seems not to be different in healthy and C9ORF72-HRE cortical neurons as shown by 
particularly using isogenic lines.  
There are, furthermore, some striking differences to published data. According to this, Farg 
and colleagues showed increased γH2AX levels in human postmortem spinal cord tissue 
derived from C9ORF72-ALS patients (Farg, Konopka et al. 2017). Data obtained from 
postmortem tissue, however, is not comparable one to one to data basing on in vitro cultures.  
Histological preparation, paraffin embedding, and staining protocols are highly different to 
protocols used for immunofluorescence staining on cell cultures. Furthermore, postmortem 
tissue only recapitulates end stage of the disease. Thus, it might only represents an 
accelerated phenotype which would not be this obvious at an earlier stage of disease. 
Accordingly, Higelin as well as Lopez-Gonzalez  et al. (Lopez-Gonzalez, Lu et al. 2016, Higelin, 
Catanese et al. 2018) showed an age-dependent increase of DNA damage in patient-derived 
spinal MNs with C9ORF72-HRE (Lopez-Gonzalez, Lu et al. 2016, Higelin, Catanese et al. 
2018). As a conclusion from those studies it can be said that the maturation time points in the 
present study were possibly too early. Analysis of DSB marker at a later time point would need 
to be implemented to clarify this. This on the other side however means, that DNA damage 
seems not to be an early event in C9ORF72-HRE cortical neurodegeneration. 
In the context of FUS-NLS mutations, DSB levels within cortical cultures were also not 
increased in mutant cell lines. Same as observed for C9ORF72-HRE lines, focusing on 
isogenic lines no difference of DNA damage levels between FUS mutant and control cells was 
observed. This is in striking contrast to a previous report of our group in which the same patient-
specific iPSC lines (FUS-R521C and FUS-P525L) were used. The data clearly showed 
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increased γH2AX levels in NPCs and spinal MNs, particularly we showed increased DSB 
levels already in young neurons (Naumann, Pal et al. 2018). Furthermore, two other studies 
exist which evaluated the same two FUS-NLS mutations as used here. Both studies showed 
an increase of γH2AX positive cells in cortex tissue carrying either FUS-NLS mutation (Wang, 
Pan et al. 2013, Qiu, Lee et al. 2014). Of note, both studies either use patient or transgenic 
mouse postmortem tissue representing again end stage of disease. Corresponding to this, 
Higelin and colleagues could show an age-dependent increase of γH2AX levels in FUS-NLS 
mutant patient-specific spinal MNs (Higelin, Demestre et al. 2016), similar as they already 
showed for C9ORF72-HRE (Higelin, Catanese et al. 2018). In conclusion, same as indicated 
for C9ORF72-HRE, the maturation time to analyze DNA damage in cortical neurons and 
astrocytes is possibly too early. However, in FUS-NLS spinal MNs DNA damage was shown 
to be an early event (Naumann, Pal et al. 2018). Both studies from Naumann (2018) and 
Higelin (2016) could show that increased DSB levels can already be detected in young spinal 
MNs or even NPCs. Interestingly, Higelin and colleagues used, similar to this thesis work, 
iPSCs as starting material for differentiation, while Naumann et al. used NPCs. That means 
different protocols for spinal MN derivation came to the same results. Thus, FUS-NLS mutation 
(as well as C9ORF72-HRE) seem to have different effects on DNA damage pathway in 
particular cortical neurons.  
Besides analyzing the effects of ALS-associated mutations on DNA damage, another aim 
of this thesis work was to evaluate if the analyzed neural cell type matters. Remarkably, spinal 
MNs and cortical astrocytes showed higher DSB levels compared to cortical neurons, 
independent of genotype (Figure 3.23 A-D and Figure 3.27 D). Various studies exist that show 
a disease-associated increase of DNA damage in neurons as well as astrocytes. Increased 
DNA damage within neurons could already be related to AD (Mullaart, Boerrigter et al. 1990), 
PD (Zhang, Perry et al. 1999), and ALS (Qiu, Lee et al. 2014, Farg, Konopka et al. 2017) and 
in astrocytes related to AD (Myung, Zhu et al. 2008) and FTD (Su, Nichol et al. 2000). In the 
present work, no ALS-mutation-associated increase of DNA damage could be shown. DDR 
seems not to be different in healthy and C9ORF72-HRE or FUS-NLS cortical cells. However, 
to my knowledge there is no other literature existing which directly compares neuronal versus 
glial DNA damage. Thus, this study is the first showing increased basal level of DNA damage 
in a cell type but not genotype dependent manner. This strengthens the hypothesis, that 
cortical cells underlie different diseases mechanism as spinal ones and shows the need to 
further investigate disease-associated pathways in cell types affected by disease, particularly 
cortical versus spinal neurons and astrocytes in ALS. 
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4.4.2 C9ORF72-HRE and FUS-NLS mutations do not affect DDR signaling and 
DSB repair upon DNA damage induction 
To further evaluate the effect of ALS-associated mutations on DNA damage accumulation, 
DSB levels were determined after DNA damage induction via etoposide. Etoposide indirectly 
induces DSBs via inhibition of topoisomerase IIα (Walker and Nitiss 2002, Schonn, Hennesen 
et al. 2010). In this study, it served as a positive control for DNA damage. Indeed, a strong 
effect of etoposide treatment on cortical cultures, independent of genotype, could be detected. 
Thus, ALS-associated mutations within FUS or C9ORF72 do not affect initiation of DDR 
signaling, as shown by increase of γH2AX and 53BP1 foci numbers in cortical neurons and 
astrocytes (Figure 3.25 and Figure 3.28). In contrast, no effect of etoposide treatment within 
C9ORF72-HRE and control spinal MNs was observed (Figure 3.24). This was unexpected but 
might be explained with a dependency of DNA damage accumulation on basal DSB levels.  
As discussed above, spinal MNs showed already increased DSB levels compared to cortical 
neurons under untreated conditions, however, contrary to cortical neurons, they do not react 
to the etoposide treatment. This leads to the assumption that cells possibly can acquire only a 
certain amount of DNA damage. This theory is strengthened by having a closer look on the 
reaction of isogenic C9ORF72 cortical cultures towards DSB induction. Both C9-WT and C9-
HRE 2 showed a less strong increase of DSBs upon etoposide treatment compared to non-
isogenic lines (Figure 3.25). However, both lines also showed already increased DNA damage 
levels in untreated conditions, compared to non-isogenic lines (Figure 3.22). Similar 
observation could also be made in a previous study of our group. Under untreated conditions, 
FUS-NLS mutant spinal MNs showed increased DSBs numbers compared to control 
(Naumann, Pal et al. 2018). However, upon etoposide treatment FUS-NLS mutants showed a 
less strong accumulation of DSBs than the control. Taken together, this indicates that cells, 
independent of the genotype, accumulate DSB after etoposide depending on initial basal levels 
of DNA damage. If and how this correlates with cell death and neurodegeneration needs 
further exploration.  
To evaluate the possible influence of FUS or C9ORF72 mutations in DNA damage repair, 
the recovery of DNA damage was analyzed upon etoposide withdrawal. Cells were allowed to 
recover for 24 h without any additional DSB induction. Clearly, all analyzed cell lines and cell 
types were able to recover from DNA damage induction. Similar DSB levels as in untreated 
conditions were detected in spinal MNs (Figure 3.24) as well as in cortical neurons and 
astrocytes (Figure 3.25 and Figure 3.28). This is consistent with previous mentioned study of 
our group, which likewise showed that control as well as FUS-NLS mutant spinal MNs 
successfully repair etoposide induced DNA damage (Naumann, Pal et al. 2018).  
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To verify that the DSB recovery is not masked by increased cell death, the effect of 
etoposide on cell viability was analyzed 24h after treatment withdrawal. No effect of etoposide 
treatment could be detected (Figure 3.29). As a conclusion, this shows that analyzed cell 
cultures carrying ALS-associated mutations are able to repair induced DNA damage and 
observations made are not due to a loss of dead cells from the analysis.  
4.4.3 Recruitment of FUS-EGFP to laser-induced DNA damage sites depends 
on cell- and genotype 
The effect of ALS-associated mutation within FUS was further evaluated by analyzing the 
recruitment of FUS protein to laser-induced DNA damage sites. For that, two isogenic iPSC 
lines that endogenously express WT or P525L EGFP-tagged FUS were used and which were 
successfully generated as part of this thesis (see section 3.2). Previous studies, using cell 
models that heterologous express FUS protein showed that WT FUS is rapidly recruited to 
laser-induced DDS. (Mastrocola, Kim et al. 2013, Wang, Pan et al. 2013, Rulten, Rotheray et 
al. 2014, Aleksandrov, Dotchev et al. 2018). Our group could recapitulate this by showing rapid 
recruitment of WT FUS to DDS in spinal MNs while using the same isogenic FUS-EGFP iPSC 
lines that were generated as part of this thesis work (Figure 3.30)(Naumann, Pal et al. 2018). 
In the present study, FUS-EGFP recruitment was analyzed in iPSCs and cortical neurons. 
Consistent with previous reports, WT FUS-EGFP was recruited quickly to DDS in both iPSCs 
and cortical neurons. Interestingly, recruitment of P525L FUS-EGFP was unaffected in iPSCs 
but seemed to be slightly delayed in cortical neurons (Figure 3.31). This is in striking contrast 
to our aforementioned study, in which recruitment of FUS-P525L within spinal MNs was 
completely diminished (Naumann, Pal et al. 2018). Further detailed quantification of the fitted 
curves needs to be implemented to confirm the observed minor shift of the graphs in Figure 
3.31.  
The detection of described differences of mutant FUS recruitment to DDS between spinal 
and cortical neurons is a noticeable discovery of this thesis work that is strengthened due to 
the use of the same cell lines and techniques as published previously. That FUS-P525L 
showed hints for a marginal impaired recruitment might be explained by a possible age-
dependent effect. As discussed above, aging affects DNA damage accumulation in neurons 
(Lopez-Gonzalez, Lu et al. 2016, Higelin, Catanese et al. 2018). This might also be the case 
for FUS recruitment to DDS within cortical neurons. Furthermore, cortical cultures consist of 
various neuron types (Figure 3.2). However, in ALS particularly MNs are affected by 
neurodegeneration. In cortical cultures MNs are rare and cannot be specifically detected within 
live cell imaging approaches. Thus, a FUS recruitment defect that is possibly specific to MNs, 
is perhaps masked by the functional recruitment of FUS within other neuronal subtypes. 
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Nevertheless, every single neuron analyzed in spinal cultures as well as their all 
neuroprogenitor cells did not respond to laser cutter (Naumann, Pal et al. 2018). Thus, 
undiscovered differential mechanisms in cortical vs. spinal neurons could affect FUS 
recruitment to DDS.  
With respect to clinical features of FUS-ALS, it represents classical ALS neuropathology 
with showing a severe loss of MNs in the spinal cord and similar loss of neurons in the 
brainstem, however only mild to moderate loss of neurons in the motor cortex (Deng, Gao et 
al. 2014). In contrast thereto, ALS patients with C9ORF72-HRE more commonly show 
behavioral and/ or cognitive impairment compared to patients without repeat expansion and 
neurodegeneration can not only be observed in spinal cord but also cortical areas (Rohrer, 
Isaacs et al. 2015). Thus, one can say that in FUS-ALS predominantly lower MNs are affected 
by disease, while in C9ORF72-ALS upper MNs are affected or both upper and lower MNs. 
This, in conclusion, fits to the here presented data. Spinal MNs carrying mutations within FUS 
are more affected by disease and thus show severe effects on DDR, while cortical neurons 
are possibly less affected by disease and thus show a normal FUS recruitment to DDS. 
Consistent with that dependency on the neuronal cell type, Birger et al. showed that survival 
of cortical and spinal neurons is differently affected by expression of disease-relevant proteins 
(Birger, Ottolenghi et al. 2018). In summary, the present work shows that FUS recruitment to 
DDS is modulated by mutation but is also highly dependent on the analyzed cell type. This 
highlights the importance of the analyzed cell types, including subtypes of neurons, which are 
used for disease modeling. 
4.5 FUS-NLS mutations affect axonal organelle trafficking differently 
as in spinal MNs 
To further analyze ALS-associated disease mechanisms, axonal organelle transport in 
compartmentalized FUS-NLS mutant cortical neuron cultures was analyzed. Especially 
neurons depend on functional organelle transport for proper energy supply (mitochondrial 
transport) and waste removal (lysosomal transport) due to their highly asymmetric structure 
and long axons (Millecamps and Julien 2013, Taylor, Brown et al. 2016). Aim of this thesis was 
to evaluate trafficking in distal and proximal parts of neuron axon, implementing the same 
experimental set up as already published for spinal MNs (Naumann, Pal et al. 2018).  
An effect of FUS mutation on axonal trafficking of mitochondria and lysosome could be 
observed within directed cortical neuron cultures. However, mutations within FUS affect 
cortical axonal trafficking differently as observed in spinal MNs (Guo, Naujock et al. 2017, 
Naumann, Pal et al. 2018). Accordingly, an increased organelle displacement of both 
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mitochondria and lysosomes was detected in distal and proximal axonal parts of FUS-NLS 
mutant cortical neurons (Figure 3.34 B + F). This is contrary to previous findings in spinal MNs, 
which showed significant decreased organelle displacement in only distal axons of FUS-NLS 
mutant spinal MNs (Naumann, Pal et al. 2018). Another parameter analyzed was the organelle 
mean speed. For this, within FUS-NLS mutant cortical neurons a significantly decreased 
lysosomal and mitochondrial mean speed within distal and proximal axons was observed 
(Figure 3.34 D + G). Thus, evaluation of mean speed is partially consistent to findings in spinal 
MNs, which showed decreased organelle mean speed only distal axonal parts. Of note, in 
spinal MNs a severe distal trafficking defect was observed, while cortical neurons show global 
trafficking effects that are, additionally, far less distinctive than observed in spinal MNs 
(Naumann, Pal et al. 2018). In summary it can be said, that FUS-NLS mutations affect cortical 
organelle trafficking much different and much less pronounced than observed in spinal MNs, 
fitting to above mentioned results on DNA damage and DDR response. 
Evaluation of organelle trafficking in cortical neurons is rather inconclusive when compared 
to previous studies on spinal MNs. A possible explanation could be an underlying age-
dependent effect as already discussed on DNA damage. Accordingly, impairment of axonal 
trafficking was shown to occur in an age-dependent manner in FUS (Guo, Naujock et al. 2017, 
Naumann, Pal et al. 2018) and TARDBP (Kreiter, Pal et al. 2018) mutant neurons. The 
timescale between spinal MN protocols and cortical differentiation protocols are different, 
ranging from 2 to 4 weeks for spinal and 2 to 4 months for derivation of cortical neurons. 
Interestingly, differently implemented protocols for spinal MN derivation come to the same 
observation of severe axonal trafficking defects in FUS-NLS mutant lines. While our group 
relies on NPCs for MN differentiation (Naumann, Pal et al. 2018), Guo et al. (2017) use, similar 
to this thesis work, iPSCs for directed differentiation into MNs. Yet, both studies could show 
that in spinal MNs no obvious trafficking defects can be observed in very young neurons (one 
week of differentiation) but that observable impairment occurs approximately after 2 to 3 weeks 
of differentiation. Thus, cortical neurons possibly need more time to develop more pronounced 
phenotypes because the range they need for differentiation, maturation, and aging is way 
longer.  
Another issue is that movies from different maturations time points (day 70 to 130) were 
pooled for analysis of cortical organelle trafficking. This is because of the high inter-
experimental variability of cortical MFC cultures as shown in Figure 3.33. Independent of the 
genotype but dependent on the individual experiment, cortical neurons need different times to 
fully grow through micro channels of MFCs. This means the same cell line might showed 
different growth behaviors in MFCs in independent differentiation pipelines. To ensure similar 
qualities of cortical MFC cultures, cells were imaged once the majority of channels were 
penetrated and before neurons showed obvious signs of neurodegeneration. Therefore, there 
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was no standardized imaging time point. This is different to spinal cultures in which cells were 
strictly imaged at one particular time point (Kreiter, Pal et al. 2018, Naumann, Pal et al. 2018, 
Pal, Glass et al. 2018). Thus, the high inter-experimental variability of cortical MFC cultures 
and the varying imaging time points might affect organelle trafficking results. To overcome this 
further experiments need to be implemented to increase the amount of independent 
experiments and narrow down the time range in which movies were taken (e.g. day 70 to 80). 
Nevertheless, phenotypes in sMNs did appear rather early, after 3 weeks of differentiation and 
also prior any obvious signs for neurodegeneration.  
As aforementioned, in FUS-ALS specifically spinal MNs are affected by neurodegeneration, 
while cortical neurons are less affected (Deng, Gao et al. 2014). In our previous work on spinal 
MNs we also could show that axonal trafficking defects occur shortly prior to onset of 
neurodegeneration-related phenotypes such as axonal swellings and fragmentation of axons 
(Naumann, Pal et al. 2018). In this thesis work no obvious effects of neurodegeneration could 
be observed such as increased cell death or fragmentation of axons, even though this still 
needs to be proven by proper quantification and evaluation at different time points. 
Nevertheless, the present study is the first showing differential axonal trafficking defects in 
cortical neurons compared to spinal ones. Similar to DNA damage analysis, trafficking result 
show that the analyzed neuron type matters and indicates different underlying disease 
mechanism in cortical vs. spinal neurons.  
4.6 Conclusion 
ALS is devastating neurodegenerative disease specifically affecting upper and lower MNs 
(Van Langenhove, van der Zee et al. 2012, Vance, Scotter et al. 2013). The overall aim of this 
thesis work was the modeling of cortical neuropathology of FUS- and C9ORF72-associated 
ALS. Differential phenotypes between cortical neurons vs. astrocytes and cortical vs. spinal 
neurons were analyzed. For that, human iPSCs derived from healthy controls and ALS patients 
carrying mutations within FUS or C9ORF72 were used for directed cortical differentiation. 
Immunofluorescence staining and live cell imaging approaches were implemented to analyze 
disease-associated proteins, DNA damage, and axonal trafficking. Until now, only few studies 
exist analyzing disease-associated pathology in human cortical in vitro models of ALS 
(Burkhardt, Martinez et al. 2013, Japtok, Lojewski et al. 2015, Birger, Ottolenghi et al. 2018). 
Most studies either concentrate on spinal MNs (Lenzi, De Santis et al. 2015, Higelin, Demestre 
et al. 2016, Lopez-Gonzalez, Lu et al. 2016, Higelin, Catanese et al. 2018, Marrone, Drexler 
et al. 2019) or rodent cortical cultures (Alami, Smith et al. 2014, Qiu, Lee et al. 2014, Farg, 
Konopka et al. 2017, Walker, Herranz-Martin et al. 2017). However, yet no proof exists that 
underlying mechanisms causing disease are the same in spinal vs. cortical MNs. For that 
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reason, experiments implemented within this thesis work should help to augment knowledge 
on particular cortical neurodegeneration in ALS and highlighting differences and importance of 
analyzed cell types.  
Within this project, a clear cell type dependent effect on analyzed phenotypes was 
observed, while ALS-associated mutations seemed to have only minor effects. Accordingly, 
cell type dependent increased basal DNA damage levels in cortical astrocytes vs. neurons and 
spinal vs. cortical neurons were detected. However, FUS or C9ORF72 mutant cortical cells do 
not recapitulate increased DNA damage levels observed in spinal MNs (Higelin, Demestre et 
al. 2016, Higelin, Catanese et al. 2018, Naumann, Pal et al. 2018). Furthermore, FUS mutation 
affected recruitment to DDS, axonal trafficking, and cytoplasmic mislocalization differently, 
depending on the analyzed cell type. Additionally, recruitment and trafficking of mutant FUS, 
showed only slight mutation dependent effects and also less pronounced phenotypes as 
observed in spinal MNs (Naumann, Pal et al. 2018). Those results show that in particular the 
analyzed cell type matters and that ALS-associated phenotypes differ between cortical and 
spinal neurons. Because known ALS-associated pathology could be recapitulated only 
partially and with less pronounced phenotypes as previously reported, further experiments 
need to be implemented to confirm findings of this thesis and evaluate other variables affecting 
phenotype. Accordingly, a putative age-dependency needs to be proven. Age-dependent 
effects are shown for various mechanisms including DNA damage (Higelin, Demestre et al. 
2016, Lopez-Gonzalez, Lu et al. 2016, Higelin, Catanese et al. 2018), organelle trafficking 
(Guo, Naujock et al. 2017, Kreiter, Pal et al. 2018, Naumann, Pal et al. 2018), and protein 
aggregation (Japtok, Lojewski et al. 2015, Higelin, Demestre et al. 2016). Furthermore, 
comparison with spinal MNs showed differential results. This indicates that disease 
progression might be caused by differential mechanisms. This needs to be taken into account 
for future investigation and particular development of treatment. 
A limiting factor of above mentioned results is that observations made in cortical neurons 
are possibly masked by various neuronal cell types. In ALS, specifically MNs are affected. 
However, within the here used cortical cultures it was difficult to differentiate cortical MNs from 
other neuron types. Furthermore, long differentiation times are required for the derivation of 
cortical neurons and astrocytes. This requires accurately planning of experiments on a long-
term scale, in which also the high inter-experimental variability needs to be taken into account. 
The use of pluripotent stem cells as starting material for differentiation and the variable 
differentiation potential of each individual cell lines makes cortical differentiation more complex. 
Nevertheless, it could be shown that directed differentiation of patient-specific iPSCs into 
cortical neurons and astrocytes is a suitable model to study ALS in those types of cells. 
Moreover, studies from Guo et al. (2017) and Higelin et al. (2016 and 2018) also use iPSCs 
for directed differentiation into spinal MNs. Yet, they made contradictory observation regarding 
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DNA damage and organelle trafficking in spinal MNs compared to data presented within this 
thesis work. This highlights the importance of the analyzed cell type and strengthens the 
hypothesis that differential mechanisms in lower and upper MNs cause disease. In conclusion, 
patient-specific cellular models are an important tool in ALS research and particular differences 
between cortical and spinal MNs further need to be investigated to decipher underlying disease 
mechanism, the interplay of cell types affected by the disease, and how they participate in 
disease progression. 
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5 Summary 
Amyotrophic lateral sclerosis (ALS) is a of neurodegenerative diseases, in which 
neurodegeneration specifically affects upper (corticospinal) and lower (spinal) motor neurons 
(MNs). At present, ALS remains an incurable disease. Death occurs on average 2 to 5 years 
after symptom onset. About 90% are sporadic cases (sALS) and 10% are familial cases (fALS). 
It is of great interest to investigate monogenetic forms causing fALS to understand its 
underlying disease pathologies and mechanisms. Over 20 genes have been linked to ALS until 
now, including Fused in sarcoma (FUS) and Chromosome 9 open reading frame 72 
(C9ORF72). About 4% of fALS cases are caused by dominant mutations within FUS, 
representing the third most common fALS form in Germany. The G4C2 hexanucleotide repeat 
expansion (HRE) in the C9ORF72 gene is the most common cause for ALS and 
Frontotemporal dementia (FTD). ALS patients differ significantly in their presentation of clinical 
symptoms, including site of onset, rate of progression, and presence of cognitive dysfunction. 
Those factors were also shown to highly depend on the underlying mutation in fALS cases. 
Aim of this thesis work is the modeling of FUS- and C9ORF72-associated ALS in a disease-
related in vitro model of particularly cortical neuropathology using patient-derived iPSCs. The 
hypothesis of the current work is that underlying disease mechanisms do differentially affect 
cortical vs. spinal neurons and act in a cell type-dependent manner. Human iPSCs derived 
from healthy controls and ALS patients carrying mutations within FUS or C9ORF72 were used 
for directed cortical and spinal differentiation. Additionally, two new FUS-WT- and FUS-P525L-
EGFP-tagged isogenic iPSC lines were generated by CRISPR/Cas9n gene editing. 
Immunofluorescence staining and live cell imaging approaches were implemented to analyze 
disease-associated proteins, DNA damage, and axonal trafficking. Within this project, a clear 
cell type-dependent effect on analyzed phenotypes was observed, while ALS-associated 
mutations seemed to have only minor effects. Accordingly, cell type-dependent increased 
basal DNA damage levels in cortical astrocytes vs. neurons and spinal vs. cortical neurons 
were detected. However, FUS or C9ORF72 mutant cortical cells do not recapitulate increased 
DNA damage levels as they have been observed in spinal MNs. Furthermore, FUS mutation 
affected recruitment to DNA damage sites, axonal trafficking, and cytoplasmic mislocalization 
differentially, depending on the analyzed cell type. In cortical neurons, recruitment and 
trafficking of mutant FUS showed only slight mutation-dependent effects and also less 
pronounced phenotypes than observed in spinal MNs. In conclusion, patient-specific cellular 
models are an important tool in ALS research and particularly differences between cortical and 
spinal MNs need to be further investigated to decipher underlying disease mechanisms, the 
interplay of cell types affected by the disease, and how they participate in disease progression. 
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6 Zusammenfassung 
Amyotrophe Lateralsklerose (ALS) ist eine neurodegenerative Erkrankung, bei welcher 
speziell erste (kortikospinal) und zweite (spinal) Motorneurone (MN) von Neurodegeneration 
betroffen sind. Gegenwärtig bleibt ALS eine unheilbare Erkrankung. Der Tod tritt 
durchschnittlich 2 bis 5 Jahre nach Auftreten der Symptome ein. Circa 90% der Fälle treten 
sporadisch auf (sALS), während 10% familiär sind (fALS). Es ist von großem Interesse 
monogenetische Formen der fALS zu untersuchen um zugrundeliegende Pathologien und 
Mechanismen zu verstehen. Bislang wurden über 20 Gene mit ALS in Verbindung gebracht, 
einschließlich Fused in sarcoma (FUS) und Chromsosome 9 open reading frame (C9ORF72). 
Circa 4% der fALS Fälle sind durch dominante Mutationen in FUS verursacht und 
repräsentieren damit die dritthäufigste Form der fALS in Deutschland. Die G4C2 
hexanucleotide repeat expansion (HRE) in C9ORF72 ist die häufigste Ursache für ALS und 
Frontotemporale Demenz (FTD). ALS Patienten unterscheiden sich erheblich in der 
Präsentation ihrer klinischen Symptome wie Ausbruchsort, Progressionsrate und Auftreten 
kognitiver Störungen. Diese Faktoren sind auch stark abhängig von der zugrundeliegenden 
Mutation in fALS. Ziel dieser Doktorarbeit ist die Modellierung von FUS- und C9ORF72-
assozierter ALS in einem krankheits-relevanten in vitro Model von speziell kortikaler 
Neuropathologie mit Hilfe von Patienten-spezifischen iPSZs. Die Hypothese der vorliegenden 
Arbeit ist das in einer Zelltyp-abhängigen Art und Weise zugrundeliegende 
Erkrankungsmechanismen in kortikalen vs. spinalen Neuronen unterschiedlich betroffen sind. 
Humane iPSZ, generiert von gesunden Kontrollen und ALS Patienten mit FUS oder C9ORF72 
Mutation, wurden für die gerichtete kortikale und spinale Differenzierung genutzt. Zusätzlich 
wurden zwei neue FUS-WT- und FUS-P525L-EGFP-markierte isogene Linien mittels 
CRISPR/Cas9n Technik generiert. Methoden basierend auf Immunfluoreszenz Färbungen 
und Lebendzell-Mikroskopie wurden angewendet um Krankheits-relevante Proteine, DNA 
Schäden und axonale Organell-Mobilität zu analysieren. In diesem Projekt konnte ein 
deutlicher Zelltyp-abhängiger Effekt auf analysierte Phänotypen beobachtet werden, während 
ALS-assoziierte Mutationen scheinbar nur geringfügige Effekte zeigten. Dementsprechend 
wurde ein Zelltyp-abhängiger Anstieg des basalen DNA Schadens in kortikalen Astrozyten vs. 
Neuronen und spinalen vs. kortikalen Neuronen detektiert. Jedoch konnte in FUS oder 
C9ORF72 mutierten kortikalen Zellen kein erhöhter DNA Schaden nachgewiesen werden, wie 
es zuvor in spinalen MN beobachtet wurde. Des Weiteren beeinflussen FUS Mutationen die 
Rekrutierung von FUS zu DNA-geschädigten Stellen, die Organell-Mobilität und die 
zytoplasmatische Fehllokalisation des Proteins in Abhängigkeit vom Zelltyp. In kortikalen 
Neuronen wurde in Bezug auf die Rekrutierung von mutiertem FUS und Organell-Mobilität nur 
leichte Mutations-abhängige und wesentlich schwächer ausgeprägte Effekte beobachtet als in 
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spinalen MN. Zusammenfassend kann gesagt werden, dass Patienten-spezifische Zellmodelle 
ein wichtiges Instrument in der ALS Forschung sind und das vor allem Unterschiede zwischen 
kortikalen und spinalen MN weiter untersucht werden müssen, um zugrundeliegende 
Krankheits-relevante Mechanismen zu entschlüsseln und wie diese zum Fortschreiten der 
Erkrankung beitragen. 
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11 Appendix 
 
11.1 Supplementary Movies 
Supplementary Movie S1 
Refers to Figure 3.31 A, showing movie frame at 116 sec of FUS-EGFP recruited to Laser cut in 
untreated iPSCs and cortical neurons. Recruitment-withdrawal of nuclear FUS-EGFP to DNA Laser 
ablation cuts in hiPSC-derived mature neurons and iPSCs expressing WT or mutant P525L FUS-EGFP 
(isogenic control lines, Table 2.15). Confocal spinning disc fluorescence imaging at 100x magnification, 
NA 1.45 oil immersion, over 15 min upon Laser irradiation with 1 fps for frame 1-150 and 0.2 fps beyond, 
LUT Green Fire Blue. 
Supplementary Movie S2-3 (general remarks) 
All movies were recorded at 100x magnification, NA 1.45 oil immersion, at 3.3 fps per channel over 2 
min (400 frames in total per channel) in epifluorescence mode if not stated otherwise below with 
illumination and filter settings as detailed in Material and Methods. Organelle motility revealed with 
Lysotracker Red DND-99 (LUT Yellow Hot), Mitotracker Deep Red FM (LUT Cyan Hot) or Mitotracker 
JC-1 (composite overlays of the red channel, LUT Red, and green channel, LUT green.) at standardized 
microchannel readout positions distal versus proximal in compartmentalized iPSC-derived MN cultures 
Supplementary Movie S2 
Refers to Figure 3.34 B showing maximum intensity projections of Mitotracker Deep Red FM. Moving 
mitochondria in distal and proximal axonal parts can be observed for controls (Ctrl 2 = AKC5, FUS-WT 
= KG WT) and FUS mutants (FUS-R521C = KG25C1, FUS-P525L = KG P525L).  
Supplementary Movie S3 
Refers to Figure 3.34 E showing maximum intensity projections of Lysotracker Red DND-99. Moving 
lysosomes in distal and proximal axonal parts can be observed for controls (Ctrl 2 = AKC5, FUS-WT = 
KG WT) and FUS mutants (FUS-R521C = KG25C1, FUS-P525L = KG P525L). 
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11.2 Supplementary Tables 
 
Supplemental Table S 1: Box plot statistics of Figure 3.34 C - mitochondrial track displacement 
in µm. 
 
Distal Proximal 
 
Ctrl FUSmt Ctrl FUSmt 
Statistics were calculated by Kolmogorov-Smirnov test (n=3-7 technical replicates from 2-4 independent 
differentiations). 
 
 
     
 
P=0.0001 P=0.0003 
     
Number of values 6194 7644 6411 9623 
     
Minimum 1.20 1.20 1.20 1.20 
25% Percentile 1.48 1.44 1.46 1.49 
Median 1.95 1.86 1.94 2.01 
75% Percentile 2.90 2.82 3.01 3.24 
Maximum 47.09 37.57 51.75 55.60 
     
Mean 2.51 2.58 2.77 2.93 
Std. Deviation 1.84 2.27 2.65 2.91 
Std. Error of Mean 0.02 0.03 0.03 0.03 
     
Lower 95% CI of mean 2.46 2.53 2.70 2.87 
Upper 95% CI of mean 2.55 2.63 2.83 2.99 
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Supplemental Table S 2: Box plot statistics of Figure 3.34 D - mitochondrial mean speed in 
µm/sec. 
Statistics were calculated by Kolmogorov-Smirnov test (n=3-7 technical replicates from 2-4 independent 
differentiations). 
 
 
 
Distal Proximal 
 
Ctrl FUSmt Ctrl FUSmt 
     
 
P<0.0001 P<0.0001 
     
Number of values 6194 7644 6411 9623 
     
Minimum 0.08 0.06 0.02 0.05 
25% Percentile 0.65 0.45 0.52 0.44 
Median 0.95 0.77 0.86 0.76 
75% Percentile 1.23 1.10 1.16 1.11 
Maximum 7.75 6.41 6.46 5.66 
     
Mean 0.96 0.81 0.90 0.82 
Std. Deviation 0.46 0.44 0.51 0.48 
Std. Error of Mean 0.01 0.01 0.01 0.00 
     
Lower 95% CI of mean 0.95 0.80 0.88 0.81 
Upper 95% CI of mean 0.97 0.82 0.91 0.83 
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Supplemental Table S 3: Box plot statistics of Figure 3.34 F - lysosomal track displacement in 
µm. 
Statistics were calculated by Kolmogorov-Smirnov test (n=3-7 technical replicates from 2-4 independent 
differentiations). 
 
 
 
 
Distal Proximal 
 
Ctrl FUSmt Ctrl FUSmt 
     
 
P<0.0001 P<0.0001 
     
Number of values 2657 5047 4907 6913 
     
Minimum 1.20 1.20 1.20 1.20 
25% Percentile 1.54 1.69 1.70 1.77 
Median 2.14 2.77 2.60 2.89 
75% Percentile 3.59 5.49 4.57 5.99 
Maximum 64.66 79.53 66.21 109.40 
     
Mean 3.45 4.93 4.19 5.53 
Std. Deviation 3.95 6.29 4.95 7.35 
Std. Error of Mean 0.08 0.09 0.07 0.09 
     
Lower 95% CI of mean 3.30 4.76 4.05 5.36 
Upper 95% CI of mean 3.60 5.11 4.33 5.70 
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Supplemental Table S 4: Box plot statistics of Figure 3.34 G - lysosomal mean speed in µm/sec. 
Statistics were calculated by Kolmogorov-Smirnov test (n=3-7 technical replicates from 2-4 independent 
differentiations). 
 
Supplemental Table S 5: Descriptive statistics related to related to Figure 3.35 A - Percentages 
moving mitochondria.  
The effect of the cell line on organelle motility was calculated by One-way ANOVA with Tukey’s post-
hoc test (n=3-7 technical replicates from ≥ 2 independent differentiations). 
 
 
Distal Proximal 
 
Ctrl FUSmt Ctrl FUSmt 
     
 
P<0.0001 P<0.0001 
     
Number of values 2657 5047 4907 6913 
     
Minimum 0.06 0.08 0.08 0.05 
25% Percentile 0.44 0.40 0.71 0.55 
Median 0.78 0.71 1.08 0.92 
75% Percentile 1.15 1.10 1.41 1.29 
Maximum 7.70 6.22 5.94 9.35 
     
Mean 0.84 0.81 1.10 0.98 
Std. Deviation 0.50 0.52 0.56 0.58 
Std. Error of Mean 0.01 0.01 0.01 0.01 
     
Lower 95% CI of mean 0.82 0.79 1.08 0.97 
Upper 95% CI of mean 0.85 0.82 1.12 0.99 
 
Distal Proximal 
 
Ctrl 2 FUS-WT FUS-R521C FUS-P525L Ctrl 2 FUS-WT FUS-R521C FUS-P525L 
         
One way ANOVA F (3, 18) = 0.61 P=0.616 F (3, 18) = 0.62 P=0.613 
         
Number of values 3 6 7 6 3 6 7 6 
         
Mean 18.42 15.31 12.70 14.29 15.48 18.15 14.90 17.79 
Std. Deviation 6.46 8.38 2.33 7.00 3.69 5.13 3.46 6.72 
Std. Error of Mean 3.73 3.42 0.88 2.86 2.13 2.10 1.31 2.74 
         
Lower 95% CI 2.36 6.51 10.54 6.95 6.31 12.77 11.69 10.74 
Upper 95% CI 34.47 24.10 14.85 21.63 24.64 23.54 18.10 24.83 
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The effect of the cell line on organelle motility was calculated by One-way ANOVA with Tukey’s post-
hoc test (n=3-7 technical replicates from ≥ 2 independent differentiations). 
 
Supplemental Table S 7: Descriptive statistics related to Figure 3.8 - Poly-GP ELISA.  
 
Supplemental Table S 6: Descriptive statistics related to related to Figure 3.35 B - Percentages 
moving lysosomes.  
 
Distal Proximal 
 
Ctrl 2 FUS-
WT 
FUS-
R521C 
FUS-
P525L 
Ctrl 2 FUS-
WT 
FUS-
R521C 
FUS-
P525L 
         
One way 
ANOVA 
F (3, 18) = 0.81 P=0.506 F (3, 18) = 1.89 P=0.168 
         
Number of 
values 
3 6 7 6 3 6 7 6 
         
Mean 15.72 19.91 24.51 23.67 36.66 22.76 30.43 29.08 
Std. Deviation 6.30 3.73 10.19 12.22 6.88 8.25 9.83 8.17 
Std. Error of 
Mean 
3.64 1.52 3.85 4.99 3.97 3.37 3.71 3.33 
         
Lower 95% CI 0.07 15.99 15.08 10.85 19.58 14.10 21.35 20.51 
Upper 95% CI 31.38 23.82 33.93 36.49 53.74 31.42 39.52 37.65 
 
D80 D120 
 
Mean SD n Mean SD n 
Ctrl 1 104.00 0.00 1 121.00 36.77 2 
Ctrl 2 43.50 0.00 1 27.50 0.00 1 
Ctrl 4 198.00 11.31 2 83.75 11.67 2 
C9-WT 159.00 0.00 1 255.50 0.00 1 
C9-HRE 1 249.17 50.04 3 301.17 110.50 3 
C9-HRE 2 1121.50 625.79 2 7638.33 8817.01 3 
C9-HRE 3 393.00 72.19 3 359.50 79.41 3 
Appendix 
156 / 163 
Statistics were calculated by One-way ANOVA with Tukey’s post-hoc test (n=3-4). 
 
Statistics were calculated by One-way ANOVA with Tukey’s post-hoc test (n=3-4).  
Supplemental Table S 8: Descriptive statistics related to Figure 3.10 A – Poly-GP granules 
relative to MAP2 area.  
 
Ctrl 1 C9-HRE 1 C9-WT C9-HRE 2 
     
One-way ANOVA F (3, 10) = 0.456 P=0.7178 
     
Number of values 4 4 3 3 
     
Minimum 0.0006 0.0007 0.0007 0.0008 
25% Percentile 0.0006 0.0007 0.0007 0.0008 
Median 0.0008 0.0008 0.0008 0.0008 
75% Percentile 0.0008 0.0009 0.0008 0.0008 
Maximum 0.0008 0.0009 0.0008 0.0008 
     
Mean 0.00075 0.00082 0.00077 0.00080 
Std. Deviation 0.00012 0.00010 0.00008 0.00002 
Std. Error of Mean 0.0001 0.0000 0.0000 0.0000 
     
Lower 95% CI 0.0006 0.0007 0.0006 0.0007 
Upper 95% CI 0.0010 0.0010 0.0010 0.0009 
Supplemental Table S 9: Descriptive statistics related to Figure 3.10 B – Poly-GP area relative to 
MAP2 area. 
 
Ctrl 1 C9-HRE 1 C9-WT C9-HRE 2 
     
One-way ANOVA F (3, 10) = 7.93 
 
P=0.005 
 
Post-hoc 
 
* 
 
*  
    
+ 
Number of values 4 4 3 3 
     
Minimum 0.0082 0.0103 0.0094 0.0111 
25% Percentile 0.0084 0.0105 0.0094 0.0111 
Median 0.0095 0.0109 0.0095 0.0113 
75% Percentile 0.0102 0.0116 0.0097 0.0116 
Maximum 0.0103 0.0119 0.0097 0.0116 
     
Mean 0.0094 0.0110 0.0095 0.0114 
Std. Deviation 0.0010 0.0006 0.0001 0.0003 
Std. Error of Mean 0.0005 0.0003 0.0001 0.0002 
     
Lower 95% CI 0.0078 0.0100 0.0092 0.0107 
Upper 95% CI 0.0110 0.0120 0.0099 0.0120 
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Asterix (*) indicates statistical significances when compared to Ctrl 1.  
Plus sign (+) indicates statistical significances when compared to C9-WT.  
 
Statistics were calculated by Kurskal-Wallis test with Dunn’s post-hoc test (n=3-4).  
Asterix (*) indicates statistical significances when compared to Ctrl 1.  
Plus sign (+) indicates statistical significances when compared to C9-WT.  
 
Supplemental Table S 10: Descriptive statistics related to Figure 3.10 C – Poly-GP granule area 
in pixel2.  
 
Ctrl 1 C9-HRE 1 C9-WT C9-HRE 2 
     
Kruskal-Wallis test P<0.0001 
Post-hoc 
 
** 
 
*** 
  
+++ 
 
++++ 
     
Number of values 2223 2480 1678 2113 
     
Minimum 4.00 4.00 4.00 4.00 
25% Percentile 5.00 6.00 5.00 6.00 
Median 8.00 9.00 8.00 9.00 
75% Percentile 15.00 16.00 14.00 17.00 
Maximum 189.00 218.00 176.00 203.00 
     
Mean 12.70 13.80 12.30 14.10 
Std. Deviation 13.10 14.40 12.80 14.80 
Std. Error of Mean 0.28 0.29 0.31 0.32 
     
Lower 95% CI 12.10 13.20 11.70 13.50 
Upper 95% CI 13.20 14.30 12.90 14.70 
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Statistics were calculated by Kurskal-Wallis test with Dunn’s post-hoc test (n=3-4).  
Asterix (*) indicates statistical significances when compared to Ctrl 1.  
Plus sign (+) indicates statistical significances when compared to C9-WT.  
 
Supplemental Table S 11: Descriptive statistics related to Figure 3.10  D – Poly-GP granule radius 
in pixel. 
 
T12-9 KDC28 MHC30-GC 33-1 
     
Kruskal-Wallis test P<0.0001 
Post-hoc 
 
*** 
 
**** 
  
++++ 
 
++++ 
     
Number of values 2223 2480 1678 2113 
     
Minimum 1.00 1.00 1.00 1.00 
25% Percentile 1.00 1.00 1.00 1.00 
Median 1.06 1.08 1.06 1.08 
75% Percentile 1.17 1.20 1.17 1.21 
Maximum 2.54 2.23 1.99 2.39 
     
Mean 1.12 1.14 1.12 1.14 
Std. Deviation 0.17 0.17 0.15 0.17 
Std. Error of Mean 0.00 0.00 0.00 0.00 
     
Lower 95% CI 1.12 1.13 1.11 1.13 
Upper 95% CI 1.13 1.14 1.12 1.15 
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Statistics were calculated by One-way ANOVA with Tukey’s post-hoc test (n=3-6). 
 
Statistics were calculated by One-way ANOVA with Tukey’s post-hoc test (n=3-6). 
Supplemental Table S 12: Descriptive statistics related to Figure 3.12 A – Poly-GA granules 
relative to MAP2 area. 
 
Ctrl 1 Ctrl 2 C9-HRE 1 C9-WT C9-HRE 2 
      
One-way ANOVA F (4, 14) = 2.14 P=0.130 
  
      
Number of values 4 3 6 3 3 
      
Minimum 0.00067 0.00025 0.00046 0.00010 0.00049 
25% Percentile 0.00068 0.00025 0.00053 0.00010 0.00049 
Median 0.00071 0.00047 0.00072 0.00042 0.00069 
75% Percentile 0.00071 0.00052 0.00087 0.00076 0.00073 
Maximum 0.00071 0.00052 0.00109 0.00076 0.00073 
      
Mean 0.00070 0.00041 0.00072 0.00043 0.00064 
Std. Deviation 0.00002 0.00014 0.00022 0.00033 0.00013 
Std. Error of Mean 0.00001 0.00008 0.00009 0.00019 0.00007 
      
Lower 95% CI 0.00066 0.00006 0.00049 -0.00039 0.00032 
Upper 95% CI 0.00074 0.00077 0.00096 0.00124 0.00096 
Supplemental Table S 13: Descriptive statistics related to Figure 3.12 B – Poly-GA area relative 
to MAP2 area. 
 
Ctrl 1 Ctrl 2 C9-HRE 1 C9-WT C9-HRE 2 
      
One-way ANOVA F (4, 14) = 2.49 P=0.091 
  
      
Number of values 4 3 6 3 3 
      
Minimum 0.0062 0.0023 0.0041 0.0009 0.0058 
25% Percentile 0.0063 0.0023 0.0052 0.0009 0.0058 
Median 0.0067 0.0039 0.0071 0.0044 0.0069 
75% Percentile 0.0070 0.0046 0.0083 0.0077 0.0075 
Maximum 0.0071 0.0046 0.0096 0.0077 0.0075 
      
Mean 0.0067 0.0036 0.0069 0.0044 0.0067 
Std. Deviation 0.0004 0.0012 0.0019 0.0034 0.0009 
Std. Error of Mean 0.0002 0.0007 0.0008 0.0020 0.0005 
      
Lower 95% CI 0.0060 0.0007 0.0048 -0.0041 0.0046 
Upper 95% CI 0.0073 0.0065 0.0089 0.0128 0.0089 
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Statistics were calculated by Kurskal-Wallis test with Dunn’s post-hoc test (n=3-6).  
Asterix (*) indicates statistical significances when compared to Ctrl 1.  
Double cross (#) indicates statistical significances when compared to Ctrl 2.  
Asterix (*) indicates statistical significances when compared to C9-HRE 1.  
 
Supplemental Table S 14: Descriptive statistics related to Figure 3.12 C – Poly-GA granule area 
in pixel2. 
 
Ctrl 1 Ctrl 2 C9-HRE 1 C9-WT C9-HRE 2 
      
Kruskal-Wallis test P<0.0001 
    
Post-hoc 
    
*** 
 
# 
 
# ### #### 
     
**** 
      
Number of values 2091 1246 3582 1207 1699 
      
Minimum 4.00 4.00 4.00 4.00 4.00 
25% Percentile 5.00 5.00 5.00 5.00 5.00 
Median 7.00 7.00 7.00 8.00 8.00 
75% Percentile 12.00 10.00 12.00 12.00 13.00 
Maximum 115.00 57.00 90.00 71.00 70.00 
      
Mean 9.62 8.62 9.41 10.30 10.50 
Std. Deviation 7.19 5.55 6.79 7.95 7.75 
Std. Error of Mean 0.16 0.16 0.11 0.23 0.19 
      
Lower 95% CI 9.31 8.31 9.19 9.81 10.20 
Upper 95% CI 9.93 8.93 9.63 10.70 10.90 
      
Mean ranks 4881 4557 4841 5056 5263 
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Statistics were calculated by Kurskal-Wallis test with Dunn’s post-hoc test (n=3-6).  
Asterix (*) indicates statistical significances when compared to Ctrl 1.  
Double cross (#) indicates statistical significances when compared to Ctrl 2.  
Plus sign (+) indicates statistical significances when compared to C9-WT.  
Asterix (*) indicates statistical significances when compared to C9-HRE 1.  
 
 
 
 
  
Supplemental Table S 15: Descriptive statistics related to Figure 3.12 D – Poly-GA granule radius 
in pixel. 
 
Ctrl 1 Ctrl 2 C9-HRE 1 C9-WT C9-HRE 2 
      
Kruskal-Wallis test P<0.0001 
    
Post-hoc 
    
** 
     
#### 
     
++ 
     
**** 
      
Number of values 2091 1246 3582 1207 1699 
      
Minimum 1.00 1.00 1.00 1.00 1.00 
25% Percentile 1.00 1.00 1.00 1.00 1.00 
Median 1.06 1.06 1.06 1.05 1.06 
75% Percentile 1.14 1.11 1.13 1.14 1.15 
Maximum 1.81 1.79 1.91 1.83 1.89 
      
Mean 1.09 1.07 1.08 1.09 1.10 
Std. Deviation 0.11 0.09 0.10 0.12 0.12 
Std. Error of Mean 0.00 0.00 0.00 0.00 0.00 
      
Lower 95% CI 1.08 1.07 1.08 1.08 1.09 
Upper 95% CI 1.09 1.08 1.09 1.09 1.11 
      
Mean ranks 4903 4715 4857 4867 5222 
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